<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002787.pub3" GROUP_ID="ANAESTH" ID="637200032617273343" MERGED_FROM="" MODIFIED="2017-01-05 14:05:49 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="014" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2017-01-05 14:05:40 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2016-06-24 14:54:02 +0100" MODIFIED_BY="[Empty name]">Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults</TITLE>
<CONTACT MODIFIED="2017-01-05 14:05:40 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="18607" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Afshari</LAST_NAME><POSITION>Consultant Paediatric anaesthetist and Intensivist</POSITION><EMAIL_1>arriba.a@gmail.com</EMAIL_1><EMAIL_2>afshari@rocketmail.com</EMAIL_2><MOBILE_PHONE>004551948186</MOBILE_PHONE><ADDRESS><DEPARTMENT>Juliane Marie Centre - Anaesthesia and Surgical Clinic Department 4013</DEPARTMENT><ORGANISATION>Rigshospitalet, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-01-05 14:05:40 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="z1403111114086144932950352286740" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fabienne</FIRST_NAME><LAST_NAME>Gebistorf</LAST_NAME><POSITION>Fellow</POSITION><EMAIL_1>fabienne.gebistorf@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Pediatric Intensive Care Unit</DEPARTMENT><ORGANISATION>Geneva University Hospital</ORGANISATION><ADDRESS_1>6 rue Willy Donzé</ADDRESS_1><CITY>Geneva</CITY><ZIP>1205</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 79 55 34 486</PHONE_1><FAX_1>+41 22 382 54 88</FAX_1></ADDRESS></PERSON><PERSON ID="98174832388226091572111026131359" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Oliver</FIRST_NAME><LAST_NAME>Karam</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><POSITION>Attending physician</POSITION><EMAIL_1>oliver.karam@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Pediatric Intensive Care Unit</DEPARTMENT><ORGANISATION>Geneva University Hospital</ORGANISATION><ADDRESS_1>6 rue Willy Donzé</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 382 47 55</PHONE_1><FAX_1>+41 22 382 54 88</FAX_1></ADDRESS></PERSON><PERSON ID="6564" ROLE="AUTHOR"><FIRST_NAME>Jørn</FIRST_NAME><LAST_NAME>Wetterslev</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Chief Physician</POSITION><EMAIL_1>wetterslev@ctu.dk</EMAIL_1><ADDRESS><DEPARTMENT>Copenhagen Trial Unit, Centre for Clinical Intervention Research</DEPARTMENT><ORGANISATION>Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7159</PHONE_1><FAX_1>+45 3545 7001</FAX_1></ADDRESS></PERSON><PERSON ID="18607" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Afshari</LAST_NAME><POSITION>Consultant Paediatric anaesthetist and Intensivist</POSITION><EMAIL_1>arriba.a@gmail.com</EMAIL_1><EMAIL_2>afshari@rocketmail.com</EMAIL_2><MOBILE_PHONE>004551948186</MOBILE_PHONE><ADDRESS><DEPARTMENT>Juliane Marie Centre - Anaesthesia and Surgical Clinic Department 4013</DEPARTMENT><ORGANISATION>Rigshospitalet, Copenhagen University Hospital</ORGANISATION><CITY>Copenhagen</CITY><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-12-17 09:49:20 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="18" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="11" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2017-01-05 13:56:55 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-01-05 13:56:38 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="5" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>Co-published in Anaesthesia (<LINK REF="REF-Karam-2017" TYPE="REFERENCE">Karam 2017</LINK>)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-01-05 13:56:55 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-01-05 13:56:55 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="18" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>A new lead author (Fabienne Gebistorf) together with a new co-author (Oliver Karam) has updated this review in collaboration with 2 of the original review authors (AA and JW). We have updated the Methods section and have included full risk of bias tables and summary of findings tables. We have applied trial sequential analysis (TSA)</P>
<P>We searched the databases until 2015 November 18. We included one new trial in this updated review (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>). We excluded from this review one randomized controlled trial (<LINK REF="STD-Cuthbertson-2000" TYPE="STUDY">Cuthbertson 2000</LINK>) that had been included in the previous version (<LINK REF="REF-Afshari-2010" TYPE="REFERENCE">Afshari 2010</LINK>), because new information provided to us indicated that most of these patients had been included in <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>. Furthermore, mortality data for <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK> have been revised since we became aware of a mistake in the last version of the review (<LINK REF="REF-Afshari-2010" TYPE="REFERENCE">Afshari 2010</LINK>)</P>
<P>This review now has 14 included studies in total (1275 participants)</P>
<P>The overall conclusion remains unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-01-05 13:56:51 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="18" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>Our conclusion remains the same</P>
<P>Two review authors - Jesper Brok and Ann Meret Møller - have left the team, and two new review authors - FG and OK - have joined the team</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-25 10:32:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-25 10:32:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-12 13:57:30 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="30" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>Typo corrected</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-06-25 10:33:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>), which included five randomized controlled trials (RCTs)</P>
<P>Previous review authors Sokol J, Jacobs SE and Bohn D decided they would not update the review (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>); new review authors Afshari A, Brok J, Møller AM and Wetterslev J have updated this version</P>
<P>This review was previously known as 'Inhaled nitric oxide for acute hypoxaemic respiratory failure in children and adults' (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>)</P>
<P>We found 10 new trials and chose to include 8 of them because they met our inclusion criteria (<LINK REF="STD-Cuthbertson-2000" TYPE="STUDY">Cuthbertson 2000</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). Two RCTs excluded from <LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK> because they were published only as abstracts were included in our analyses (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>). We excluded 2 other trials (<LINK REF="STD-Meade-2003" TYPE="STUDY">Meade 2003</LINK>; <LINK REF="STD-Perrin-2006" TYPE="STUDY">Perrin 2006</LINK>)</P>
<P>In general, our review presents the same conclusions as were presented in <LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>. However, we included more trials and thus have provided more precise estimates on, for example, mortality. Furthermore, we applied several additional sensitivity and subgroup analyses that support the overall results</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-06-25 10:32:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>In the previous version (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>), databases were searched until 2002. We reran the searches until 31 January 2010. We have included risk of bias tables</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-06-25 10:33:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>In this updated systematic review, we have applied several new statistical methods to explore and reduce the size of bias, such as complete case analysis, test of interaction, trial sequential analysis, overall methodological bias assessment and analyses of various relevant clinical and physiological outcomes that were not addressed in <LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>. We have extended our search strategy to include additional electronic databases</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-25 10:33:09 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-06-02 19:27:22 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-06-02 19:27:22 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-06-02 19:27:22 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Anaesthesia Review Group and Copenhagen University Hospital, Rigshosptialet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>CARG and Rigshospitalet have provided funding for attendance of various relevant courses in the field of meta-analytic statistics </P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-08-12 12:51:09 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-08-12 12:51:09 +0100" MODIFIED_BY="[Empty name]">
<NAME>No external support</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>No external support</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-06-27 11:28:21 +0100" MODIFIED_BY="Jane Cracknell">
<SUMMARY MODIFIED="2016-06-25 09:41:00 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-06-25 09:40:10 +0100" MODIFIED_BY="[Empty name]">Use of inhaled nitric oxide in patients with acute respiratory failure with low blood oxygen does not improve survival</TITLE>
<SUMMARY_BODY MODIFIED="2016-06-25 09:41:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>When a person has acute respiratory failure, some physicians administer nitric oxide (NO), which is a colourless gas that can dilate the pulmonary vasculature. This gas has been hypothesized to improve acute respiratory failure, as it could improve oxygenation by selectively improving blood flow to healthy lung segments.</P>
<P>Our objective was to evaluate whether this treatment improves outcomes of adults and children with acute respiratory failure.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included in this updated review 14 trials with 1275 participants. We found the overall quality of trials to be moderate, with little information provided on how experiments were carried out. Results were limited, and most included trials were small. In most trials, we identified risk of misleading information. Thus, results must be interpreted with caution. The evidence is up-to-date to 18 November 2015.</P>
<P>
<B>Key results</B>
</P>
<P>No strong evidence is available to support the use of INO to improve survival of adults and children with acute respiratory failure and low blood oxygen levels. In the present systematic review, we set out to assess the benefits and harms of its use in adults and children with acute respiratory failure. We identified 14 randomized trials comparing INO versus placebo or no intervention. We found no beneficial effects: despite signs of oxygenation and initial improvement, INO does not appear to improve survival and might be hazardous, as it may cause kidney function impairment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-06-25 11:07:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-06-25 11:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Acute hypoxaemic respiratory failure (AHRF) and mostly acute respiratory distress syndrome (ARDS) are critical conditions. AHRF results from several systemic conditions and is associated with high mortality and morbidity in individuals of all ages. Inhaled nitric oxide (INO) has been used to improve oxygenation, but its role remains controversial. This Cochrane review was originally published in 2003, and has been updated in 2010 and 2016.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-06-24 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>The primary objective was to examine the effects of administration of inhaled nitric oxide on mortality in adults and children with ARDS<I>. </I>
</P>
<P>Secondary objectives were to examine secondary outcomes such as pulmonary bleeding events, duration of mechanical ventilation, length of stay, etc. We conducted subgroup and sensitivity analyses, examined the role of bias and applied trial sequential analyses (TSAs) to examine the level of evidence.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-24 14:56:44 +0100" MODIFIED_BY="[Empty name]">
<P>In this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015 Issue 11); MEDLINE (Ovid SP, to 18 November 2015), EMBASE (Ovid SP, to 18 November 2015), CAB, BIOSIS and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). We handsearched the reference lists of the newest reviews and cross-checked them with our search of MEDLINE. We contacted the main authors of included studies to request any missed, unreported or ongoing studies. The search was run from inception until 18 November 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-06-24 14:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomized controlled trials (RCTs), irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted trial investigators and study authors to retrieve relevant and missing data.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-06-24 14:57:00 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and resolved disagreements by discussion. Our primary outcome measure was all-cause mortality. We performed several subgroup and sensitivity analyses to assess the effects of INO in adults and children and on various clinical and physiological outcomes. We presented pooled estimates of the effects of interventions as risk ratios (RRs) with 95% confidence intervals (CIs). We assessed risk of bias through assessment of trial methodological components and risk of random error through trial sequential analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-25 09:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Our primary objective was to assess effects of INO on mortality. We found no statistically significant effects of INO on longest follow-up mortality: 250/654 deaths (38.2%) in the INO group compared with 221/589 deaths (37.5%) in the control group (RR 1.04, 95% CI 0.9 to 1.19; I² statistic = 0%; moderate quality of evidence). We found no statistically significant effects of INO on mortality at 28 days: 202/587 deaths (34.4%) in the INO group compared with 166/518 deaths (32.0%) in the control group (RR 1.08, 95% CI 0.92 to 1.27; I² statistic = 0%; moderate quality of evidence). In children, there was no statistically significant effects of INO on mortality: 25/89 deaths (28.1%) in the INO group compared with 34/96 deaths (35.4%) in the control group (RR 0.78, 95% CI 0.51 to 1.18; I² statistic = 22%; moderate quality of evidence).</P>
<P>Our secondary objective was to assess the benefits and harms of INO. For partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>)/fraction of inspired oxygen (FiO<SUB>2</SUB>), we found significant improvement at 24 hours (mean difference (MD) 15.91, 95% CI 8.25 to 23.56; I² statistic = 25%; 11 trials, 614 participants; moderate quality of evidence). For the oxygenation index, we noted significant improvement at 24 hours (MD -2.31, 95% CI -2.73 to -1.89; I² statistic = 0%; five trials, 368 participants; moderate quality of evidence). For ventilator-free days, the difference was not statistically significant (MD -0.57, 95% CI -1.82 to 0.69; I² statistic = 0%; five trials, 804 participants; high quality of evidence). There was a statistically significant increase in renal failure in the INO groups (RR 1.59, 95% CI 1.17 to 2.16; I² statistic = 0%; high quality of evidence)<I>.</I>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-06-25 09:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence is insufficient to support INO in any category of critically ill patients with AHRF. Inhaled nitric oxide results in a transient improvement in oxygenation but does not reduce mortality and may be harmful, as it seems to increase renal impairment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-06-25 10:20:31 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-06-25 09:43:16 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-06-25 09:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>Since this review was first published (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>), the definition of acute respiratory failure has changed. Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) in any adult or child older than one month of age were initially defined by the American-European Consensus Conference (AECC) in 1994 (<LINK REF="REF-Bernard-1994" TYPE="REFERENCE">Bernard 1994</LINK>).. The ARDS definition task force produced the latest definition and has developed the Berlin definition (<LINK REF="REF-ARDS-Definition-Task-Force-2012" TYPE="REFERENCE">ARDS Definition Task Force 2012</LINK>). Acute lung injury no longer exists and has been replaced by a gradation of ARDS that is based on the severity of hypoxaemia: mild (200 mm Hg &lt; partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>)/fraction of inspired oxygen (FiO<SUB>2</SUB>) &#8804; 300 mm Hg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) &#8805; 5 cm H<SUB>2</SUB>O), moderate (100 mm Hg &lt; PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 200 mm Hg with PEEP &#8805; 5 cm H<SUB>2</SUB>O) or severe (PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 100 mm Hg with PEEP &#8805; 5 cm H<SUB>2</SUB>O). The Berlin criteria also include onset within one week of a known clinical insult or worsening respiratory symptoms, bilateral opacities on chest x-ray not explained by effusion, collapse or nodule and no cardiac failure or fluid overload.</P>
<P>ARDS is characterized by an inflammatory process of the alveolar-capillary membrane that may arise from a primary lung disease or secondary to several systemic disease processes (<LINK REF="REF-Jain-2006" TYPE="REFERENCE">Jain 2006</LINK>). It is mainly due to a ventilation-perfusion mismatch, resulting in increased intrapulmonary shunting due to pulmonary vasodilatation in non-ventilated lung regions and vasoconstriction in ventilated areas, as well as pulmonary hypertension (<LINK REF="REF-Dahlem-2007" TYPE="REFERENCE">Dahlem 2007</LINK>).</P>
<P>The incidence of ARDS is reported to be between 14 and 86 persons per 100,000 per year in a general adult population (<LINK REF="REF-Luhr-1999" TYPE="REFERENCE">Luhr 1999</LINK>; <LINK REF="REF-Rubenfeld-2005" TYPE="REFERENCE">Rubenfeld 2005</LINK>). However, a recent report from Finland indicates a smaller incidence of ARDS of five per 100,000 per year (<LINK REF="REF-Linko-2009" TYPE="REFERENCE">Linko 2009</LINK>). In Minnnesota, during an eight-year period of study between 2001 and 2008, the incidence decreased from 82.4 to 38.9 per 100,000 person-years (<LINK REF="REF-Li-2011" TYPE="REFERENCE">Li 2011</LINK>). Mortality among adults with ARDS has been reported as 24% to 60%, depending on age and underlying health status of the patient (<LINK REF="REF-Anderson-2003" TYPE="REFERENCE">Anderson 2003</LINK>; <LINK REF="REF-MacCallum-2005" TYPE="REFERENCE">MacCallum 2005</LINK>; <LINK REF="REF-Rubenfeld-2005" TYPE="REFERENCE">Rubenfeld 2005</LINK>). The worst prognosis is seen among patients with sepsis or multi-organ failure, those who are immunocompromised and those without improvement in oxygenation after six days (<LINK REF="REF-TenHoor-2001" TYPE="REFERENCE">TenHoor 2001</LINK>; <LINK REF="REF-Ware-2000" TYPE="REFERENCE">Ware 2000</LINK>).</P>
<P>Recent evidence indicates that the incidence of ARDS among children is 2.0 to 12.8 persons per 100,000 per year (<LINK REF="REF-Zimmerman-2009" TYPE="REFERENCE">Zimmerman 2009</LINK>). Paediatric in-hospital mortality was recently reported at 18% to 27%, with pneumonia, aspiration and sepsis as primary causes of the condition (<LINK REF="REF-Dahlem-2003" TYPE="REFERENCE">Dahlem 2003</LINK>; <LINK REF="REF-Dahlem-2007" TYPE="REFERENCE">Dahlem 2007</LINK>; <LINK REF="REF-Flori-2005" TYPE="REFERENCE">Flori 2005</LINK>; <LINK REF="REF-L_x00f3_pez_x002d_Fern_x00e1_ndez-2012" TYPE="REFERENCE">López-Fernández 2012</LINK>; <LINK REF="REF-Zimmerman-2009" TYPE="REFERENCE">Zimmerman 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-06-25 09:42:25 +0100" MODIFIED_BY="[Empty name]">
<P>Nitric oxide (NO) is a potent endogenous vasodilator that can be exogenously administered via inhalation. It is synthesized by conversion of the terminal guanidine nitrogen atom of L-arginine via endothelial cell calcium-dependent enzyme nitric oxide synthetase, then diffuses across the cell membrane to activate the enzyme guanylate cyclase. This enzyme enhances the synthesis of cyclic guanosine monophosphate (cGMP), causing relaxation of vascular and bronchial smooth muscle and vasodilatation of blood vessels (<LINK REF="REF-Palmer-1998" TYPE="REFERENCE">Palmer 1998</LINK>). Inhaled NO (INO) was first used in clinical practice in 1991 (<LINK REF="REF-Hsu-2008" TYPE="REFERENCE">Hsu 2008</LINK>; <LINK REF="REF-Rossaint-1993" TYPE="REFERENCE">Rossaint 1993</LINK>).</P>
<P>Inhaled NO has the ability to provide selective pulmonary vasodilatation in well-ventilated lung units, to improve ventilation-perfusion mismatch and subsequently to reduce the elevated pulmonary vascular resistance and pulmonary hypertension seen in ARDS (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="REF-Sokol-2003b" TYPE="REFERENCE">Sokol 2003b</LINK>). A reduction in pulmonary arterial pressure and a decrease in intrapulmonary shunting occur within 40 minutes of INO treatment initiation (<LINK REF="REF-Rossaint-1993" TYPE="REFERENCE">Rossaint 1993</LINK>). Inhaled NO also increases the right ventricular ejection fraction and decreases right end-systolic volume, thus preventing decompensation of acute cor pulmonale (<LINK REF="REF-Fierobe-1995" TYPE="REFERENCE">Fierobe 1995</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-06-25 09:43:02 +0100" MODIFIED_BY="[Empty name]">
<P>Inhaled NO has a half-life of three to five seconds and is rapidly inactivated on contact with haemoglobin. As a result, its vasodilatory effect may be limited to well-ventilated regions of the lung (<LINK REF="REF-Hsu-2008" TYPE="REFERENCE">Hsu 2008</LINK>). Nitric oxide is involved in production of and protection from oxidative injury, regulates both immune and inflammatory responses, decreases neutrophil sequestration in the lung, decreases oedema formation and regulates its own production (<LINK REF="REF-McAndrew-1997" TYPE="REFERENCE">McAndrew 1997</LINK>; <LINK REF="REF-Prodhan-2004" TYPE="REFERENCE">Prodhan 2004</LINK>).</P>
<P>Inhaled NO is rapidly converted to active intermediates, including nitrogen dioxide, peroxy-nitrite and nitro-tyrosine, in the presence of superoxide (<LINK REF="REF-Pryor-1995" TYPE="REFERENCE">Pryor 1995</LINK>). However, systemic exposure to INO, which is a cytotoxic free radical, or accumulation of its degradation products could result in deleterious side effects through formation of other free radicals, causing further lung tissue damage (<LINK REF="REF-Beckman-1990" TYPE="REFERENCE">Beckman 1990</LINK>), impaired surfactant function (<LINK REF="REF-Haddad-1996" TYPE="REFERENCE">Haddad 1996</LINK>) or aggravated circulatory failure (<LINK REF="REF-K_x00f6_stler-2005" TYPE="REFERENCE">Köstler 2005</LINK>).</P>
<P>Nitric oxide alters immune function by modifying the release of cytokines and other components of the inflammatory cascade from alveolar macrophages (<LINK REF="REF-Chollet_x002d_Martin-1996" TYPE="REFERENCE">Chollet-Martin 1996</LINK>; <LINK REF="REF-Thomassen-1997" TYPE="REFERENCE">Thomassen 1997</LINK>); it inhibits active adhesion molecules and the neutrophil oxidative burst involved in neutrophil migration (<LINK REF="REF-Kubes-1991" TYPE="REFERENCE">Kubes 1991</LINK>). </P>
<P>Inhaled NO rapidly binds to haemoglobin, with high affinity, to form methaemoglobin at doses of 40 ppm or greater (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>). This occurs after INO diffuses from alveoli to vascular smooth muscle cells adjacent to the alveoli.</P>
<P>Adenosine diphosphate (ADP) and collagen-induced platelet aggregation are significantly inhibited by INO via an increase in intraplatelet cGMP during passage of platelets through the lung, and bleeding time is significantly prolonged in a non-dose-related manner during inhalation (<LINK REF="REF-Barrington-2007" TYPE="REFERENCE">Barrington 2007</LINK>; <LINK REF="REF-Gries-1998" TYPE="REFERENCE">Gries 1998</LINK>; <LINK REF="REF-Gries-2000" TYPE="REFERENCE">Gries 2000</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-06-25 09:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>Inhaled NO is still used extensively worldwide as a rescue agent in severely hypoxaemic patients with ARDS. A survey from Canada found that 39% of specialists still used INO in the treatment of ARDS (<LINK REF="REF-Meade-2004" TYPE="REFERENCE">Meade 2004</LINK>). Most patients with ARDS who receive INO respond with improved oxygenation, but the benefit appears to be transient, lasting less than 72 hours (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>; <LINK REF="REF-Calfee-2007" TYPE="REFERENCE">Calfee 2007</LINK>). Furthermore, two systematic reviews found little evidence on clinical outcomes and increased risk of adverse effects, for example, renal dysfunction (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>; <LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>; <LINK REF="REF-Sokol-2003b" TYPE="REFERENCE">Sokol 2003b</LINK>). Thus INO application remains controversial, especially in the light of recent evidence. The aim of this review was to update the best available evidence on this topic and to assess whether INO therapy has any role in the treatment of patients with ARDS.</P>
<P>We aimed to systematically review randomized controlled trials (RCTs) of INO administration in children and adults with ARDS. More compelling evidence is needed on this topic and on its potential benefits. This is an update of a review first published in 2003 (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>) and updated in 2010 (<LINK REF="REF-Afshari-2010" TYPE="REFERENCE">Afshari 2010</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-06-25 09:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>The primary objective was to examine the effects of administration of inhaled nitric oxide on mortality in adults and children with ARDS<I>. </I>
</P>
<P>Secondary objectives were to examine secondary outcomes such as pulmonary bleeding events, duration of mechanical ventilation, length of stay, etc. We conducted subgroup and sensitivity analyses, examined the role of bias and applied trial sequential analyses (TSAs; <LINK REF="REF-Trial-Sequential-Analysis-_x0028_TSA_x0029_" TYPE="REFERENCE">Trial Sequential Analysis (TSA)</LINK>) to examine the level of evidence.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-06-25 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-06-25 09:47:59 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-06-25 09:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>We included RCTs irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted trial investigators and study authors to ask for relevant data. We included unpublished trials only if trial data and methodological descriptions were provided in written form or could be retrieved from the trial authors. We excluded cross-over trials. We identified no cluster-RCTs but planned to include these, if found, in future updates.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-06-25 09:45:47 +0100" MODIFIED_BY="[Empty name]">
<P>We included participants with a diagnosis of ARDS or ALI, according to the various definitions present in the literature. In the case of an intervention effect, we performed a subgroup analysis based on enrolment of participants to the ARDS groups. We chose to accept the terms 'standard treatment' of ARDS and critically ill patients as reported by many study authors, despite the ongoing controversy. We excluded neonates described as having 'bronchopulmonary dysplasia' or 'chronic lung disease' because of different pathophysiology, treatment, prognosis and progression of the disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-06-25 09:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials comparing INO versus placebo or no intervention in adults and children with ARDS. We included any type or dose of INO and any duration of administration. We permitted a co-intervention if it was administered in both groups. We excluded trials that compared only different INO treatment regimens and those in which INO was compared with interventions other than placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-06-25 09:47:59 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-06-25 09:47:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Overall mortality (longest follow-up, regardless of the duration of follow-up).</LI>
<LI>Overall 28-day mortality (studies reporting mortality at 25 to 30 days were included in the same analysis).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-06-25 09:47:59 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bleeding events: defined as pulmonary bleeding or systemic bleeding requiring transfusion.</LI>
<LI>Complications during the in-patient stay (e.g. hypotensive episodes, direct irritation on administration, thrombosis, congestive cardiac failure, myocardial infarction, renal failure, cerebrovascular accident).</LI>
<LI>PaO<SUB>2</SUB>/FiO<SUB>2 </SUB>ratio.</LI>
<LI>Ventilator-free days.</LI>
<LI>Duration of mechanical ventilation.</LI>
<LI>Oxygenation index.</LI>
<LI>Improvement in mean pulmonary arterial pressure (mm Hg).</LI>
<LI>Methaemoglobin concentration &gt; 5%.</LI>
<LI>Nitric oxide concentration &gt; 3 ppm.</LI>
<LI>Resolution of multi-organ failure (according to different organ dysfunction scores).</LI>
<LI>Quality of life assessment, as defined by authors of included studies.</LI>
<LI>Length of stay in intensive care unit and in hospital.</LI>
<LI>Cost-benefit analyses.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-06-25 09:48:29 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-06-25 09:48:15 +0100" MODIFIED_BY="[Empty name]">
<P>For this review update, we performed a search update to 18 November 2015. Thus, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 11); SilverPlatter MEDLINE (WebSPIRSOvid SP, 1950 to 18 November 2015); SilverPlatter EMBASE (WebSPIRSOvid SP, 1980 to 18 November 2015); SilverPlatter BIOSIS Previews (WebSPIRS 1993 to 18 November 2015); International Institute for Scientific Information (ISI) Web of Science (1964 to 18 November 2015); Latin American Caribbean Health Sciences Literature (LILACS) (via BIREME) (1982 to 18 November 2015); the Chinese Biomedical Literature Database; advanced Google; and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCO host) (1980 to 18 November 2015) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-06-25 09:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>We handsearched the reference lists of reviews, randomized and non-randomized studies and editorials for additional studies. We contacted the main authors of included studies to ask about any missed, unreported or ongoing studies. We searched for ongoing clinical trials and unpublished studies on the following Internet sites.</P>
<OL>
<LI>
<A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>
</LI>
<LI>
<A HREF="http://clinicaltrials.gov">http://clinicaltrials.gov</A>
</LI>
<LI>
<A HREF="http://www.centerwatch.com">http://www.centerwatch.com</A>
</LI>
</OL>
<P>We applied no language restriction to eligible reports and performed the latest search on 18 November 2015.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-06-25 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (FG, OK, AA) independently screened and classified all citations as potential primary studies, review articles or other. All review authors independently examined all potential primary studies and decided on their inclusion in the review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We evaluated all trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat analysis, funding and completeness of follow-up) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We assessed each trial quality factor separately and defined trials as having low risk of bias only if they adequately fulfilled all of the criteria. We independently extracted from each trial and evaluated data on methods and outcomes in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved disagreements by reaching consensus among review authors.</P>
<STUDY_SELECTION MODIFIED="2016-06-25 09:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the articles identified via the described searches and excluded obviously irrelevant reports. Three review authors (FG, OK, AA) independently examined articles for eligibility and screened titles and abstracts to identify studies for eligibility (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). We performed this process without blinding of study authors, institutions, journals of publication or results. We resolved disagreements by reaching consensus among review authors. We provide here a detailed description of the search and assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-06-25 09:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>We independently extracted and collected data without blinding to study authors, source institutions or publication source of trials. We resolved disagreements by discussion and approached all first authors of included trials for additional information on risks of bias. For more detailed information, please see <LINK TAG="CONTRIBUTIONS" TYPE="SECTION">Contributions of authors</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-06-25 09:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated the validity and design characteristics of each trial.</P>
<P>We evaluated trials for major potential sources of bias (random sequence generation, allocation concealment, blinding, intention-to-treat (ITT) analysis and completeness of follow-up; see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We assessed each trial quality factor separately and defined trials as having low risk of bias only if they adequately fulfilled all of the criteria described below.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-06-25 09:53:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data (binary outcomes). These included the following:</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<OL>
<LI>Mortality by duration and overall mortality.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Number of infectious complications.</LI>
<LI>Adverse events.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We used the mean difference (MD) or the RR if data were continuous and were measured in the same way between trials as follows:</P>
<OL>
<LI>Length of stay in an intensive care unit (ICU).</LI>
<LI>Number of days on a ventilator.</LI>
<LI>Length of hospital stay.</LI>
</OL>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-06-25 09:53:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We excluded cross-over trials from our meta-analyses because of the potential risk for &#8220;carry-over&#8221; of treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple intervention groups</HEADING>
<P>In studies designed with multiple intervention groups, we combined groups to create a single pair-wise comparison in accordance with <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>. In trials with two or more groups receiving different doses, we combined data for primary and secondary outcomes.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-06-25 09:53:19 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of trials with missing data to retrieve the relevant information. For all included studies, we noted levels of attrition and any exclusion of participants. In cases of missing data, we chose &#8217;complete-case analysis&#8217; for our primary outcomes, thus excluding from the analysis all participants with missing outcomes. Selective outcome reporting, which occurs when non-significant results are selectively withheld from publication (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>), is defined as selection, on the basis of results, of a subset of the original variables recorded for inclusion in publication of trials (<LINK REF="REF-Hutton-2000" TYPE="REFERENCE">Hutton 2000</LINK>). The most important types of selective outcome reporting are selective omission of outcomes from reports; selective choice of data for an outcome; selective reporting of different analyses using the same data; selective reporting of subsets of the data; and selective under-reporting of data (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-06-25 09:53:30 +0100" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity using the I² statistic and the Chi² test. An I² statistic higher than 50% represents substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In case of an I² statistic &gt; 0%, we tried to determine the cause of heterogeneity by performing relevant subgroup analyses. We used the Chi² test to obtain an indication of heterogeneity between studies, with P value &#8804; 0.1 considered significant.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-06-25 09:53:33 +0100" MODIFIED_BY="[Empty name]">
<P>Funding bias is related to possible publication delay or discouragement of undesired results in trials sponsored by the industry (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). To explore the role of funding, we planned to conduct a sensitivity analysis based on our primary endpoint.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-06-25 09:54:15 +0100" MODIFIED_BY="[Empty name]">
<P>We used Review Manager software (<LINK REF="REF-RevMan-5.3.5" TYPE="REFERENCE">RevMan 5.3.5</LINK>) and calculated RRs with 95% CIs for dichotomous variables and MDs with 95% CIs for continuous outcomes. We used the Chi² test to obtain an indication of heterogeneity between studies, with P value &#8804; 0.1 considered significant. We quantified the degree of heterogeneity observed in the results by using the I² statistic, which can be interpreted as the proportion of total variation observed between studies that is attributable to differences between studies rather than to sampling error (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). An I² statistic value &gt; 75% is considered very heterogeneous. We used both a random-effects model and a fixed-effect model. If the I² statistic value was 0%, we reported only results from the fixed-effect model, and with an I² statistic value &gt; 0%, we reported only results from the random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial sequential analysis</HEADING>
<P>Risk of type 1 errors in meta-analyses due to sparse data and repeated significance testing following updates with new trials remains a serious concern (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). As a result, spurious P values due to systematic errors from trials with high risk of bias, outcome reporting bias, publication bias, early stopping for benefit and small trial bias may result in false conclusions. In a single trial, interim analysis increases the risk of type 1 errors. To avoid type 1 errors, group sequential monitoring boundaries (<LINK REF="REF-Lan-1983" TYPE="REFERENCE">Lan 1983</LINK>) are used to decide whether a trial could be terminated early because of a sufficiently small P value, thus the cumulative Z curve crosses the monitoring boundary.</P>
<P>Equally, sequential monitoring boundaries can be applied to meta-analyses and are labelled &#8217;trial sequential monitoring boundaries&#8217;. In 'trial sequential analysis&#8217; (TSA), the addition of each new trial to a cumulative meta-analysis is viewed as an interim meta-analysis, which provides useful information on the need for additional trials (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>It is appropriate and wise to adjust new meta-analyses for multiple testing on accumulating data to control overall type 1 error risk in cumulative meta-analysis (<LINK REF="REF-Pogue-1997" TYPE="REFERENCE">Pogue 1997</LINK>; <LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>When TSA is performed, the cumulative Z curve crossing the boundary indicates that a sufficient level of evidence has been reached; as a consequence, one may conclude that no additional trials may be needed. However, evidence is insufficient to allow a conclusion if the Z curve does not cross the boundary or does not surpass the required information size.</P>
<P>To construct trial sequential monitoring boundaries (TSMBs), one needs a required information size, which is calculated as the least number of participants required in a well-powered single trial with low risk of bias (<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>In this updated review, we adjusted the required information size for heterogeneity by using the diversity adjustment factor (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). We applied TSA, as it prevents an increase in the risk of type 1 errors (20%). If the actual accrued information size was too small, we provided the required information size in the light of actual diversity (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-06-25 09:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted the following subgroup analyses:</P>
<OL>
<LI>Benefits and harms of INO in participants with ALI or ARDS based on the cause (primary lung injury vs secondary lung injury).</LI>
<LI>Benefits and harms of INO in paediatric participants (paediatric participants (&lt; 18 years) vs adult participants).</LI>
<LI>Benefits and harms of INO based on duration of drug administration (short-term vs long-term administration).</LI>
</OL>
<P>If analyses of various subgroups were significant, we performed a test of interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>). We considered P values &lt; 0.05 as indicating significant interaction between INO treatment and subgroup categories.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-06-25 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>We decided to carry out a sensitivity analysis on the results by applying fixed-effect and random-effects models to assess the impact of heterogeneity on our results.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We used the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) approach to provide an overall assessment of evidence related to all of our outcomes. We constructed a 'Summary of findings' table using GRADEpro software. As outcomes of public interest, we chose to present overall mortality (regardless of the follow-up period), ICU length of stay, days on ventilator and length of hospital stay (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-06-25 10:16:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-06-25 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>; and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2016-06-25 09:55:18 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated review, we identified two new trials via the search strategy; we included one of them (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>), and the second one is ongoing. A total of 1275 participants were included in this review update. We found one of the studies (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>) by handsearching. We have provided the flow chart for this updated review in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-06-25 10:00:04 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials except two (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>) used the ARDS definition based on the European-American consensus statement as an entry criterion (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No currently included study used the Berlin ARDS definition, as patient enrolment for the most recent study took place from 2003 through 2005 (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>). One trial used the Murray Lung Injury Score &gt; 2.5 (<LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>), and another used oxygenation index (OI) criteria (<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>). Two trials (<LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>) used a definition of ALI that was modified from that used the consensus statement. Two studies were published in abstract form (<LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>). We identified no duplicate reports. In <LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK>, study authors described the 'activity of daily living scale' (ADL) and the 'quality of well being scale' (QWB), hospital costs and resource use, as well as long-term mortality, on the basis of <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>. All studies except one (<LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>) reported mortality. Analyses of the impact of INO on oxygenation were hindered as the result of application of different indicators of oxygenation, different time points for oxygenation measurement and demonstration of therapeutic effects in graphic form without adjacent numerical data in most publications. Investigators inconsistently reported other clinical outcome variables in line with our defined primary and secondary outcomes.</P>
<P>We classified four trials as paediatric trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>); one trial included a few children (<LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>); and the remaining trials consisted of mixed populations of critically ill adults with ALI and ARDS. Sample size varied from 14 to 385 participants with ALI or ARDS (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Intervention duration ranged from less than 24 hours to four weeks. The estimated median length of interventions was seven days. Follow-up ranged from 24 hours to one year. The comparison group received placebo in six trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). Nitrogen was used as placebo, except in one trial, which used air (<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>).</P>
<P>Nine trials applied a fixed dose of INO (median 10 ppm; range 5 to 10 ppm) (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). Four trials used the lowest dose to achieve an oxygenation response (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>), and one trial used different doses of INO (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>). One trial enrolled only INO responders (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>).</P>
<P>In five trials, a few participants allocated to the control group crossed over to INO as rescue therapy after randomization, according to predefined protocols (<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>). In one trial, all randomized participants (in control and INO groups) received INO after 24 hours (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>). Thus, we chose to report only mortality data gathered before this cross-over took place (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>). At the clinician's discretion, nitric oxide treatment was discontinued (<LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>) or was tapered after a pre-specified time period (<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>) or after pre-defined gas exchange endpoints were reached (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>). Only one trial did not provide information on INO discontinuation criteria (<LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>). Investigators applied various co-interventions, such as the recruitment manoeuvre (<LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>), the prone position (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>)) and use of corticosteroids (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>).</P>
<P>Four unblinded trials (<LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>) and one blinded trial used pre-defined protocols for mechanical ventilation (<LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>); three unblinded trials adhered to guidelines (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-06-25 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded nine potentially relevant publications (<LINK REF="STD-Cuthbertson-2000" TYPE="STUDY">Cuthbertson 2000</LINK>; <LINK REF="STD-Johannigman-1997" TYPE="STUDY">Johannigman 1997</LINK>; <LINK REF="STD-Khan-2009" TYPE="STUDY">Khan 2009</LINK>; <LINK REF="STD-Meade-2003" TYPE="STUDY">Meade 2003</LINK>; <LINK REF="STD-Perrin-2006" TYPE="STUDY">Perrin 2006</LINK>; <LINK REF="STD-Puybasset-1994" TYPE="STUDY">Puybasset 1994</LINK>; <LINK REF="STD-Puybasset-1995" TYPE="STUDY">Puybasset 1995</LINK>; <LINK REF="STD-Rossaint--1995" TYPE="STUDY">Rossaint 1995</LINK>; <LINK REF="STD-Tang-1998" TYPE="STUDY">Tang 1998</LINK>;) for reasons detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> section.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified one ongoing study (<LINK REF="STD-Godinez" TYPE="STUDY">Godinez</LINK>). This study was reported to be completed in 2006 but no results have been published so far; for details, see the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> section.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-06-25 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>We classified four trials as having low risk of bias for the main outcome - overall mortality (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). For a more detailed description of individual trial qualities, see the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. We have presented the various bias domains in the 'Risk of bias graph' and a 'Risk of bias summary' figure (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-06-25 10:00:32 +0100" MODIFIED_BY="[Empty name]">
<P>Six trials (43%) adequately reported random sequence generation (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>), whereas seven trials (50%) reported allocation concealment (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-06-25 10:00:40 +0100" MODIFIED_BY="[Empty name]">
<P>Six trials provided sufficient data to be categorized as double-blinded (46%) (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). Remaining trials were open-label studies or did not provide sufficient data on how double-blinding was achieved (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-06-25 10:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>All trials except two provided complete follow-up for the primary outcome (<LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). The <LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK> publication is based on one-year follow-up of the same cohort of participants as were described in <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>, which presented complete follow-up. Study authors reported 90.2% follow-up at one year (<LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK>). In <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>, study authors did not provide data on mortality nor on length of follow-up. Six trials (43%) performed analysis according to the ITT method or provided sufficient data to permit ITT analyses (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>). Additionally, some trials did not provide explicit information on duration of the longest follow-up (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Many of our analyses were subject to limitations because most studies demonstrated therapeutic effects in graphic form, without providing numerical data.</P>
<P>We found one trial on <A HREF="http://Clinical Trial.gov">Clinical Trial.gov</A> (<LINK REF="STD-Godinez" TYPE="STUDY">Godinez</LINK>) and found that no other data had been published yet. We tried to contact study authors without success.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-06-25 10:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>Thirteen trials provided adequate information to be classified as low-risk trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>). Supplementary information was often obtained through online registration, available protocols or clarifying responses to our questions as provided by study authors. One trial did not provide sufficient data on selective reporting (high-risk) (<LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-06-25 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials reported a sample size calculation (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>), but only two were powered to show statistically significant benefit for primary endpoints (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK> was stopped early for slow enrolment (at 45% of calculated sample size), <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK> enrolled only 75% of the planned sample size, for unknown reasons, and <LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK> was terminated prematurely because of slow enrolment (planned 338 participants, enrolled 55 participants).</P>
<P>The funnel plot of standard error versus risk ratio for overall longest follow-up mortality (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) and the funnel plot for 28-day to 30-day mortality (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) showed a symmetrical distribution that indicated no bias or publication bias. As we noted no asymmetry or heterogeneity in the funnel plot, we found no need to apply the arcsine-Thompson test, as proposed by Rücker (<LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK>). Additionally, we found no statistical significance (P value = 0.33) upon applying Egger's regression intercept test.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-06-25 10:16:48 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall mortality (longest follow-up, regardless of the duration of follow-up)</HEADING>
<P>Combining data from the 13 included trials (1243 participants) and applying complete-case analysis revealed no statistically significant effects of INO on longest follow-up mortality: 250/654 deaths (38.2%) in the INO group compared with 221/589 deaths (37.5%) in the control group (RR 1.04, 95% CI 0.9 to 1.19; I² <I>= </I>0%) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We upgraded the outcome from low to moderate quality of evidence because most trials had moderate risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall 28-day mortality (studies reporting mortality as 25 to 30 days were included in the same analysis)</HEADING>
<P>We combined nine trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>) (1105 participants) in the 28-day mortality analysis and obtained the following results: 202/587 deaths (34.4%) in the INO group and 166/518 deaths (32%) in the control group (RR 1.08, 95% CI 0.92 to 1.27; I² = 0%) (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). We upgraded the outcome from low to moderate quality of evidence because most trials had moderate risk of bias.</P>
<P>We carried out a total of five subgroup and sensitivity analyses regarding our primary outcomes. We detected no statistically significant effects in any of these analyses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bleeding events</HEADING>
<P>Data from five trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; 614 participants) show no statistically significant increase in bleeding events in the INO group compared with the control group (RR 0.88, 95% CI 0.43 to 1.79; I² = 0%) (see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). We upgraded the outcome from low to moderate quality of evidence because most trials had moderate risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complications during the in-patient stay</HEADING>
<P>Inhaled nitric oxide increased the risk of renal impairment, according to data from four adult trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>, 945 participants; RR 1.59, 95% CI 1.17 to 2.16; I² = 0%) (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). However, the test of interaction for the RR of renal impairment from trials with low risk of bias (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 765 participants) (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) versus the one trial with high risk of bias (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; 180 participants) (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) did not reach statistical significance (P value = 0.22). We accepted various definitions of renal impairment as proposed by study authors (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We upgraded this outcome from moderate to high quality of evidence because most trials had low risk of bias.</P>
<P>One trial (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>) involving 180 participants revealed that the rate of respiratory failure decreased in the INO group (RR 0.21, 95% CI 0.05 to 0.94) (see <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>). One trial (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>) involving 180 participants provided data on reversal of ALI, showing no statistically beneficial effects of INO (RR 1.13, 95% CI 0.88 to 1.46). No trial provided data on reversal of ARDS (see <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>). The quality of evidence was moderate.</P>
<P>Other adverse events were variably reported, and events such as pneumothorax (see <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), circulatory failure and shock (see <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>), pneumonia, sepsis, encephalopathy, myocardial infarction, liver impairment, myopathy, agitation and hypertension (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) did not reach statistical significance. The quality of evidence was high for pneumothorax and circulatory failure but was moderate for the other adverse events.</P>
<P>Only one trial (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 385 participants) provided data indicating increased risk of infection in the INO group (RR 1.62, 95% CI 1.16 to 2.26; I² = 0) (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PaO<SUB>2</SUB>/FiO<SUB>2 </SUB>ratio</HEADING>
<P>Eleven trials (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK> ; 614 participants) indicated an improved PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio at 24 hours (MD 15.91, 95% CI 8.25 to 23.56; I² = 25%) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). An additional analysis of PaO<SUB>2</SUB>/FiO<SUB>2</SUB> difference from baseline at 24 hours, based on data from three trials (<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>; 155 participants), revealed a similar finding (MD 42.90, 95% CI 20.57 to 65.23; I² = 58%) (see <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). The PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio at 48 and 72 hours no longer showed a statistically significant beneficial effect (see <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>), but the analysis at 96 hours, based on four trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; 334 participants), showed improved oxygenation in the INO group (MD 14.51, 95% CI 3.64 to 25.38; I² = 0%) (see <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). We upgraded the outcome from low to moderate quality of evidence because most trials had moderate risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ventilator-free days</HEADING>
<P>Data from five trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>; 804 participants) show no statistically significant effect of INO on ventilator-free days up to day 28 or 30 (MD -0.57, 95% CI -1.82 to 0.69; I² = 0%) (see <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). We upgraded the outcome from moderate to high quality of evidence because most trials had low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of mechanical ventilation</HEADING>
<P>Six trials (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>; 390 participants) reported no effects of INO on duration of mechanical ventilation (MD 1.02, 95% CI -2.08 to 4.12; I² = 76%) (see <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). The quality of evidence was moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oxygenation index</HEADING>
<P>Five studies (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; 368 patients) reported that the oxygenation index was significantly lower in the INO group at 24 hours (MD -2.31, 95% CI -2.73 to -1.89; I² = 0%). Two studies (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; 183 participants) noted no statistically significant differences at 48 hours (MD 1.99, 95% CI -10.40 to 14.38; I² = 74%) but <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK> and <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK> (245 participants) reported statistically significant differences at 72 hours (MD -3.48, 95% CI -6.80 to -0.15; I² = 0%) (see <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>; <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>; <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). We upgraded the outcome from low to moderate quality of evidence because most trials had moderate risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mean pulmonary arterial pressure (mm Hg)</HEADING>
<P>Differences in mean pulmonary arterial pressure were significant at day one (MD -1.76, 95% CI -3.41 to -0.12; I² = 1%) but were no longer significant on days two, three and four (see <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>; <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>; 1275 participants). The quality of evidence was moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Methaemoglobin &gt; 5%</HEADING>
<P>All trials assessed methaemoglobin concentrations (1275 participants). Four participants in the INO group and three in the control group had methaemoglobin values &gt; 5% (RR 0.88, 95% CI 0.20 to 3.79; I² = 0%) (see <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>). The quality of evidence was moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NO<SUB>2</SUB> concentration &gt; 3 ppm</HEADING>
<P>Seven trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 959 participants) reported data on nitrogen dioxide, but only one trial reported three of 385 participants with raised concentrations; all had received 80 ppm INO (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Resolution of multi-organ failure (according to different organ dysfunction scores)</HEADING>
<P>Only one trial (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 385 participants) met our requirements in terms of trial intervention effects on resolution of multi-organ failure based on various illness scores, with no statistically beneficial effects reported (TISS score) (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life assessment</HEADING>
<P>One trial assessed quality of life (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 385 participants) using the 'activities of daily living scale' (ADL) and the 'quality of well being scale' (QWB). Neither assessment supported intervention with INO. The ADL score at six months and at one year did not indicate an improvement (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>), and the QWB of survivors at six months and at one year showed similar improvements in INO and control groups, with slightly better scores in the control group, although this finding was not statistically significant (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of stay in intensive care unit and in hospital</HEADING>
<P>Length of stay in ICU and in hospital was provided by only one trial (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 385 participants), which did not indicate reduced stay in ICU or hospital (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cost-benefit analyses</HEADING>
<P>Only one trial (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; 385 participants) provided data for cost-benefit analysis.. Study authors described similar hospital costs in the INO group (48,500 USD) and in the control group (47,800 USD; P value = 0.8) (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). The quality of evidence was high.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity and subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>Sensitivity analysis excluding data from articles published as abstracts did not change overall results regarding significance (see <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Benefits and harms of INO in participants with ALI or ARDS based on the cause (primary lung injury vs secondary lung injury)</HEADING>
<P>Only one trial provided data for analysis of mortality based on origin of the lesion (primary vs secondary lung injury) without showing statistical significance (<LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>) (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Benefits and harms of INO in paediatrics (paediatric participants (age &lt; 18 years) vs adult participants)</HEADING>
<P>Three paediatric trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>) with a total of 185 participants showed no statistically significant beneficial effects of INO (RR 0.78, 95% CI 0.51 to 1.18; I² = 22%), nor did the adult population subgroup (RR 1.08, 95% CI 0.93 to 1.25; I² = 0%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The quality of evidence was moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Benefits and harms of INO based on duration of drug administration (short-term vs long-term administration)</HEADING>
<P>A total of 12 trials (<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>) with a total of 1190 participants had a median duration of intervention longer than one week (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Current evidence does not support a longer duration of intervention (RR 1.07, 95% CI 0.89 to 1.29; I² = 0%) nor a shorter duration of intervention (RR 1.04, 95% CI 0.84 to 1.29; I² = 0%). We did not conduct a subgroup analysis to assess the effects of different INO dosages as no evidence appears to support this and many reported trials did not use a fixed dose of INO but applied dose titration (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>; <LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Definition of respiratory failure</HEADING>
<P>Studies designed before 2012 used the AECC definition (<LINK REF="REF-Bernard-1994" TYPE="REFERENCE">Bernard 1994</LINK>) of acute respiratory distress syndrome, whereas more recent studies use the 2012 definitions (<LINK REF="REF-ARDS-Definition-Task-Force-2012" TYPE="REFERENCE">ARDS Definition Task Force 2012</LINK>). Sensitivity analysis performed to examine the role of inclusion by AECC criteria did not alter the overall result (see <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bias assessment</HEADING>
<P>Comparison of estimates of the pooled intervention effect based on random sequence generation, allocation concealment, blinding, follow-up, sample size calculation, early stopping and overall risk of bias revealed no statistically significant findings in any of the subgroups examined (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). We identified four trials with low risk of bias (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>), which showed no statistically significant findings for our primary endpoint.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial sequential analysis (TSA)</HEADING>
<P>We conducted trial sequential analysis (TSA) of INO versus control to examine longest follow-up mortality (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The TSA alfa-spending-adjusted confidence interval for meta-analysis of the primary outcome with continuity correction for zero event trials (0.001 event in each arm) in a fixed-effect model resulted in an RR of 1.04 (95% CI 0.87 to 1.23; I² = 0%, diversity D² = 0%). However, for trials with low risk of bias, the TSA-adjusted RR was 1.02 with 95% CI of 0.79 to 1.33 (I² = 0%, diversity D² = 0%). With an accrued information size of 1243 participants (for all trials) and no boundaries crossed so far, only 41.92% of the required information size is actually available at this stage for rejection or acceptance of a 4% relative risk increase for overall mortality. However, solid evidence may be obtained with fewer participants if eventually the cumulative meta-analysis z-curve crosses the trial sequential monitoring boundary constructed for a required information size of 3015 randomized participants. However, when the TSA analysis for this outcome is examined, it is important to bear in mind that only four out of the 14 included studies are classified as trials with low risk of bias. Therefore, TSA is not able to directly adjust for the impact of bias.</P>
<P>Application of TSA to analysis of the PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio at 24 hours did indicate statistical significance in favour of improved oxygenation, even with adjustment for repetitive testing of accumulating data in the cumulative meta-analysis, as the z-curve crossed the trial sequential monitoring boundary (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The a priori information size (335 participants) is determined by a TSA alfa-spending-adjusted mean difference (MD) of 15.91. The cumulative z-curve (blue line with filled squares) at the current accrued information size of 614 participants crosses the boundary (red lines with open diamonds) (with 80% power and alpha 0.05, assuming a double-sided type 1 risk of 5% and type 2 risk of 20%). However, it is important to note that only two trials were at low risk of bias, and the TSA alfa-spending-adjusted confidence interval for the meta-analysis in a random-effects model results in an MD of 15.91 with substantial heterogeneity and diversity (95% CI 9.67 to 22.15; I² = 25%, diversity D² = 49%). However, the required information size based on the two trials (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; 276 participants) with low risk of bias is 5137 participants (MD 14.94, TSA-adjusted 95% CI -73.70 to -103.58; I² = 87%, diversity D² = 91%).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-06-25 10:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>In this systematic review of 14 trials with 1275 participants with acute hypoxaemic respiratory failure (AHRF), we found no benefits of inhaled nitric oxide (INO) for survival. The analysis on mortality showed no heterogeneity and was robust when different subgroup and sensitivity analyses were performed. Conversely, INO increased the risk of renal failure among an adult population and transiently improved oxygenation, only for the first 24 hours. Sparse data on mortality are not promising but do not provide evidence of the absence of a beneficial effect; the data suggest that a potentially beneficial effect of INO must be modest, and the actual point estimate suggests harm (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In addition, our mortality analysis on the longest follow-up may have been influenced by the fact that only one trial (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>) provided long-term follow-up for more than six months (<LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK>).</P>
<P>The point estimate of the potential intervention effect, as suggested by low-bias trials, shows a 2% relative risk increase (RRI) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). To demonstrate or reject an a priori anticipated beneficial effect on mortality in a single trial, assuming a relative risk reduction (RRR) of 10%, at least 3015 participants should be randomized (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) (with 80% power and alpha 0.05, assuming a double-sided type 1 risk of 5% and type 2 risk of 20%). However, solid evidence may be obtained with fewer participants if the RRR is higher than 10%, that is, if the cumulative meta-analysis z-curve crosses the trial sequential monitoring boundary before the required information size of 3015 randomized participants is reached.</P>
<P>We found no statistically significant differences when examining effects in subgroups according to duration of the intervention, looking at interventions among different populations (paediatric, adult) and performing sensitivity analyses, which excluded trials published only as abstracts. The three paediatric trials (<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>) that provided information on mortality had a combined total of 185 participants, which is insufficient to demonstrate any benefits or harms of INO therapy in paediatric acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).</P>
<P>Subgroup and sensitivity analyses assessing the impact of varied primary origins, reversal of ALI resolution of multi-organ failure and assessments of quality of life and bias did not result in statistically significant findings. Additional analyses, such as those involving adverse events, indicated increased risk of renal failure among adults with no signs of increased risk of bleeding, methaemoglobinaemia or increased nitrogen dioxide concentration, except possibly among participants receiving INO doses greater than 80 ppm. Outcomes such as duration of stay in both ICU and hospital and other clinically relevant outcomes were inconsistently reported. We did not perform a subgroup analysis of reversal of ARDS, as insufficient data were provided. We contacted study authors to request missing data. Few responded, and they did not provide much additional information beyond that originally published.</P>
<P>Despite evidence of initial but transient improved oxygenation in the INO group, these analyses were hampered by the fact that various trials described effects on oxygenation differently, thus preventing adequate pooling of data. Even though a beneficial effect may be noted, oxygenation may be only a surrogate outcome, and it is uncertain whether it predicts any clinical benefits. Additionally, many trials were conducted before the general recommendation of a lung protective, low tidal volume ventilation strategy was introduced (<LINK REF="REF-Petrucci-2013" TYPE="REFERENCE">Petrucci 2013</LINK>). The latter combined with oxygen toxicity, surfactant inhibition and ongoing fibrosis resulting from ARDS may have influenced the results of these trials. However, given that no differences in the mode of ventilation were noted between INO and control groups, this should not account for our findings of lack of benefit for survival and potential harm.</P>
<P>We suggest several possible explanations for why INO may not be beneficial. By reducing ventilation-perfusion mismatch in patients with ARDS, INO appears to initially improve oxygenation. However, theoretically, INO could worsen the clinical condition by reversing hypoxic pulmonary vasoconstriction, thereby causing vasodilatation of poorly ventilated areas, increasing the ventilation-perfusion mismatch and resulting in worsening oxygenation (<LINK REF="REF-Kass-1998" TYPE="REFERENCE">Kass 1998</LINK>). However, we found little evidence to support the latter based on both published data and our respiratory analyses (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>) (see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>Additonally, prolonged exposure to INO and its toxic metabolites could cause sensitization, over-riding the possible benefits of INO (<LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>). Improved oxygenation is not associated with increased survival because improved oxygenation does not necessarily indicate improved lung function, reduction of lung injury or resolution of the underlying cause of ARDS and often co-existing multi-organ failure (<LINK REF="REF-ARDS-network-2000" TYPE="REFERENCE">ARDS network 2000</LINK>; <LINK REF="REF-Petrucci-2013" TYPE="REFERENCE">Petrucci 2013</LINK>). Nitric oxide (NO) is an important regulator of renal vascular tone and a modulator of glomerular function. At the same time, it has been suggested that changes in NO production could cause acute renal failure by altering the function of mitochondria, various enzymes, deoxyribonucleic acid and membranes (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>; <LINK REF="REF-Valdivielso-2002" TYPE="REFERENCE">Valdivielso 2002</LINK>). The latter suggestion is consistent with our finding of a possible harmful effect of INO on renal function.</P>
<SUMMARY_OF_RESULTS MODIFIED="2016-06-25 10:18:37 +0100" MODIFIED_BY="[Empty name]">
<P>Our systematic review showed that INO, despite transiently improving oxygenation, partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>)/fraction of inspired oxygen (FiO<SUB>2</SUB>) and the oxygenation index, and despite providing signs of reducing the rate of severe respiratory failure, does not reduce mortality or length of stay in ICU or hospital. Conversely, it appears that INO results in impairment of renal function among adults. We conducted multiple subgroup and sensitivity analyses, and none indicated relevant benefits of INO. We classified only four trials as having low risk of bias. Current evidence does not support the routine use of INO for severe respiratory failure.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-06-25 10:18:48 +0100" MODIFIED_BY="[Empty name]">
<P>The overall quantity of data on which robust conclusions can be based is limited to 14 trials with 1275 participants. Evidence indicating that INO was not beneficial for patients with acute respiratory failure is of moderate to high quality. The definition of acute respiratory failure was usually that provided by the American-European Consensus Conference (AECC) in 1994 (<LINK REF="REF-Bernard-1994" TYPE="REFERENCE">Bernard 1994</LINK>), which allows for appropriate comparison between trials. Primary outcomes of mortality were generally well reported, and secondary outcomes were often reported as well.</P>
<P>Therefore, despite the limited number of studies and participants identified, available evidence seems to be applicable to intensive care patients.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-06-25 10:18:59 +0100" MODIFIED_BY="[Empty name]">
<P>The randomized controlled trial (RCT) is considered the most rigorous method of determining whether a cause-effect relationship exists between an intervention and an outcome. The strength of the RCT lies in the process of randomization.</P>
<P>The quality of findings ranks from moderate to high across different outcomes. The main limiting factors that accounted for a decrease in quality included high risk of bias and small and poorly described trials.</P>
<P>Four trials were reported as having low risk of bias (<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>). We applied several statistical methods to explore and reduce the extent of bias, such as complete case analysis, trial sequential analysis, overall methodological bias assessment and analyses of various relevant clinical and physiological outcomes.</P>
<P>Application of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) approach enables us to incorporate risk of bias, directness of evidence, heterogeneity, precision of effect estimate and risk of publication bias. On the basis of the criteria mentioned above, we deemed the quality of evidence in this review to be moderate to high.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-06-25 10:19:38 +0100" MODIFIED_BY="[Empty name]">
<P>Upon reading the systematic review (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>) and acknowledging that very few trials had been published subsequently, we became aware of some of the conclusions that we would reach. Addtitionally, we realized that retrieving data from the authors of included trials relatively close to the latest systematic review could be difficult because providing additional data is a time-consuming process for trial authors. This has been the case.</P>
<P>Our systematic review has several potential limitations, that is, our findings and interpretations are limited by the quality and quantity of available evidence. We assessed the risk of bias of included trials mainly by using published data, which ultimately may not reflect the truth. We contacted all study authors, but only a few responded and provided further information. We were not able to retrieve protocols of the published trials and thus could not compare published outcomes versus outcomes proposed in the protocols. The value of these analyses is limited by the fact that only a small number of trials contributed to our subgroup and sensitivity analyses. Further, two trials with 51 participants did not report mortality during the trial (<LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>).</P>
<P>We noted variation in participant populations; type, dose and duration of INO treatment; and length of follow-up, along with consistent lack of improved survival across trials; we found the most beneficial effect among the subgroup of trials with high risk of bias, although these findings did not reach statistical significance (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). This minimizes the possibility that some subgroups of patients may benefit from INO. No trial has used short-term INO among the subgroup of patients with critically low oxygenation to buy valuable time to instigate other treatments to improve lung function, and this issue remains controversial.</P>
<P>Although we noted minimal heterogeneity among trial results on mortality, we are aware that we pooled heterogeneous trials in terms of age, participants, settings and treatment regimens. Thus, the validity of our meta-analysis may be criticized. However, all trials included patients with acute respiratory failure with similar inflammatory pathways, providing in our opinion good biological reasons to perform a broad meta-analysis, which also considerably increases the generalizability and usefulness of the review. Further, a broad meta-analysis increases power, reduces the risk of erroneous conclusions and facilitates exploratory analyses that can generate hypotheses for future research (<LINK REF="REF-Gotzsche-2000" TYPE="REFERENCE">Gotzsche 2000</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-06-25 10:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>In general, our review presents the same conclusions as were provided by Adhikari et al (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>) and by authors of previous versions of this Cochrane review. However, we included more trials and thus were able to determine more precise estimates of mortality. Furthermore, we applied several sensitivity and subgroup analyses, trial sequential analysis and GRADE, which supported the overall results. It is important to note that Dr. Neill Adhikari has provided us with valuable data on physiological and clinical outcomes, such as PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, oxygenation index, mean pulmonary arterial pressure, duration of mechanical ventilation and number of ventilator-free days up to 30 days, on behalf of several authors of included trials.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-06-25 10:20:31 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-06-25 10:20:21 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence is insufficient to support the use of INO in patients with any category of ARDS and ALI. Despite signs of improved oxygenation, we did not find a statistically significant effect of INO on mortality or other clinical outcomes. Additionally, INO appeared to increase the risk of renal failure. Subgroup analyses performed according to duration of intervention, length of follow-up and different patient groups did not show differences in the estimates of intervention effects. In terms of the paediatric population, data are insufficient to support or refute the routine use of INO. Therefore, it is important to emphasize that no evidence from randomized trials is available to support application of INO in the clinical setting among children or adults.</P>
<P>The GRADE approach only reaffirmed our interpretation of the level of evidence, and we are confident that at this stage, the quality of evidence related to our outcomes is moderate to high, despite the fact that many trials have some risk of bias.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-25 10:20:31 +0100" MODIFIED_BY="[Empty name]">
<P>Large randomized trials with low risk of bias with a sample size of up to several thousand participants are needed to evaluate INO for adults and children before this intervention can be definitively rejected or accepted for critically ill patients with ALI and ARDS. However, current results are not promising, and the potential for benefit seems modest, with the actual point estimate of the intervention effect on mortality suggesting harm. Despite the heterogeneity that might exist in the patient population of included trials, and despite the high mortality rate among patients with ARDS and ALI, we believe that INO should be used as only one part of randomized clinical trials. Additional trials need to focus on other relevant outcomes, such as long-term survival, duration of stay in the intensive care unit and hospital, number of ventilator-free days and assessment of quality of life.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-06-25 10:29:57 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Harald Herkner (Content Editor), Jing Xie (Statistical Editor), Marjolein de Wit (Peer Reviewer) for help and editorial advice provided during preparation of this systematic review update.</P>
<P>We would like to acknowledge the work of Drs. Sokol, Jacobs and Bohn on the original review (<LINK REF="REF-Sokol-2003a" TYPE="REFERENCE">Sokol 2003a</LINK>).</P>
<P>We would like to thank Karen Hovhannisyan for assistance in devising our different search strategies, gathering search results and facilitating contact with various study authors. We would like to thank Jane Cracknell for extensive support provided throughout the editorial process, as well as Dolores Matthews for the copy-editing. We send special thanks to Dr. Neill Adhikari for valuable data on INO treatment from various trials and on various outcomes on behalf of several lead authors of included studies. Additionally, we would like to thank Dr. R Scott Watson and Dr. Peter Dahlem for their peer review contributions and constructive criticism. Finally, special thanks to Dr. Harald Herkner and Dr. Nathan L Pace for their great editorial criticism and assistance, which enabled us to improve the overall quality of this paper.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-06-27 11:19:24 +0100" MODIFIED_BY="Jane Cracknell">
<P>Fabienne Gebistorf: none.</P>
<P>Oliver Karam: none.</P>
<P>Jørn Wetterslev is a member of the Copenhagen Trial Unit (CTU) task force. The CTU develop the theory and software for Trial Sequential Analysis (TSA) which is available free of charge at: <A HREF="http://www.ctu/tsa">www.ctu/tsa</A>.</P>
<P>Arash Afshari: none.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-06-25 10:37:02 +0100" MODIFIED_BY="[Empty name]">
<P>Fabienne Gebistorf (FG), Oliver Karam (OK), Jørn Wetterslev (JW), Arash Afshari (AA).</P>
<P>Conceiving of the review: AA, JW.<BR/>Co-ordinating the review: AA.<BR/>Undertaking manual searches: AA.<BR/>Screening search results: AA, FG, OK.<BR/>Organizing retrieval of papers: AA.<BR/>Screening retrieved papers against inclusion criteria: AA, FG, OK.<BR/>Appraising the quality of papers: AA, FG, OK.<BR/>Abstracting data from papers: AA, FG, OK.<BR/>Writing to authors of papers to ask for additional information: AA, OK.<BR/>Providing additional data about papers: AA.<BR/>Obtaining and screening data from unpublished studies: AA, FG, OK.<BR/>Managing data for the review: AA, JW, FG, OK.<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-5.3.5" TYPE="REFERENCE">RevMan 5.3.5</LINK>): AA, JW, FG, OK.<BR/>Analysing RevMan statistical data: JW, AA, FG, OK.<BR/>Performing other statistical analysis not using RevMan: JW, AA.<BR/>Performing double entry of data: data entered by person one: AA; data entered by person two: OK.<BR/>Interpreting data: AA, JW, FG, OK.<BR/>Performing statistical analysis: JW, AA, FG, OK.<BR/>Writing the review: AA, JW, FG, OK.</P>
<P>
<BR/>Performing previous work that was the foundation of the present study: Dr. Sokol, AA.<BR/>Serving as guarantor for the review (one review author): AA.<BR/>Taking responsibility for reading and checking the review before submission: OK.</P>
<P>Defining abbreviations (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>): FG, AA, OK.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-06-27 11:28:21 +0100" MODIFIED_BY="Jane Cracknell">
<P>2016</P>
<P>Title of the review changed. Acute lung injury is no longer mentioned in the title of the review. This is because as the <LINK TAG="CONDITION" TYPE="SECTION">Description of the condition</LINK> section states, acute lung injury no longer exists and has instead been replaced by a gradation of ARDS that is based on the severity of hypoxaemia; the title of the updated review reflects this change.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-06-27 21:07:08 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-01-05 14:05:49 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2016-06-25 10:58:59 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-06-25 10:58:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Bronicki-2015" MODIFIED="2016-03-04 14:02:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bronicki 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-03-04 14:02:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronicki RA, Fortenberry J, Schreiber, M, Checchia PA, Anas NG</AU>
<TI>Multicenter randomized controlled trial of inhaled nitric oxide for pediatric acute respiratory distress syndrome</TI>
<SO>The Journal of Pediatrics</SO>
<YR>2015</YR>
<VL>66</VL>
<NO>2</NO>
<PG>365-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-12-18 08:41:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-1997" MODIFIED="2010-03-17 11:10:01 +0000" MODIFIED_BY="Jane Cracknell" NAME="Day 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-16 11:00:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Day RW, Allen EM, Witte MK</AU>
<TI>A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>5</NO>
<PG>1324-31</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:07:40 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227911"/><IDENTIFIER MODIFIED="2010-03-15 12:07:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9367476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-17 11:10:01 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellinger-1998" MODIFIED="2010-03-15 12:12:13 +0000" MODIFIED_BY="Jane Cracknell" NAME="Dellinger 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-15 12:12:13 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al</AU>
<TI>Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group</TI>
<SO>Critical Care Medicine</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>1</NO>
<PG>15-23</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:12:12 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227913"/><IDENTIFIER MODIFIED="2010-03-15 12:12:12 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="PMID: 9428538"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobyns-1999" MODIFIED="2016-03-04 14:03:44 +0000" MODIFIED_BY="[Empty name]" NAME="Dobyns 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-15 12:12:12 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, et al</AU>
<TI>Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>11</NO>
<PG>2425-9</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:09:13 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227915"/><IDENTIFIER MODIFIED="2010-03-15 12:09:13 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12441749"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-04 14:03:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, et al</AU>
<TI>Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>134</VL>
<NO>4</NO>
<PG>406-12</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:11:41 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227916"/><IDENTIFIER MODIFIED="2010-03-15 12:11:41 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10190913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227914"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-2003" MODIFIED="2010-03-16 11:01:03 +0000" MODIFIED_BY="[Empty name]" NAME="Gerlach 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-16 11:01:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach H, Keh D, Semmerow A, Busch T, Lewandowski K, Pappert DM, et al</AU>
<TI>Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>7</NO>
<PG>1008-15</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:13:22 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227918"/><IDENTIFIER MODIFIED="2010-03-15 12:13:22 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12663340"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227917"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibrahim-2007" MODIFIED="2016-06-25 10:58:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ibrahim 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-06-25 10:58:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibrahim TS, El-Mohamady HS</AU>
<TI>Inhaled nitric oxide and prone position: how far they can improve oxygenation in pediatric patients with acute respiratory distress syndrome?</TI>
<SO>Journal of Medical Science</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>390-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227920"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227919"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundin-1999" MODIFIED="2010-05-29 16:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lundin 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-29 16:02:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C</AU>
<TI>Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide</TI>
<SO>Intensive Care Medicine</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>9</NO>
<PG>911-9</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:15:35 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227922"/><IDENTIFIER MODIFIED="2010-03-15 12:15:35 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10501745"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehta-2001" MODIFIED="2009-06-29 13:25:23 +0100" MODIFIED_BY="[Empty name]" NAME="Mehta 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-06-29 13:25:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehta S, Simms HH, Levy MM, Hill NS, Schwartz W, Nelson D, et al</AU>
<TI>Inhaled nitric oxide improves oxygenation acutely but not chronically in acute respiratory distress syndrome: a randomized, controlled trial</TI>
<SO>Journal of Applied Research in Clinical and Experimental Therapeutics</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>73-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227924"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227923"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michael-1998" MODIFIED="2010-03-15 12:50:40 +0000" MODIFIED_BY="Jane Cracknell" NAME="Michael 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-15 12:50:40 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, et al</AU>
<TI>Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>5 Pt 1</NO>
<PG>1372-80</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:50:40 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227926"/><IDENTIFIER MODIFIED="2010-03-15 12:50:40 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9603111"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227925"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2003" MODIFIED="2010-03-15 12:51:03 +0000" MODIFIED_BY="Jane Cracknell" NAME="Park 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-15 12:51:03 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park KJ, Lee YJ, Oh YJ, Lee KS, Sheen SS, Hwang SC</AU>
<TI>Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome</TI>
<SO>Yonsei Medical Journal</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>2</NO>
<PG>219-26</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:51:03 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227928"/><IDENTIFIER MODIFIED="2010-03-15 12:51:03 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 12728461"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227927"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payen-1999" MODIFIED="2010-05-29 16:03:32 +0100" MODIFIED_BY="[Empty name]" NAME="Payen 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-29 16:03:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payen D, Vallet B, Group d'étude du NO dans l'ARDS</AU>
<TI>Results of the French prospective multicentric randomized double-blind placebo-controlled trial on inhaled nitric oxide (NO) in ARDS [abstract]</TI>
<SO>Intensive Care Medicine</SO>
<YR>1999</YR>
<VL>25 Suppl 1</VL>
<PG>166</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227929"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwebel-1997" MODIFIED="2010-05-29 16:04:01 +0100" MODIFIED_BY="[Empty name]" NAME="Schwebel 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-29 16:04:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwebel C, Beuret P, Perdrix JP, Jospe R, Duperret S, Fogliani J, et al</AU>
<TI>Early inhaled nitric oxide inhalation in acute lung injury: results of a double-blind randomized study [abstract]</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23 Suppl 1</VL>
<PG>2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227932"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-2004" MODIFIED="2016-06-25 10:58:59 +0100" MODIFIED_BY="[Empty name]" NAME="Taylor 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-06-25 10:58:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, et al</AU>
<TI>Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>12</NO>
<PG>2883-90</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:56:30 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227934"/><IDENTIFIER MODIFIED="2010-03-15 12:56:30 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17075373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-15 12:56:53 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, et al</AU>
<TI>Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>13</NO>
<PG>1603-9</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:56:53 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227935"/><IDENTIFIER MODIFIED="2010-03-15 12:56:53 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15069048"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227933"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Troncy-1998" MODIFIED="2010-03-15 12:57:34 +0000" MODIFIED_BY="Jane Cracknell" NAME="Troncy 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-15 12:57:34 +0000" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, et al</AU>
<TI>Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>5 Pt 1</NO>
<PG>1483-8</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:57:34 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227937"/><IDENTIFIER MODIFIED="2010-03-15 12:57:34 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9603127"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227936"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-02-04 12:44:14 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY DATA_SOURCE="PUB" ID="STD-Cuthbertson-2000" MODIFIED="2016-01-20 13:56:49 +0000" MODIFIED_BY="[Empty name]" NAME="Cuthbertson 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-01-20 13:56:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuthbertson BH, Galley HF, Webster NR</AU>
<TI>Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>1736-41</PG>
<IDENTIFIERS MODIFIED="2015-09-28 02:10:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227939"/><IDENTIFIER MODIFIED="2015-09-28 02:10:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10890611"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-09-28 02:11:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227938"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johannigman-1997" MODIFIED="2010-03-16 11:02:17 +0000" MODIFIED_BY="[Empty name]" NAME="Johannigman 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-16 11:02:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johannigman JA, Davis K, Campbell RS, Luchette F, Hurst JM, Branson RD</AU>
<TI>Inhaled nitric oxide in acute respiratory distress syndrome</TI>
<SO>The Journal of Trauma</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>6</NO>
<PG>904-10</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:58:00 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227941"/><IDENTIFIER MODIFIED="2010-03-15 12:58:00 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9420103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227940"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2009" MODIFIED="2010-05-29 16:06:01 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-29 16:06:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, et al</AU>
<TI>A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2009</YR>
<VL>138</VL>
<NO>6</NO>
<PG>1417-24</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:59:16 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227943"/><IDENTIFIER MODIFIED="2010-03-15 12:59:16 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19931670"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227942"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meade-2003" MODIFIED="2010-03-16 11:02:05 +0000" MODIFIED_BY="[Empty name]" NAME="Meade 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-16 11:02:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meade MO, Granton JT, Matte-Martyn A, McRae K, Weaver B, Cripps P, et al</AU>
<TI>A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>11</NO>
<PG>1483-9</PG>
<IDENTIFIERS MODIFIED="2010-03-15 12:59:50 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227945"/><IDENTIFIER MODIFIED="2010-03-15 12:59:50 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12770854"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-07-18 10:42:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227944"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrin-2006" MODIFIED="2010-03-16 11:01:49 +0000" MODIFIED_BY="[Empty name]" NAME="Perrin 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-16 11:01:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrin G, Roch A, Michelet P, Reynaud-Gaubert M, Thomas P, Doddoli C, et al</AU>
<TI>Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>4</NO>
<PG>1024-30</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:00:08 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227947"/><IDENTIFIER MODIFIED="2010-03-15 13:00:08 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16608953"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227946"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puybasset-1994" MODIFIED="2010-05-29 16:06:33 +0100" MODIFIED_BY="[Empty name]" NAME="Puybasset 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-29 16:06:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puybasset L, Rouby JJ, Mourgeon E, Stewart TE, Cluzel P, Arthoud M, et al</AU>
<TI>Inhaled nitric oxide in acute respiratory failure: dose-response curves</TI>
<SO>Intensive Care Medicine</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>5</NO>
<PG>319-27</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:00:27 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227949"/><IDENTIFIER MODIFIED="2010-03-15 13:00:27 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 7930025"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227948"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puybasset-1995" MODIFIED="2010-05-17 16:33:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Puybasset 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-17 16:33:41 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puybasset L, Rouby JJ, Mourgeon E, Cluzel P, Souhil Z, Law-Koune JD, et al</AU>
<TI>Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>1</NO>
<PG>318-28</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:00:44 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227951"/><IDENTIFIER MODIFIED="2010-03-15 13:00:44 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7599840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227950"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossaint--1995" MODIFIED="2010-03-16 11:01:41 +0000" MODIFIED_BY="[Empty name]" NAME="Rossaint  1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-16 11:01:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossaint R, Slama K, Gerlach H, Pappert D, Veit S, Falke K</AU>
<TI>Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome</TI>
<SO>Intensive Care Medicine</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>3</NO>
<PG>197-203</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:00:59 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227953"/><IDENTIFIER MODIFIED="2010-03-15 13:00:59 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7790604"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-1998" MODIFIED="2010-03-16 11:01:32 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-16 11:01:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang SF, Sherwood MC, Miller OI</AU>
<TI>Randomised trial of three doses of inhaled nitric oxide in acute respiratory distress syndrome</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>5</NO>
<PG>415-8</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:01:17 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3227955"/><IDENTIFIER MODIFIED="2010-03-15 13:01:17 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10193254"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227954"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-09-28 02:29:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Godinez" MODIFIED="2015-09-28 02:29:02 +0100" MODIFIED_BY="[Empty name]" NAME="Godinez" YEAR="">
<IDENTIFIERS MODIFIED="2015-09-28 02:29:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3227956"/><IDENTIFIER MODIFIED="2015-09-28 02:29:02 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="Nitric Oxide Administration For Acute Respiratory Distress Syndrome"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-01-05 13:55:04 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2016-06-25 11:02:26 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adhikari-2007" MODIFIED="2009-09-21 10:25:01 +0100" MODIFIED_BY="Jane Cracknell" NAME="Adhikari 2007" TYPE="JOURNAL_ARTICLE">
<AU>Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO</AU>
<TI>Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>7597</NO>
<PG>779</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:25:01 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:25:01 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17383982"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-2003" MODIFIED="2010-03-15 13:02:38 +0000" MODIFIED_BY="Jane Cracknell" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:02:38 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-03-15 13:02:38 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12543843"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2003" MODIFIED="2009-09-23 19:58:58 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Anderson MR</AU>
<TI>Update on pediatric acute respiratory distress syndrome</TI>
<SO>Respiratory Care</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>3</NO>
<PG>261-76</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:25:55 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:25:55 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12667276"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Angus-2006" MODIFIED="2016-06-25 10:59:08 +0100" MODIFIED_BY="[Empty name]" NAME="Angus 2006" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, et al</AU>
<TI>Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide</TI>
<SO>Critical Care Medicine</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>12</NO>
<PG>2883-90</PG>
<IDENTIFIERS MODIFIED="2010-03-15 13:02:57 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-03-15 13:02:57 +0000" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17075373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ARDS-Definition-Task-Force-2012" MODIFIED="2016-06-25 10:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="ARDS Definition Task Force 2012" TYPE="JOURNAL_ARTICLE">
<AU>The ARDS Definition Task Force</AU>
<TI>Acute respiratory distress syndrome - the Berlin definition</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>307</VL>
<NO>23</NO>
<PG>2526-33</PG>
<IDENTIFIERS MODIFIED="2015-12-18 08:14:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-12-18 08:14:11 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22797452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ARDS-network-2000" MODIFIED="2009-09-23 19:59:51 +0100" MODIFIED_BY="[Empty name]" NAME="ARDS network 2000" TYPE="JOURNAL_ARTICLE">
<AU>The Acute Respiratory Distress Syndrome Network</AU>
<TI>Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>18</NO>
<PG>1301-8</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:26:36 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:26:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10793162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barrington-2007" MODIFIED="2016-01-21 09:53:46 +0000" MODIFIED_BY="[Empty name]" NAME="Barrington 2007" TYPE="COCHRANE_REVIEW">
<AU>Barrington KJ, Finer NN</AU>
<TI>Inhaled nitric oxide for respiratory failure in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-01-21 09:53:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-21 09:53:46 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000509.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beckman-1990" MODIFIED="2009-09-23 20:03:02 +0100" MODIFIED_BY="[Empty name]" NAME="Beckman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA</AU>
<TI>Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1990</YR>
<VL>87</VL>
<NO>4</NO>
<PG>1620-4</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:28:24 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:28:24 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="2154753"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bernard-1994" MODIFIED="2009-09-23 20:03:22 +0100" MODIFIED_BY="[Empty name]" NAME="Bernard 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al</AU>
<TI>The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<NO>3 Pt 1</NO>
<PG>818-24</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:29:33 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:29:33 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7509706"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2016-06-25 10:59:32 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:30:36 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:30:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18824466"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Calfee-2007" MODIFIED="2016-06-25 10:59:43 +0100" MODIFIED_BY="[Empty name]" NAME="Calfee 2007" TYPE="JOURNAL_ARTICLE">
<AU>Calfee CS, Matthay MA</AU>
<TI>Nonventilatory treatments for acute lung injury and ARDS</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>131</VL>
<NO>3</NO>
<PG>913-20</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:30:46 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:30:46 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17356114"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2009-09-21 10:30:53 +0100" MODIFIED_BY="Jane Cracknell" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:30:53 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:30:53 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15161896"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chollet_x002d_Martin-1996" MODIFIED="2009-09-23 20:04:08 +0100" MODIFIED_BY="[Empty name]" NAME="Chollet-Martin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo MA, Payen DM</AU>
<TI>Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>3</NO>
<PG>985-90</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:31:15 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:31:15 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8630584"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahlem-2003" MODIFIED="2010-05-17 16:33:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dahlem 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dahlem P, van Aalderen WM, Hamaker ME, Dijkgraaf MG, Bos AP</AU>
<TI>Incidence and short-term outcome of acute lung injury in mechanically ventilated children</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>6</NO>
<PG>980-5</PG>
<IDENTIFIERS MODIFIED="2010-01-10 12:36:33 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-01-10 12:36:33 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 14680089"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahlem-2007" MODIFIED="2009-09-23 20:05:48 +0100" MODIFIED_BY="[Empty name]" NAME="Dahlem 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dahlem P, van Aalderen WM, Bos AP</AU>
<TI>Pediatric acute lung injury</TI>
<SO>Paediatric Respiratory Reviews</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>4</NO>
<PG>348-62</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:31:33 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:31:33 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18005903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dobyns-2002" MODIFIED="2009-09-23 20:06:22 +0100" MODIFIED_BY="[Empty name]" NAME="Dobyns 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, et al</AU>
<TI>Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>11</NO>
<PG>2425-9</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:32:37 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:32:37 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12441749"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fierobe-1995" MODIFIED="2009-09-23 20:06:48 +0100" MODIFIED_BY="[Empty name]" NAME="Fierobe 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fierobe L, Brunet F, Dhainaut JF, Monchi M, Belghith M, Mira JP, et al</AU>
<TI>Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>5</NO>
<PG>1414-9</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:33:08 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:33:08 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7735594"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flori-2005" MODIFIED="2010-05-17 16:33:41 +0100" MODIFIED_BY="Jane Cracknell" NAME="Flori 2005" TYPE="JOURNAL_ARTICLE">
<AU>Flori HR, Glidden DV, Rutherford GW, Matthay MA</AU>
<TI>Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<NO>9</NO>
<PG>995-1001</PG>
<IDENTIFIERS MODIFIED="2010-01-18 21:17:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-01-18 21:17:27 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 15618461"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gotzsche-2000" MODIFIED="2016-02-29 14:29:59 +0000" MODIFIED_BY="[Empty name]" NAME="Gotzsche 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gotzsche PC 10977820]</AU>
<TI>Why we need a broad perspective on meta-analysis. It may be crucially important for patients</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7261</NO>
<PG>585&#8211;6</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:33:41 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:33:41 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10977820"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gries-1998" MODIFIED="2009-09-23 20:07:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gries 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gries A, Bode C, Peter K, Herr A, Böhrer H, Motsch J, et al</AU>
<TI>Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>15</NO>
<PG>1481-7</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:33:54 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:33:54 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9576429"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gries-2000" MODIFIED="2009-09-24 15:50:43 +0100" MODIFIED_BY="Jane Cracknell" NAME="Gries 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gries A, Herr A, Motsch J, Holzmann A, Weimann J, Taut F, et al</AU>
<TI>Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>2</NO>
<PG>309-15</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:34:43 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:34:43 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10739391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haddad-1996" MODIFIED="2009-09-24 15:50:43 +0100" MODIFIED_BY="Jane Cracknell" NAME="Haddad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Haddad IY, Zhu S, Crow J, Barefield E, Gadilhe T, Matalon S</AU>
<TI>Inhibition of alveolar type II cell ATP and surfactant synthesis by nitric oxide</TI>
<SO>The American Journal of Physiology</SO>
<YR>1996</YR>
<VL>270</VL>
<NO>6 Pt 1</NO>
<PG>L898-906</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:34:50 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:34:50 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8764213"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-06-25 11:00:14 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2015-08-20 02:08:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-08-20 02:08:37 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/><IDENTIFIER MODIFIED="2015-08-20 02:08:50 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from www.cochrane-handbook.org. [DOI: 10.1002/9780470712184]"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hsu-2008" MODIFIED="2009-09-21 10:36:50 +0100" MODIFIED_BY="Jane Cracknell" NAME="Hsu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hsu CW, Lee DL, Lin SL, Sun SF, Chang HW</AU>
<TI>The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndrome</TI>
<SO>Respiration</SO>
<YR>2008</YR>
<VL>75</VL>
<NO>3</NO>
<PG>288-95</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:36:50 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:36:50 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17396026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2000" MODIFIED="2009-09-23 20:36:17 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL, Williamson PR</AU>
<TI>Bias in meta-analysis due to outcome variable selection within studies</TI>
<SO>Journal of the Royal Statistical Society Series C</SO>
<YR>2000</YR>
<VL>49</VL>
<PG>359-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jain-2006" MODIFIED="2016-06-25 11:00:24 +0100" MODIFIED_BY="[Empty name]" NAME="Jain 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jain R, DalNogare A</AU>
<TI>Pharmacological therapy for acute respiratory distress syndrome</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>2</NO>
<PG>205-12</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:37:04 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:37:04 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16471076"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kass-1998" MODIFIED="2010-05-29 16:11:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kass 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kass LJ, Apkon M</AU>
<TI>Inhaled nitric oxide in the treatment of hypoxemic respiratory failure</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>3</NO>
<PG>284-90</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:38:00 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:38:00 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE=" 9716891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kubes-1991" MODIFIED="2009-09-23 20:34:51 +0100" MODIFIED_BY="[Empty name]" NAME="Kubes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kubes P, Suzuki M, Granger DN</AU>
<TI>Nitric oxide: an endogenous modulator of leukocyte adhesion</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1991</YR>
<VL>88</VL>
<NO>11</NO>
<PG>4651-5</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:39:48 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:39:48 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="1675786"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-K_x00f6_stler-2005" MODIFIED="2010-05-29 16:12:35 +0100" MODIFIED_BY="[Empty name]" NAME="Köstler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Köstler WJ, Rabitsch W, Locker GJ, Staudinger T, El-Menyawi I, Frass M, et al</AU>
<TI>Influence of inhaled nitric oxide on plasma nitrate concentrations in patients with adult respiratory distress syndrome and sepsis: results of a pilot study</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>179-84</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:40:06 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:40:06 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="16731319"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lan-1983" MODIFIED="2008-09-11 11:02:32 +0100" MODIFIED_BY="Arash Afshari" NAME="Lan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lan KKG, DeMets DL</AU>
<TI>Discrete sequential boundaries for clinical trials</TI>
<SO>Biometrika</SO>
<YR>1983</YR>
<VL>70</VL>
<PG>659-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2011" MODIFIED="2016-06-25 11:00:47 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2011" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Malinchoc M, Cartin-Ceba R, Venkata CV, Kor DJ, Peters SG, et al</AU>
<TI>Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>1</NO>
<PG>59-66</PG>
<IDENTIFIERS MODIFIED="2015-08-19 08:01:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-08-19 08:01:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20693377 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Linko-2009" MODIFIED="2009-09-23 20:33:49 +0100" MODIFIED_BY="[Empty name]" NAME="Linko 2009" TYPE="JOURNAL_ARTICLE">
<AU>Linko R, Okkonen M, Pettilä V, Perttilä J, Parviainen I, Ruokonen E, et al</AU>
<TI>Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1352-61</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:40:36 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:40:36 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="19526218"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luhr-1999" MODIFIED="2009-09-23 20:32:47 +0100" MODIFIED_BY="[Empty name]" NAME="Luhr 1999" TYPE="JOURNAL_ARTICLE">
<AU>Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, et al</AU>
<TI>Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1849-61</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:40:59 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:40:59 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10351930"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Fern_x00e1_ndez-2012" MODIFIED="2016-06-25 11:01:01 +0100" MODIFIED_BY="[Empty name]" NAME="López-Fernández 2012" TYPE="JOURNAL_ARTICLE">
<AU>López-Fernández Y, Azagra AM, de la Oliva P, Modesto V, Sánchez JI, Parrilla J, et al</AU>
<TI>Pediatric acute lung injury epidemiology and natural history study: incidence and outcome of the acute respiratory distress syndrome in children</TI>
<SO>Critical Care Medicine</SO>
<YR>2012</YR>
<VL>40</VL>
<NO>12</NO>
<PG>3238-45</PG>
<IDENTIFIERS MODIFIED="2015-08-19 08:03:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-08-19 08:03:04 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22990455 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MacCallum-2005" MODIFIED="2009-09-23 20:34:31 +0100" MODIFIED_BY="[Empty name]" NAME="MacCallum 2005" TYPE="JOURNAL_ARTICLE">
<AU>MacCallum NS, Evans TW</AU>
<TI>Epidemiology of acute lung injury</TI>
<SO>Current Opinion in Critical Care</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:41:55 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:41:55 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15659944"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McAndrew-1997" MODIFIED="2009-09-23 20:32:00 +0100" MODIFIED_BY="[Empty name]" NAME="McAndrew 1997" TYPE="JOURNAL_ARTICLE">
<AU>McAndrew J, Patel RP, Jo H, Cornwell T, Lincoln T, Moellering D, et al</AU>
<TI>The interplay of nitric oxide and peroxynitrite with signal transduction pathways: implications for disease</TI>
<SO>Seminars in Perinatology</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>5</NO>
<PG>351-66</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:42:46 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:42:46 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9352609"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meade-2004" MODIFIED="2016-06-25 11:01:18 +0100" MODIFIED_BY="[Empty name]" NAME="Meade 2004" TYPE="JOURNAL_ARTICLE">
<AU>Meade MO, Jacka MJ, Cook DJ, Dodek P, Griffith L, Guyatt GH, et al</AU>
<TI>Survey of interventions for the prevention and treatment of acute respiratory distress syndrome</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>4</NO>
<PG>946-54</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:43:04 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:43:04 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15071383"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-1998" MODIFIED="2009-09-21 10:43:10 +0100" MODIFIED_BY="Jane Cracknell" NAME="Palmer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Palmer RM, Ashton DS, Moncada S</AU>
<TI>Vascular endothelial cells synthesize nitric oxide from L-arginine</TI>
<SO>Nature</SO>
<YR>1988</YR>
<VL>333</VL>
<NO>6174</NO>
<PG>664-6</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:43:10 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:43:10 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="3131684"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Petrucci-2013" MODIFIED="2016-03-04 14:05:58 +0000" MODIFIED_BY="[Empty name]" NAME="Petrucci 2013" TYPE="COCHRANE_REVIEW">
<AU>Petrucci N, De Feo C</AU>
<TI>Lung protective ventilation strategy for the acute respiratory distress syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-03-04 14:05:58 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-04 14:05:31 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003844.pub4"/><IDENTIFIER MODIFIED="2016-03-04 14:05:58 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CD003844"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1997" MODIFIED="2016-06-25 11:01:33 +0100" MODIFIED_BY="[Empty name]" NAME="Pogue 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pogue JM, Yusuf S</AU>
<TI>Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>580-93</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:44:33 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:44:33 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9408720"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1998" MODIFIED="2009-09-21 10:44:38 +0100" MODIFIED_BY="Jane Cracknell" NAME="Pogue 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pogue J, Yusuf S</AU>
<TI>Overcoming the limitations of current meta-analysis of randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9095</NO>
<PG>45-52</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:44:38 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:44:38 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9433436"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prodhan-2004" MODIFIED="2009-09-23 20:30:31 +0100" MODIFIED_BY="[Empty name]" NAME="Prodhan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Prodhan P, Noviski N</AU>
<TI>Pediatric acute hypoxemic respiratory failure: management of oxygenation</TI>
<SO>Journal of Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>3</NO>
<PG>140-53</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:44:51 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:44:51 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="15154995"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pryor-1995" MODIFIED="2009-09-24 15:50:43 +0100" MODIFIED_BY="Jane Cracknell" NAME="Pryor 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pryor WA, Squadrito GL</AU>
<TI>The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide</TI>
<SO>The American Journal of Physiology</SO>
<YR>1995</YR>
<VL>268</VL>
<NO>5 Pt 1</NO>
<PG>L699-722</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:44:59 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:44:59 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="7762673"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.3.5" MODIFIED="2016-01-04 21:43:38 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 5.3.5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.3.5</TI>
<YR>2015</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossaint-1993" MODIFIED="2009-09-23 20:11:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rossaint 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM</AU>
<TI>Inhaled nitric oxide for the adult respiratory distress syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>6</NO>
<PG>399-405</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:47:57 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:47:57 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="8357359"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rubenfeld-2005" MODIFIED="2016-02-29 14:28:00 +0000" MODIFIED_BY="[Empty name]" NAME="Rubenfeld 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al</AU>
<TI>Incidence and outcomes of acute lung injury</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>16</NO>
<PG>1685-93</PG>
<IDENTIFIERS MODIFIED="2010-01-10 12:58:48 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-01-10 12:58:48 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 16236739"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2009-09-23 20:11:35 +0100" MODIFIED_BY="[Empty name]" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter J</AU>
<TI>Arcsine test for publication bias in meta-analyses with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>5</NO>
<PG>746-63</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:48:10 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:48:10 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="17592831"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sokol-2003b" MODIFIED="2009-09-23 20:09:49 +0100" MODIFIED_BY="[Empty name]" NAME="Sokol 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Sokol J, Jacobs SE, Bohn D</AU>
<TI>Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>4</NO>
<PG>989-98</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:48:21 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:48:21 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="14500146"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-TenHoor-2001" MODIFIED="2009-09-21 10:48:51 +0100" MODIFIED_BY="Jane Cracknell" NAME="TenHoor 2001" TYPE="JOURNAL_ARTICLE">
<AU>TenHoor T, Mannino DM, Moss M</AU>
<TI>Risk factors for ARDS in the United States: analysis of the 1993 National Mortality Followback Study</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>4</NO>
<PG>1179-84</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:48:51 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:48:51 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="11296187"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomassen-1997" MODIFIED="2009-09-24 15:50:43 +0100" MODIFIED_BY="Jane Cracknell" NAME="Thomassen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS</AU>
<TI>Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages</TI>
<SO>American Journal of Respiratory Cell and Molecular Biology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>3</NO>
<PG>279-83</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:48:58 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:48:58 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="9308913 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2009-09-24 15:50:43 +0100" MODIFIED_BY="Jane Cracknell" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:50:01 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:50:01 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18824467"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Trial-Sequential-Analysis-_x0028_TSA_x0029_" MODIFIED="2016-06-25 11:02:07 +0100" MODIFIED_BY="[Empty name]" NAME="Trial Sequential Analysis (TSA)" TYPE="COMPUTER_PROGRAM">
<AU>Copenhagen Trial Unit, Center for Clinical Intervention Research</AU>
<TI>Trial Sequential Analysis</TI>
<YR>2011</YR>
<PB>Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet</PB>
<CY>Copenhagen, Denmark</CY>
<IDENTIFIERS MODIFIED="2016-01-21 09:47:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-21 09:47:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valdivielso-2002" MODIFIED="2016-02-29 14:27:31 +0000" MODIFIED_BY="[Empty name]" NAME="Valdivielso 2002" TYPE="JOURNAL_ARTICLE">
<AU>Valdivielso JM, Blantz RC</AU>
<TI>Acute renal failure: is nitric oxide the bad guy?</TI>
<SO>Antioxidants and Redox Signaling</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>6</NO>
<PG>925-34</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:51:14 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:51:14 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="12573141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-2000" MODIFIED="2009-09-23 19:55:16 +0100" MODIFIED_BY="[Empty name]" NAME="Ware 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ware LB, Matthay MA</AU>
<TI>The acute respiratory distress syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>18</NO>
<PG>1334-49</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:52:22 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:52:22 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="10793167"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2009-09-23 19:54:55 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2009-09-21 10:52:39 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-21 10:52:39 +0100" MODIFIED_BY="Jane Cracknell" TYPE="PUBMED" VALUE="18083463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2016-06-25 11:02:26 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2015-08-20 02:37:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-08-20 02:37:50 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20042080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zimmerman-2009" MODIFIED="2010-01-18 21:19:34 +0000" MODIFIED_BY="[Empty name]" NAME="Zimmerman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD</AU>
<TI>Incidence and outcomes of pediatric acute lung injury</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>1</NO>
<PG>87-95</PG>
<IDENTIFIERS MODIFIED="2010-01-10 12:25:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-01-10 12:25:03 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 19564287"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-01-05 13:55:04 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Afshari-2010" MODIFIED="2016-02-29 14:27:15 +0000" MODIFIED_BY="[Empty name]" NAME="Afshari 2010" TYPE="COCHRANE_REVIEW">
<AU>Afshari A, Brok J, Møller AM, Wetterslev J</AU>
<TI>Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-01-28 14:51:53 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2016-01-28 14:51:51 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD002787.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karam-2017" MODIFIED="2017-01-05 13:55:01 +0000" MODIFIED_BY="Jane Cracknell" NAME="Karam 2017" TYPE="JOURNAL_ARTICLE">
<AU>Karam O, Gebistorf F, Wetterslev J, Afshari A</AU>
<TI>The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis</TI>
<SO>Anaesthesia</SO>
<YR>2017</YR>
<VL>72</VL>
<NO>1</NO>
<PG>106-17</PG>
<IDENTIFIERS MODIFIED="2017-01-05 13:55:01 +0000" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2017-01-05 13:55:01 +0000" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="doi: 10.1111/anae.13628. Epub 2016 Oct 20"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sokol-2003a" MODIFIED="2016-01-28 14:53:22 +0000" MODIFIED_BY="Jane Cracknell" NAME="Sokol 2003a" TYPE="COCHRANE_REVIEW">
<AU>Sokol J, Jacobs SE, Bohn D</AU>
<TI>Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-09-18 15:31:29 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2009-09-18 15:31:29 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD002787"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-06-27 11:28:55 +0100" MODIFIED_BY="Jane Cracknell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-06-27 11:28:55 +0100" MODIFIED_BY="Jane Cracknell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-06-25 10:26:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronicki-2015">
<CHAR_METHODS MODIFIED="2016-06-25 10:25:29 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, multi-centre (9), placebo-controlled RCT</P>
<P>ITT: no</P>
<P>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:25:42 +0100" MODIFIED_BY="[Empty name]">
<P>53 children from 44 weeks post-conceptional age to 16 years of age with oxygenation index (OI) &#8805; 12; chest radiograph with pulmonary infiltrates; mechanically ventilated &#8804; 7 days; with signed institutional research board&#8211;approved informed consent</P>
<P>
<BR/>Exclusion criteria: immunocompromised host, history of bone marrow transplantation, active oncological condition, long-term (&gt; 30 days) or recent (&lt; 72 hours) high-dose glucocorticoids, right to left cardiac shunt, cardiovascular surgery within the past 14 days, status asthmaticus, treatment with INO or other investigational medications within 24 hours before study initiation, chronically ventilated, and decision by primary care physician to not provide full support<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 24 participants, 5 ppm INO until death, ventilator-free or at day 28 after enrolment (whichever came first)</P>
<P>Control group: 29 participants, 5 ppm nitrogen</P>
<P>Gas initiation and daily gas manipulation performed by study therapist. Ventilation strategy and weaning of INO standardized</P>
<P>CMV management: low-volume tidal strategy (4 to 8 mL/kg and plateau pressure &lt; 30 cm H<SUB>2</SUB>O); PEEP based on serial chest radiographs (every 6 to 12 hours) with the goal of 8 ribs posteriorly. Target arterial blood gas values: SaO<SUB>2</SUB> 88% to 95% with FiO<SUB>2</SUB> &lt; 0.60; PaO<SUB>2</SUB> 55 to 80 mm Hg; pH 7.25 to 7.40</P>
<P>HFOV settings: based on serial chest radiographs (as CMV); target FiO<SUB>2</SUB> and PaO<SUB>2</SUB> same as for CMV. FiO<SUB>2</SUB> weaned over mean airway pressure until FiO<SUB>2</SUB> &lt; 0.60. Transfer to CMV before weaning</P>
<P>Prone position &#8805; 8 hours daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:26:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: ventilator-free days at 28 days after randomization</P>
<P>Secondary outcomes: oxygen index at 4 and 12 hours, survival at 28 days, ECMO-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Participant enrolment from 2003 to 2005</P>
<P>Authors' conclusion: We found that INO led to a significant decrease in duration of ventilation and a significant increase in ECMO-free survival among paediatric patients with ARDS.Given the limitations of this study and of previous studies on children, the high mortality rate of ARDS among children and the findings of this trial, a larger, prospective, randomized controlled trial on the impact of INO on outcomes among children with ARDS is indicated</P>
<P>Rate of ECMO-free survival: placebo group 51.7% vs intervention group 91.7%; 7 participants in the placebo group and 1 in the iNO group received ECMO</P>
<P>Oxygenation index favoured INO at 4 and 12 hours, but findings became insignificant at 24 hours. Study authors provide no numbers in the manuscript</P>
<P>Funded by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:27:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day-1997">
<CHAR_METHODS MODIFIED="2016-06-25 10:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre<BR/>ITT: no<BR/>Overall study quality: high risk of bias<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:26:38 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-four children with acute bilateral lung disease (chest x-ray infiltrates) requiring PEEP &gt; 6 cm H<SUB>2</SUB>O and FiO<SUB>2</SUB> &gt; 0.5 for more than 12 hours. Enrolment &#8804; 48 hours after meeting study criteria</P>
<P>Exclusion criteria: unrepaired congenital heart defect or a poor neurological prognosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:26:44 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 12 participants, 10 ppm INO until ventilatory support was decreased to PEEP of 6 cm H<SUB>2</SUB>O and FiO<SUB>2</SUB> of 0.5</P>
<P>Control group: 12 participants initially maintained on a regimen of conventional therapy alone. No placebo. After 24 hours, all participants received 10 ppm INO</P>
<P>Ventilation at discretion of the clinician. No additional co-intervention described. No cross-over before 24 hours. INO therapy withdrawn in gradual decrements over a period of 6 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: improved oxygenation (oxygenation index) or improved ratio of pulmonary vascular resistance to systemic vascular resistance (PVR/SVR)</P>
<P>Secondary outcomes: mortality, adverse events, FiO<SUB>2</SUB>, mean airway pressure (cm H<SUB>2</SUB>O), pH, PCO<SUB>2</SUB> (mm Hg), PO<SUB>2</SUB> (mm Hg)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Letter sent to study authors in June 2009. Reply received in June 2009</P>
<P>Length of follow-up: unclear. Mortality for longest follow-up was 6 in the INO group and 4 in the control group. As both groups received INO at the same concentration in the initial 24 hours, we have included only 24-hour mortality data in our analyses<BR/>Study authors' conclusions: Pulmonary vascular resistance and systemic oxygenation are acutely improved by 10 ppm inhaled nitric oxide in some children with severe lung disease. However, sustained improvement in oxygenation may not occur during prolonged therapy. Thus, inhaled nitric oxide may have a limited therapeutic role in children with acute hypoxaemic respiratory failure</P>
<P>Funding: not for profit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:27:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dellinger-1998">
<CHAR_METHODS MODIFIED="2016-06-25 10:27:23 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, phase 2, multi-centre, placebo-controlled RCT<BR/>ITT: yes<BR/>Overall study quality: low risk of bias despite funding bias<BR/>Sample size calculation reported. Not powered to show statistically significant benefit for any outcome</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:27:28 +0100" MODIFIED_BY="[Empty name]">
<P>Included: 177 adults from 30 centres with ARDS &lt; 72 hours before randomization. ARDS defined by American-European Consensus Conference and minimal FiO<SUB>2</SUB> of 0.5 and minimal PEEP of 8 cm H<SUB>2</SUB>O<BR/>Exclusion criteria: pregnancy, &lt; 18 years old, immunocompromised, sepsis-induced ARDS, &gt; 20% body surface burns, persistent hypotension (inotropic support) and multi-system organ failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:27:33 +0100" MODIFIED_BY="[Empty name]">
<P>NO group: 120 participants at doses of 1.25, 5, 20, 40 or 80 ppm, for 28 days or until extubation</P>
<P>Control group: 57 participants, placebo gas (nitrogen)</P>
<P>Ventilation strategy and weaning of INO standardized (plateau airway pressure &lt; 35 cm H<SUB>2</SUB>O; PEEP to optimize compliance; FiO<SUB>2</SUB> minimized). No cross-over of treatment failures</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:27:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: duration of mechanical ventilation<BR/>Secondary outcomes: changes in oxygenation (PaO<SUB>2</SUB>, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, OI), percent responders, mortality, number of participants alive and off ventilator at 28 days, decrease in mean PA pressure, adverse events, methaemoglobin, hypotension, renal failure, pneumothorax</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Letter sent to study authors in June 2009. No reply received</P>
<P>Follow-up: 28 days. Treatment stopped before oxygenation threshold criteria were reached in 56 participants. 20 participants in INO group received steroids after day 6, and only 6 in the control group received steroids. Only 8 participants received 80 ppm INO; 80 ppm INO dose was eliminated mid-study because international consensus suggests an unlikely advantage over lower concentrations. Data accounted for in analysis. Post hoc assessment for ventilator-free days. Not stratified for origin</P>
<P>Data on ventilator-free days for the INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study authors' conclusions: "Inhaled NO appears to be well tolerated in the population of ARDS patients studied. With mechanical ventilation held constant, inhaled NO is associated with a significant improvement in oxygenation compared with placebo over the first 4 hrs of treatment. An improvement in oxygenation index was observed over the first 4 days. Larger phase III studies are needed to ascertain if these acute physiologic improvements can lead to altered clinical outcome"</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:28:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobyns-1999">
<CHAR_METHODS MODIFIED="2016-06-25 10:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, multi-centre, placebo-controlled RCT<BR/>ITT: not stated<BR/>Overall study quality: low risk of bias despite no information on sample size calculation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>108 children &gt; 1 month old, from 7 centres, median age 2.5 years, with acute hypoxaemic respiratory failure and oxygenation index &gt; 15, × 2 values within 6 hours and chest infiltrates</P>
<P>Exclusion criteria: congenital heart disease, cardiac surgery within 14 days and treatment considered futile<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 53 children, 10 ppm for 3 days, then weaned if failure criteria not met. Maximum of 7 days after entry</P>
<P>Control group: 55 children, placebo gas (air)</P>
<P>Usual care in both groups. Ventilation strategy and weaning of gas standardized (peak airway pressure &lt; 35 to 40 cm H<SUB>2</SUB>O, tidal volume limitation, titrated PEEP, high-frequency oscillatory ventilation by clinician discretion). Cross-over of participants meeting treatment failure criteria</P>
<P>Follow-up: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: acute effect on oxygen index and PaO<SUB>2</SUB>/FiO<SUB>2</SUB>
<BR/>Secondary outcomes: rate of decline in oxygenation; oxygenation, PEEP, MAP, mortality, adverse event, methaemoglobin and NO<SUB>2</SUB> levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:28:26 +0100" MODIFIED_BY="[Empty name]">
<P>Countries: USA and UK<BR/>Letter sent to study authors in June 2009. Reply received in June 2009. No additional data supplied<BR/>27 participants from the control group received INO. Two dropouts from the control group</P>
<P>Post hoc analysis of immunocompromised participants. Follow-up unclear, but ventilation data reported at day 108</P>
<P>Additonal data on PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, duration of mechanical ventilation and oxygenation index provided in <LINK REF="REF-Dobyns-2002" TYPE="REFERENCE">Dobyns 2002</LINK> based on mode of ventilation (high-frequency oscillatory ventilation (HFOV) and conventional mechanical ventilation (CMV)). Participants were divided into 4 groups (HFOV, HFOV + INO, CMV, CMV + INO). Data for our meta-analyses of PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 72 hours, duration of mechanical ventilation and oxygenation index at 72 hours provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study not stratified for origins. According to data provided by <LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>, this trial fulfils the criteria set by American-European Consensus Conference for ARDS</P>
<P>Study authors' conclusions: "INO causes an acute improvement in oxygenation in children with severe AHRF. Two subgroups (immunocompromised and an entry oxygen index &gt; 25) appear to have a more sustained improvement in oxygenation, and we speculate that these subgroups may benefit from prolonged therapy"</P>
<P>Trial funded by industry</P>
<P>Funding: not for profit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:28:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlach-2003">
<CHAR_METHODS MODIFIED="2016-06-25 10:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre<BR/>Follow-up: adequate. No post-trial follow-up<BR/>ITT: yes<BR/>Overall study quality: high risk of bias<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>40 adults with ARDS according to American-European Consensus Conference: FiO<SUB>2</SUB> &#8805; 0.6, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 150 mm Hg, PEEP &#8805; 10 cm H<SUB>2</SUB>O, PAOP &#8804; 18 mm Hg</P>
<P>No exclusion criteria defined specifically</P>
<P>Median duration of ventilation before randomization: 5.3 vs 5.9 days (INO vs control)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 20 participants, 10 ppm with daily dose response analysis until weaning initiated</P>
<P>Control group: 20 participants, no placebo</P>
<P>Standard care according to standardized protocols. No cross-overs. Protocols for prone position (4 to 6 hours), extracorporeal membrane oxygenation (ECMO), permissive hypercapnia and measures to reduce pulmonary oedema</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:28:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, mean pulmonary artery pressure, FiO<SUB>2</SUB> reduction</P>
<P>Secondary outcomes: duration of ventilation, intensive care unit stay, ECMO use, additional organ failure, mortality, cardiac index, central venous pressure, mean arterial pressure, various respiratory pressures, MPAP, PCWP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Letter sent to study authors in June 2009. No reply received</P>
<P>Length of follow-up: unclear, but data for length of stay reported at day 91</P>
<P>Study authors' conclusion: "Long-term inhaled NO with constant doses of 10 ppm leads to enhanced sensitivity"</P>
<P>Funding: not for profit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:30:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ibrahim-2007">
<CHAR_METHODS MODIFIED="2016-06-25 10:28:52 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre<BR/>ITT: no<BR/>Overall study quality: high risk of bias<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>32 children 8 weeks to 10 years of age with the diagnosis of ARDS and on mechanical ventilation (PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 200 mm Hg, positive inspiratory pressure &#8805; 30 cm H<SUB>2</SUB>O, FiO<SUB>2</SUB> &#8805; 0.5 for &gt; 12 hours), divided into 3 groups. Study period of 24 hours</P>
<P>Exclusion criteria: cardiac or neurological disease (cyanotic), chest or abdominal trauma, neurological surgeries, haemodynamic instability, extracorporeal membrane oxygenation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>INO group with children in supine position during 24-hour study period: 11 participants</P>
<P>INO group with children in prone position during 24-hour study period: 11 participants</P>
<P>INO used continuously for 20 hours (5 ppm for 18 hours, then decreased to 1 ppm in the last 2 hours)</P>
<P>INO administered at 5 ppm for 18 hours, then decreased to 1 ppm</P>
<P>Control group: 10 participants kept in prone position for 20 hours, then back to supine position for remaining 4 hours. No placebo. No cross-overs</P>
<P>Standard care. Lung protective strategy (tidal volume 5 to 10 mL/kg), permissive hypercapnia (PaCO<SUB>2</SUB> &gt; 50 mm Hg) as long as arterial pH &gt; 7.2. Ventilation and weaning protocol for all participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, oxygenation index, methaemoglobin, NO<SUB>2</SUB>, critical incidents related to prone position or repositioning</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Egypt</P>
<P>Letter sent to study authors in June 2009. No reply received. Two children withdrawn from the trial and did not have oxygenation measured</P>
<P>For PaO<SUB>2</SUB>/FiO<SUB>2</SUB> and oxygenation index meta-analyses, we have chosen to include data from the control group (prone position) and INO with prone position group, thus having the same co-intervention (prone position). No mortality data provided. Although bilateral infiltrates are not explicitly mentioned as a criterion for inclusion, it does appear from reading the article that they have been used clinically to include participants. Thus this trial has been characterized as fulfilling the American-European Consensus Conference definition of ARDS</P>
<P>Length of follow-up: 24 hours</P>
<P>Study authors' conclusion: "The present study showed that in mechanically ventilated paediatric patients with ARDS, the combined use of prone position and INO is safe and has an additive effect, which causes a greater sustained improvement in oxygenation than either treatment strategy alone"</P>
<P>Funding: unknown</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:30:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundin-1999">
<CHAR_METHODS MODIFIED="2016-06-25 10:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, multi-centre, open, phase 3 RCT<BR/>ITT: yes<BR/>Overall study quality: high risk of bias<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:30:36 +0100" MODIFIED_BY="[Empty name]">
<P>After a test response to INO, 180 adult INO responders with ALI (unilateral or bilateral lung infiltrates, ventilated for 18 to 96 hours with PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 165 mm Hg, PEEP &gt; 5 cm H<SUB>2</SUB>O, MAP &gt; 10 cm H<SUB>2</SUB>O, pressure- or volume-controlled ventilation and I:E ratio between 1:2 and 2:1) were randomized. Duration of ventilation before randomization: 0.75 to 4 days<BR/>Exclusion criteria: pregnancy, age &lt; 18 years, mechanical ventilation &gt; 10 days or ventilator treatment &gt; 96 hours at FiO<SUB>2</SUB> &gt; 0.5, independent lung ventilation, ongoing high-dose vasodilators, treatment with extracorporeal lung assist, malignancy, severe heart failure, ongoing intracranial haemorrhage, AIDS, immunocompromised, chronic renal, liver or pulmonary disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 93 participants randomized after INO test response with 2, 10, 40 ppm for 10 minutes daily until response, up to 30 days. Considered responders if positive PaO<SUB>2</SUB> increased by 25% (20% after protocol amendment). When randomized, participants received 1 to 40 ppm INO at the lowest effective dose for up to 30 days, or until endpoint was reached. Mean INO dose was 9 ppm, and mean number of days of INO was 9</P>
<P>Control group: 87 participants, no placebo gas</P>
<P>Ventilation strategy and weaning of test gas was performed according to usual standards of care of each hospital. Cross-over of treatment failures allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: reversal of ALI<BR/>Secondary outcomes: reduction of frequency of severe respiratory failure, mortality, ICU and hospitalisation status at 30 and 90 days, safety (methaemoglobinaemia, organ failure), reduction in days to reverse ALI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:30:58 +0100" MODIFIED_BY="[Empty name]">
<P>Country: multi-centre (43) European study, main country Sweden</P>
<P>Letter sent to study authors in June 2009. No reply received</P>
<P>Powered for 600 participants, stopped early because of slow recruitment. 268 patients were evaluated but only 67% were included on the basis of INO response. Protocol amendment after 140 participants randomized. Stratified per study centre and to APACHE II for 140 participants, then according to hypoxia score (PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio) for remaining participants. Post hoc analysis of reversal of ALI (participants alive and off ventilator over time). 6 participants in the control group received NO. Length of follow-up: 90 days</P>
<P>Study authors defined severe respiratory failure (SRF) as follows: "FiO<SUB>2 </SUB>&gt; 0.9 with PaO<SUB>2</SUB> &lt; 8 kPa in three blood gas analyses each 4 hours apart, with pressure controlled/limited ventilation, respiratory frequency between 5 and 30, a PEEP &#8805; 10 cmH<SUB>2</SUB>O and mean airway pressure &#8805;20 cmH<SUB>2</SUB>O. SRF could also be defined as two arterial blood gases 2 hours apart at a FiO<SUB>2</SUB> &#8805; 1.00 resulting in a PaO<SUB>2 </SUB>&lt; 6 kPa." Additionally, reversal of ALI was defined as participants on ventilator/mask CPAP system, PEEP &#8804; 5 cm H<SUB>2</SUB>O, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &gt; 31 kPa if &lt; 60 years and PaO<SUB>2</SUB>/FiO<SUB>2 </SUB>&gt; 29 kPa if &gt; 60 years</P>
<P>Additional data on duration of mechanical ventilation provided by Dr. Neill Adhikari, who extracted data from a Kaplan-Meier curve of participants alive and off mechanical ventilation over time (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study authors' conclusion: "Improvement of oxygenation by INO did no increase the frequency of reversal of ALI. Use of inhaled NO in early ALI did not alter mortality although it did reduce the frequency of severe respiratory failure in patients developing severe hypoxaemia"</P>
<P>Funding: funded in part by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:37:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mehta-2001">
<CHAR_METHODS MODIFIED="2016-06-25 10:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre<BR/>Follow-up: adequate. No post-trial follow-up<BR/>ITT: no<BR/>Overall study quality: high risk of bias<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:37:18 +0100" MODIFIED_BY="[Empty name]">
<P>14 adults with ARDS &#8804; 5 days, bilateral chest infiltrates, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 200 mm Hg, PAOP &lt; 18 cm H<SUB>2</SUB>O, PEEP &#8805; 8 cm H<SUB>2</SUB>O</P>
<P>Exclusion criteria: intravenous nitroglycerin or prostacyclin, high-dose corticosteroids (&gt; 10 mg methylprednisolone per day), unconventional modes of mechanical ventilation (e.g. high-frequency ventilation, prone position), myocardial infarction &lt; previous 72 hours, 2,3-DPG deficiency, entry criteria &gt; 5 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 8 participants, daily titration for 4 days of INO at 5, 10 and 20 ppm for 30 minutes at each dose, with the dose resulting in use of the highest PaO<SUB>2</SUB>/FiO<SUB>2</SUB> until the following day. INO continued until PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &gt; 200 mm Hg on FiO<SUB>2</SUB> &lt; 0.5. Mean duration of INO treatment 8 days</P>
<P>Control group: 6 participants, no placebo gas, conventional therapy</P>
<P>Usual care for all participants. No cross-overs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, peak inspiratory pressure, PEEP, cardiac output, oxygen delivery index, mean arterial pressure, heart rate, PAOP, central venous pressure, systemic and pulmonary vascular resistances, arterial blood gas values, methaemoglobin, NO<SUB>2</SUB>, mortality, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Letter sent to study authors in June 2009. Reply received in June 2009</P>
<P>Additional data on ventilator-free days, duration of mechanical ventilation, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>; oxygenation index for the INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>). Length of follow-up unclear, data on ARDS duration provided for day 25</P>
<P>Study authors' conclusion: "In patients with ARDS, NO reduces mean pulmonary artery pressure and improves oxygenation acutely but fails to improve these variables beyond 24 hours"</P>
<P>Funding: financed in part by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:37:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michael-1998">
<CHAR_METHODS MODIFIED="2016-06-25 10:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre<BR/>ITT: no<BR/>Overall study quality: high risk of bias<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>40 adults and children 1 to 79 years of age. Only 3 participants younger than 18 years of age. ARDS defined by American-European Consensus Conference, except PaO2/FiO2 &lt; 150 mm Hg and FiO<SUB>2</SUB> &gt; 0.8 for &#8805; 12 hours or 0.65 for &#8805; 24 hours<BR/>Exclusion criteria: pregnancy, patients not expected to survive hospitalisation because of underlying disease such as active malignancy, heart failure or left atrial hypertension<BR/>Time period of study: January 1994 to June 1996</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 20 participants, increasing doses of INO each 6 hours (at 5, 10, 15, and 20 ppm) for 24 hours, then clinically adjusted. Mean dose of INO was 13 ppm. INO tapered if oxygenation did not improve by 72 hours</P>
<P>Control group: 20 participants. No placebo gas</P>
<P>All participants received conventional therapy. Mode of ventilation remained unchanged throughout the study period, with similar PEEP between groups for 72 hours. Cross-over in case of treatment failure, pre-defined criteria for clinical deterioration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: improvement in oxygenation within 72 hours of treatment, correlation between changes in PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio acutely and after 72 hours<BR/>Secondary outcomes: PEEP, PaO<SUB>2</SUB>, FiO<SUB>2</SUB>, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, respiratory compliance, pulmonary artery pressure, central venous pressure, pulmonary and systemic vascular resistance and mortality, adverse events, methaemoglobin levels, bleeding diathesis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:37:48 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Letter sent to study authors in June 2009. No reply received. Length of follow-up unclear, but data on ARDS duration were provided for day 25</P>
<P>Two participants in control group received INO before 72 hours, and seven received INO after 72 hours</P>
<P>Powered to detect 35% to 40% difference in frequency of persistent decrease in FiO<SUB>2</SUB> &#8805; 0.15, not mortality</P>
<P>Study authors' conclusion: "In patients with severe ARDS, our results indicate that INO does not lead to sustained improvement in oxygenation as compared with conventional therapy"</P>
<P>Funding: not for profit<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:38:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2003">
<CHAR_METHODS MODIFIED="2016-06-25 10:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>Three-group parallel RCT, 1 centre<BR/>ITT: no</P>
<P>Overall study quality: high risk of bias<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>23 adults with ARDS defined by American-European Consensus Conference</P>
<P>Exclusion criteria: COPD, cardiac disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:38:00 +0100" MODIFIED_BY="[Empty name]">
<P>INO and lung recruitment manoeuvre (LRM) group: 11 participants, 5 ppm, and 1 LRM 2 hours after INO treatment initiation, twice daily; mean duration of INO treatment 3.5 days. No stopping criteria reported</P>
<P>INO group: 6 participants received INO 5 ppm, mean duration of INO treatment 8.2 days</P>
<P>Control group: 6 participants, LRM twice daily, no placebo gas</P>
<P>Standard care for all participants. Weaning protocol. Ventilation protocol (LRM with inflation pressure of 30 to 35 cm H<SUB>2</SUB>O for 30 seconds, volume control mode, tidal volume of 6 mL/kg ideal body weight, respiratory rate 20 to 25/min, plateau airway pressure &#8804; 30 cm H<SUB>2</SUB>O, PEEP to optimize PaO<SUB>2</SUB>, FiO<SUB>2</SUB> minimized). No cross-overs. No prone position</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:38:01 +0100" MODIFIED_BY="[Empty name]">
<P>Mechanical variables, mortality, blood pressure, heart rate, central venous pressure, mean pulmonary arterial pressure, pulmonary artery occlusion pressure, cardiac index. No data on distinction between primary vs secondary outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:38:10 +0100" MODIFIED_BY="[Empty name]">
<P>Country: South Korea</P>
<P>Letter sent to study authors in June 2009. Reply received in June 2009</P>
<P>Mortality data from groups 1 and 3 were combined, as we considered use of the recruitment maneuver as standard care. We have included data from INO + LRM group vs control group in meta-analyses of PaO<SUB>2</SUB>/FiO<SUB>2</SUB>. Length of follow up: 28 days</P>
<P>Additional data on ventilator-free days, duration of mechanical ventilation, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>; oxygenation index for the INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study authors' conclusion: "the combined application of NO inhalation and recruitment maneuver could be beneficial and safe for patients with ARDS, showing an enhancing effect in improvement of oxygenation"</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:39:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Payen-1999">
<CHAR_METHODS MODIFIED="2016-06-25 10:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 23 centres<BR/>ITT: yes<BR/>Overall study quality: low risk of bias, despite publication bias (not published)<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:38:15 +0100" MODIFIED_BY="[Empty name]">
<P>203 adults (&gt; 15 years old) with ARDS according to American-European Consensus Conference and Murray Score, range 2 to 3</P>
<P>Exclusion criteria: pregnancy, chronic respiratory insufficiency, haemorrhagic disorder, malignancy, haematological disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:38:17 +0100" MODIFIED_BY="[Empty name]">
<P>INO: 98 participants, fixed INO of 10 ppm until oxygenation and PEEP criteria were met with median INO administration of 5 days</P>
<P>Control group: 105 participants, placebo gas (nitrogen)</P>
<P>Various ventilation guidelines were applied. Cross-overs when treatment failure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:38:20 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: participants alive and off mechanical ventilation at day 28</P>
<P>Secondary outcomes: 28-day mortality and at hospital discharge, duration of mechanical ventilation, proportion of participants weaned from adjunctive inhaled therapy, proportion of participants with a shift of inhaled gas before day 28, methaemoglobin, N<SUB>2</SUB>O, haemodynamics, oxygenation variables, PEEP levels, length of stay in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:39:02 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France</P>
<P>This trial was published only as an abstract. Letter sent to study authors in April and June 2009. Reply received in April and June 2009. Additional and valuable information received (unpublished manuscript). 19 participants in the control group and 12 in the INO group crossed over. Length of follow-up: 90 days</P>
<P>Additional data on ventilator-free days, duration of mechanical ventilation, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, oxygenation index for the INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study authors' conclusion: "In ARDS patients (Murray score 2-3), 10 ppm of NO did not alter either duration of mechanical ventilation, 28 day mortality, or clinical worsening of their ARDS"</P>
<P>Funding: not for profit, industry supplied gas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:39:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwebel-1997">
<CHAR_METHODS MODIFIED="2016-06-25 10:39:09 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, multi-centre (17 centres)<BR/>Overall study quality: high risk of bias<BR/>Sample size calculation not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:39:13 +0100" MODIFIED_BY="[Empty name]">
<P>19 participants with ARDS defined by PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 200, 6 &lt; PEEP &lt; 10, 10 &lt; pulmonary capillary wedge pressure &lt; 18 and &#8805; 1 infiltrate on chest x-ray</P>
<P>Exclusion criteria: COPD, haemodynamic instability</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:39:16 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 9 participants, 10 ppm INO for 17 hours, then at the clinician's discretion. Mean INO treatment 4.6 days</P>
<P>Control group: 10 participants, placebo gas (nitrogen)</P>
<P>Standard care. Fixed mechanical ventilation. If PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 100 before 17 hours of treatment, cross-over and thereafter clinician free to add NO, other technic, or to change respiratory variables</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:39:16 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamics, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>, arterial oxygenation and other gas exchange variables, methaemoglobin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:39:22 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France, 17 centres</P>
<P>Published only as abstract. At least 5 participants in the control group received INO</P>
<P>Letter sent to study authors in June 2009. Reply received in June 2009. No data on length of follow-up. No data on mortality</P>
<P>Additional data on ventilator-free days, duration of mechanical ventilation, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>; oxygenation index for the INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>)</P>
<P>Study authors' conclusion: "Beneficial effects of inhaled NO on arterial oxygenation may be delayed, not necessary related to high baseline PVR level, as it has been previously suggested by uncontrolled studies. Delayed NO administration still improve gas exchanges. Finally this prospective trial is in favour of early clinical use of inhaled NO in ALI"</P>
<P>Funding: not for profit, industry supplied gas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:39:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taylor-2004">
<CHAR_METHODS MODIFIED="2016-06-25 10:39:27 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, phase 2, multi-centre (46 centres), placebo-controlled RCT<BR/>ITT: yes</P>
<P>Overall study quality: low risk of bias despite funding bias<BR/>Sample size calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>385 adults with moderately severe acute lung injury due to causes other than severe sepsis (modified American-European Consensus Conference definition): PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 250, regardless of amount of PEEP, bilateral infiltrates on frontal chest radiograph, PAOP &#8804; 18 mm Hg when measured or no clinical evidence of left atrial hypertension, FiO<SUB>2</SUB> of 0.5 to 0.95 or set PEEP &#8805; 8 cm H<SUB>2</SUB>O</P>
<P>Exclusion criteria: pregnancy, age &#8804; 18 years, ALI &gt; 72 hours, sepsis-induced ARDS, non-pulmonary organ system dysfunction at randomization, history of immunocompromise, persistent systemic hypotension and shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:39:31 +0100" MODIFIED_BY="[Empty name]">
<P>INO: 192 participants, INO at 5 ppm until end of trial (28 days)</P>
<P>Control: 193 participants, placebo (nitrogen gas), until end of trial (28 days) or until oxygenation and PEEP criteria were met</P>
<P>Standard care, ventilation and weaning protocol for both groups. No cross-overs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:39:32 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: days alive and off assisted breathing to day 28</P>
<P>Secondary outcomes: mortality, days alive and meeting oxygenation criteria for extubation, days alive following a successful unassisted ventilation test, adverse events, methaemoglobin, NO<SUB>2</SUB>, oxygenation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:39:35 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA. 46 centres<BR/>Letter sent to study authors in June 2009. No reply received</P>
<P>One-year follow-up data published as <LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK>. Letter sent to study authors in June 2009 and reply received in 2009. No additional data provided </P>
<P>10 participants in INO group and 14 in control group received prone position ventilation</P>
<P>Study authors' conclusion: "Inhaled nitric oxide at a dose of 5 ppm in patients with acute lung injury not due to sepsis and without evidence of non-pulmonary organ system dysfunction results in short-term oxygenation improvements but has no substantial impact on the duration of ventilatory support or mortality"</P>
<P>Funding: funded by industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Troncy-1998">
<CHAR_METHODS MODIFIED="2016-06-25 10:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, single-centre RCT<BR/>ITT: yes<BR/>Overall study quality: high risk of bias<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:39:44 +0100" MODIFIED_BY="[Empty name]">
<P>Included: 30 participants with ARDS, between 18 and 75 years of age. Lung injury score minimum 2.5</P>
<P>Exclusion criteria: pregnancy, severe immunosuppression from end-stage neoplasia, pulmonary capillary wedge pressure &gt; 18 mm Hg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 15 participants, with increasing doses initially from 2.5, 5, 10, 20, 30 to 40 ppm every 10 minutes and daily re-titration until oxygenation and PEEP criteria were met Mean duration of INO treatment 8 days and mean dose 5.3 ppm</P>
<P>Control group: 15 participants, no placebo gas</P>
<P>Standard care and no cross-overs. Ventilation strategy and weaning of INO standardized (tidal volume of 10 mL/kg, goal PaCO<SUB>2</SUB> 35 to 45 mm Hg, maximum PEEP 15 cm H<SUB>2</SUB>O, goal PaO<SUB>2</SUB> &gt; 85 mm Hg, no prone position). Standardized protocols for sedation, curarization, intravenous perfusion, blood transfusion, parenteral or enteral feeding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: therapeutic failure, death before 30 days, continued ventilation after 30 days, effects of INO on lung function<BR/>Secondary outcomes: lung compliance, pulmonary arterial pressure, PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>, pH, bicarbonate, volume dead space/tidal volume, alveolar-arterial oxygen difference, cardiac output, adverse events, methaemoglobin levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Canada</P>
<P>Letter sent to study authors in June 2009. No reply received. Length of follow-up: 30 days</P>
<P>Additional data on ventilator-free days, duration of mechanical ventilation, PaO<SUB>2</SUB>/FiO<SUB>2</SUB>; oxygenation index for INO group provided by Dr. Neill Adhikari on the basis of his work on his recent systematic review in BMJ (<LINK REF="REF-Adhikari-2007" TYPE="REFERENCE">Adhikari 2007</LINK>). Troncy et al reported duration of ventilation but assigned participants who died a duration of ventilation of 30 days. Adhikari et al assumed that all participants who died before day 30 were ventilated and derived the mean number of ventilator-free days to 30 days</P>
<P>Study authors' conclusion: "This study shows that inhNO, in this population, may improve gas exchange but does not affect mortality"</P>
<P>Funding: not for profit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AHRF: acute ischaemic heart failure; AIDS: acquired immune deficiency syndrome; ALI: acute lung injury; APACHE: Acute Physiology and Chronic Health Evaluation; ARDS: acute respiratory distress syndrome; BMJ: British Medical Journal; cm: centimetre; CMV: continuous mandatory ventilation; COPD: chronic obstructive pulmonary disease; DPG: diphosphoglycerate; ECMO: extracorporeal membrane oxygenation; FiO<SUB>2</SUB>: inspired fraction of oxygen; HFOV: high-frequency oscillatory ventilation; ICU: intensive care unit; INO: inhaled nitric oxide; ITT: intention-to-treat; kg: kilogram; kPa: kilopascal; LRM: lung recruitment manoeuvre; MAP: mean arterial pressure; mL: millilitres; mm Hg: millimetre of mercury; MPAP: mean pulmonary artery pressure; NO: nitric oxide; NO<SUB>2</SUB>: nitrogen dioxide; OI: oxygen index; PA: pulmonary artery; PAOP: pulmonary artery occlusion pressure; PCO<SUB>2</SUB>: partial pressure of carbon dioxide; PCWP: pulmonary capillary wedge pressure; PEEP: positive end-expiratory pressure; pH: potential hydrogen; PO<SUB>2</SUB>: partial pressure of oxygen; ppm: parts per million; PVR: pulmonary vascular resistance; RCT: randomized controlled trial; SaO<SUB>2</SUB>: peripheral capillary saturation; SRF: severe respiratory failure; SVR: systemic vascular resistance; vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-06-25 10:41:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuthbertson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:45 +0100" MODIFIED_BY="[Empty name]">
<P>Two-group parallel RCT, 1 centre. ITT: no evaluation of reversal of ALI in participant receiving INO compared with participant given no treatment other than conventional therapy. Study excluded because most participants (24 of 30 randomized) were included in a European multi-centre study (<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>) and therefore would be counted twice if both studies were included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johannigman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:46 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective non-blinded RCT, evaluating clinical response to 4 randomly administered concentrations (1, 15, 30 and 60 ppm) of INO, each for a 3-hour period in 20 adults with ARDS. Study excluded because of short period of treatment and documentation of outcomes only up to 3 hours. Method of randomization and blinding to doses of administered gas unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:48 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, randomized, cross-over pilot trial comparing nitric oxide and prostacyclin in the treatment of pulmonary hypertension, refractory hypoxaemia and right ventricular dysfunction in thoracic transplant recipients. Study excluded owing to inclusion of a different patient category</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meade-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:50 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective placebo-controlled RCT enrolling 84 participants to evaluate effects of inhaled NO (20 ppm NO or nitrogen) initiated 10 minutes after reperfusion on outcomes after lung transplantation. Study excluded owing to different patient category, diagnosis and outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perrin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:51 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective RCT with 32 double-lung transplant recipients randomized to control or to 20 ppm INO at the time of reperfusion. Study excluded owing to different patient category, diagnosis and outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puybasset-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:53 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective non-blinded RCT to determine the dose-response curve of inhaled INO in 6 adult participants with ARDS. 8 concentrations of inhaled NO administered at random: 100, 400, 700, 1000, 1300, 1600, 1900 and 5000 parts per billion (ppb), with measurements made after 20 minutes of exposure. Study excluded because of short-term administration of INO and assessment at 20 minutes post treatment only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puybasset-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective RCT examining effects of INO with and without PEEP in 21 adults with ARDS. Excluded because of short-term documentation of outcomes and short-term administration of INO at 30 minutes post stabilization only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossaint--1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective non-blinded RCT in which 10 adult participants with ARDS in random sequence inhaled NO at a concentration of 18 parts per million (ppm) followed by 36 ppm, and received an intravenous infusion of prostaglandin PGI2 (4 ng/kg/mn) compared with conventional therapy. Study excluded as intravenous prostacyclin was included in the treatment regimen, because it is an active intervention not provided to the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-25 10:40:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-25 10:40:59 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective non-blinded RCT examining effects of 3 concentrations of INO (1, 10 and 20 parts per million (ppm) in random order) for 12 children with ARDS. Study excluded because measurements were taken 1 hour after administration of study gas only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ALI: acute lung injury; ARDS: acute respiratory distress syndrome; INO: inhaled nitric oxide; ITT: intention-to-treat; kg: kilogram; mn: minutes; NO: nitric oxide; PEEP: positive end-expiratory pressure; PGI: prostaglandin; ppb: parts per billion; ppm: parts per million; RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-06-25 10:43:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-06-25 10:42:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godinez">
<CHAR_STUDY_NAME MODIFIED="2016-06-25 10:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>Nitric Oxide Administration for Acute Respiratory Distress Syndrome</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-06-25 10:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, 1-centre, group-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-25 10:41:14 +0100" MODIFIED_BY="[Empty name]">
<P>52 children from 1 month to 18 years of age, mechanically ventilated with PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio &#8804; 100, FiO<SUB>2</SUB> &#8805; 0.60, PEEP &#8805; 10 and Murray score &#8805; 2.5</P>
<P>Exclusion criteria: neonates (1 week to 28 days) and/or patients on extracorporeal membrane oxygenation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-25 10:41:17 +0100" MODIFIED_BY="[Empty name]">
<P>INO group: 28 participants; 10 ppm NO for 4 hours; initiation after 4 hours</P>
<P>Control group: 24 participants; no intervention; initiation after administration of INO for 4 hours (then stop)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-25 10:41:21 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: mean PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio</P>
<P>Secondary outcomes: duration of FiO<SUB>2 </SUB>&gt; 0.60, effect of early vs delayed onset of NO therapy, evaluation of characteristics of patients who respond to NO compared with those who do not</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-10 13:33:45 +0000" MODIFIED_BY="[Empty name]">
<P>October 14, 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-11-10 13:33:47 +0000" MODIFIED_BY="[Empty name]">
<P>Richard Lin, The Children's Hospital of Philadelphia; e-mail: <A HREF="mailto:linr%40email.chop.edu?subject=NCT00240487,%202000-9-2088,%20Nitric%20Oxide%20Administration%20for%20Acute%20Respiratory%20Distress%20Syndrome">linr@email.chop.edu</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-06-25 10:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>According to the data available on <A HREF="http://ClinicalTrials.gov">ClinicalTrials.gov</A>, the study was completed in February 2006. However, no results have been published so far. We tried to contact study authors but unsuccessfully.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>FiO<SUB>2</SUB>: fraction of inspired oxygen; </P>
<P>INO: inhaled; </P>
<P>NO: nitric oxide; </P>
<P>PaO<SUB>2</SUB>: partial pressure of oxygen in arterial blood; </P>
<P>PEEP: positive end-expiratory pressure; </P>
<P>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-06-25 10:39:58 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-29 14:18:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>Randomization by central registry. Lack of information about sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:27:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 11:30:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>Blocked for each site, unclear method. Considered adequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>Appears adequate, randomization cards, type not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 15:24:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:28:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-29 14:18:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>Central computer randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>Computer-generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>Randomized within each ICU with balanced blocks of 14 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-23 01:35:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Central computer randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-29 14:20:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>Central computer randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:27:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>Blinded draw of 1 lot per participant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 15:18:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>Sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>Envelopes sealed, sequentially numbered and opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 17:38:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>Drawing a closed lot. Envelopes sealed and sequentially numbered and opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 15:27:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:28:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>Central computer allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>At the time of randomization, investigator was granted access to entire randomization list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 15:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>Inadequte. One random number generated when patient eligible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:29:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Adequate, central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>Table of gas cylinder codes revealed in sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:30:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>Adequate, central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>Inadequate, sealed envelopes sequentially numbered and opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>Attending physician and care team blinded to study gas used and not allowed to manipulate blinded delivery system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-04 21:27:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:27:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>Clinicians and outcome assessors blinded during entire course of the trial. One unblinded investigator at each site, responsible for determining treatment allocation for each participant by using a supplied masked randomization code and daily recording of NO, NO<SUB>2</SUB> and methaemoglobin concentrations. These values were kept strictly confidential</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:28:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>Clinicians and outcome assessors blinded during entire course of the trial. One unblinded investigator (respiratory therapist or nurse) at each site determined treatment allocation for each participant and monitored INO and NO<SUB>2</SUB> concentrations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-03 12:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-04 21:28:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-04 21:28:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>Neither participants nor medical personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-04 21:29:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-04 21:29:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Adequate, blinding of participants, caregivers, data collectors, assessors of outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>Clinicians and outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:39:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>Blinding of participants, caregivers, data collectors, assessors of outcomes and data analysts (triple-blind)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-06-25 10:39:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>Unclear, no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-06-25 10:39:57 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>All participants followed until 28 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:27:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:28:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>Yes. Appears to have complete follow-up during trial period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:28:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>Follow up: adequate. No post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:30:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>Follow-up: adequate, 90 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>Unable to assess degree of follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:37:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:38:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>Unclear follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>Follow-up sufficient during the trial period. However, <LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK> describes 1-year follow-up of the same trial, and some participants were lost to follow-up. Despite this fact, this is the only trial with long-term follow-up, thus we have labelled it as having complete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-25 10:39:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>Follow-up: adequate, no post-trial follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-06-25 10:39:58 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:26:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>Yes. Unable to compare versus protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:27:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:30:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:38:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>No data on mortality provided in the abstract although this was an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>Yes. Unable to compare with protocol but appears to be free of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-06-25 10:39:58 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:26:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bronicki-2015">
<DESCRIPTION>
<P>Study terminated prematurely owing to slow enrolment (planned 338 participants, enrolled 55 participants)</P>
<P>Lack of explicit protocol for management of mechanical ventilation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:28:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Day-1997">
<DESCRIPTION>
<P>No apparent other type of bias except that no sample size calculation was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:28:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dellinger-1998">
<DESCRIPTION>
<P>No apparent bias except funding bias (industry)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dobyns-1999">
<DESCRIPTION>
<P>No apparent other type of bias, except that no sample size calculation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:28:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerlach-2003">
<DESCRIPTION>
<P>No apparent other type of bias except that no sample size calculation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:30:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibrahim-2007">
<DESCRIPTION>
<P>No apparent other type of bias except that no sample size calculation or funding reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lundin-1999">
<DESCRIPTION>
<P>Powered for 600 participants, stopped early because of slow recruitment. 268 patients evaluated, but only 67% included on the basis of INO response. Protocol amendment after 140 participants randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mehta-2001">
<DESCRIPTION>
<P>No apparent bias except funding bias (financed in part by industry)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-04 21:29:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michael-1998">
<DESCRIPTION>
<P>Appears to be free of other types of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:38:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2003">
<DESCRIPTION>
<P>No apparent other type of bias except that no sample size calculation or funding reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 15:39:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Payen-1999">
<DESCRIPTION>
<P>Publication bias. This trial was not published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schwebel-1997">
<DESCRIPTION>
<P>Publication bias (published only as an abstract)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-29 14:16:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taylor-2004">
<DESCRIPTION>
<P>No apparent other type of bias except possible funding bias (industry)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-25 10:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troncy-1998">
<DESCRIPTION>
<P>No apparent other type of bias except no sample size calculation reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-06-25 10:45:02 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-06-25 10:45:02 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-06-25 10:45:02 +0100" MODIFIED_BY="[Empty name]">INO compared with control group for acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) in children and adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD ALIGN="LEFT" COLSPAN="7">
<P>
<B>INO compared with control group for acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) in children and adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> critically ill participants with ALI and ARDS</P>
<P>
<B>Setting:</B> intensive care units, worldwide<BR/>
<B>Intervention:</B> INO</P>
<P>
<B>Comparison:</B> control<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INO</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Overall mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>375 per 1000</B>
</P>
<P>(337 to 415)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>382 per 1000</B>
</P>
<P>(346 to 420)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.9 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1243<BR/>(13 studies<SUP>a</SUP>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TSA alfa-spending-adjusted analysis results in an RR of 1.04 (95% CI 0. to 1.23; I² = 0%, diversity D² = 0%). Only 41.92% of the required information size is actually available at this stage for rejection or acceptance of a 4% RRI for overall mortality. However, solid evidence may be obtained with fewer participants if eventually the cumulative meta-analysis z-curve crosses the trial sequential monitoring boundary constructed for a required information size of 3015 randomized participants (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>)</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Overall mortality at 28 days</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>320 per 1000</B>
</P>
<P>(282 to 362)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>344 per 1000</B>
</P>
<P>(307 to 383)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 1.08</B> (0.92 to 1.27)</P>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1105<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Mortality in paediatric population (subgroup)</B>
</P>
</TD>
<TD>
<P>
<B>354 per 1000</B>
</P>
<P>(266 to 454)</P>
</TD>
<TD>
<P>
<B>281 per 1000</B>
</P>
<P>(181 to 382)</P>
</TD>
<TD>
<P>
<B>RR 0.78 </B>
<BR/>(0.51 to 1.18)</P>
</TD>
<TD>
<P>185 (3 paediatric studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>b</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 24 hours</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 24 hours was <B>higher</B>
<BR/>(<B>15.91, </B>95% CI 8.25 to 23.56 higher) in the intervention group</P>
<P/>
<P/>
</TD>
<TD>
<P>
<B>MD 15.91 </B>
<BR/>(8.25 to 23.56)</P>
</TD>
<TD>
<P>614<BR/>(11 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>b</SUP>
</P>
<P/>
</TD>
<TD>
<P>TSA-adjusted results with a mean difference of 15.91 with substantial heterogeneity and diversity (95% CI 8.25 to 23.56; I² = 25%, diversity D² = 49%)</P>
<P>TSA alfa-spending-adjusted confidence interval for the meta-analysis in a random-effects model results in an MD of 15.91 with substantial heterogeneity and diversity (95% CI 9.67 to 22.15; I² = 25%, diversity D² = 49%) with a required information size of 315 (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). However, the required information size based on the 2 trials with low risk of bias is 5137 participants (MD 14.94, TSA-adjusted 95% CI -73.70 to -103.58; I² = 87%, diversity D² = 91%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Oxygenation index, 24 hours</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Mean oxygenation index at 24 hours was <B>lower</B>
<BR/>(<B>2.31, </B>95% CI 2.73 to 1.89) in the intervention group</P>
</TD>
<TD>
<P>
<B>MD -2.31 </B>
<BR/>(-2.73 to -1.89)</P>
</TD>
<TD>
<P>368<BR/>(5 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ventilation-free days, up to 30 days</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<B>No statistically significant difference was noted</B> between control and intervention groups</P>
</TD>
<TD>
<P>
<B>MD -0.57 </B>(-1.82 to 0.69)</P>
</TD>
<TD>
<P>804 (5 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>c</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Renal impairment </B>
</P>
</TD>
<TD>
<P>
<B>115 per 1000</B>
</P>
<P>(89 to 149)</P>
</TD>
<TD>
<P>
<B>181 per 1000</B>
</P>
<P>(150 to 217)<BR/>
</P>
</TD>
<TD>
<P>
<B>RR 1.59 </B>
<BR/>(1.17 to 2.16)</P>
</TD>
<TD>
<P>945<BR/>(4 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>c</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>INO:</B> inhaled nitric oxide; <B>MD:</B> mean difference; <B>RR:</B> risk ratio; <B>RRI:</B> relative risk increase; <B>TSA:</B> trial sequential analysis; <B>vs:</B> versus</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Sensitivity analysis excluding trials published as abstracts did not change the overall mortality effect estimate</P>
<P>
<SUP>b</SUP>The outcome was upgraded from low to moderate quality of evidence because most trials had moderate risk of bias</P>
<P>
<SUP>c</SUP>The outcome was upgraded from moderate to high quality of evidence because most trials had low risk of bias<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-06-27 11:29:09 +0100" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-06-27 11:29:09 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2010-03-16 11:56:51 +0000" MODIFIED_BY="[Empty name]">Details of included studies</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Population and inclusion criteria</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>INO group characteristics and details of INO administration</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Control group characteristics</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Ventilation strategy</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Duration of longest follow-up</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Co-interventions</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>53 children, 9 centres, oxygenation index (OI) &#8805; 12; chest radiograph with pulmonary infiltrates; mechanically ventilated &#8804; 7 days</P>
</TD>
<TD ALIGN="CENTER">
<P>24 participants, 5 ppm INO until death, ventilator-free or at day 28 after enrolment (whichever came first)</P>
</TD>
<TD ALIGN="CENTER">
<P>29 participants, 5 ppm nitrogen</P>
</TD>
<TD ALIGN="CENTER">
<P>CMV: low-volume tidal strategy (4-8 mL/kg and plateau pressure &lt; 30 cm H<SUB>2</SUB>O); PEEP based on serial chest radiographs. Target arterial blood gas values: SaO<SUB>2</SUB> 88%-95% with FiO<SUB>2</SUB> &lt; 0.60; PaO<SUB>2</SUB> 55-80 mm Hg; pH 7.25-7.40</P>
<P>HFOV settings: based on serial chest radiographs (as CMV); target FiO<SUB>2</SUB> and PaO<SUB>2</SUB> same as for CMV. FiO<SUB>2</SUB> weaned over mean airway pressure until FiO<SUB>2</SUB> &lt; 0.60. Transfer to CMV before weaning</P>
</TD>
<TD ALIGN="CENTER">
<P>28 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Prone position</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Day-1997">Day 1997</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>24 children, 1 centre, acute bilateral lung disease (chest x-ray infiltrates), PEEP &gt; 6 cm H<SUB>2</SUB>O, FiO<SUB>2</SUB> &gt; 0.5 for &gt; 12 hours. Enrolment &#8804; 48 hours of meeting study criteria</P>
</TD>
<TD ALIGN="CENTER">
<P>INO group: 12 participants, 10 ppm INO until ventilatory support decreased to PEEP of 6 cm H<SUB>2</SUB>O and FiO<SUB>2</SUB> of 0.5. INO withdrawn over 6 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>12 participants, initially conventional therapy alone, no placebo. After 24 hours, all participants received 10 ppm INO. No cross-over before 24 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation at clinician discretion. INO therapy withdrawn in gradual decrements over a period of 6 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear, only 24-hour data included because of cross-over</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Dellinger-1998">Dellinger 1998</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>177 adults, 30 centres, ARDS &lt; 72 hours before randomization, AECC criteria and FiO<SUB>2</SUB> &#8805; 0.5, PEEP &gt; 8 cm H<SUB>2</SUB>O</P>
</TD>
<TD ALIGN="CENTER">
<P>120 participants at doses of 1.25, 5, 20, 40 or 80 ppm, for 28 days or until extubation</P>
</TD>
<TD ALIGN="CENTER">
<P>57 participants, usual care, placebo gas (nitrogen), no cross-over of treatment failures</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation strategy and weaning of INO standardized (plateau airway pressure &lt; 35 cm H<SUB>2</SUB>O; PEEP to optimize compliance, FiO<SUB>2</SUB> minimized)</P>
</TD>
<TD ALIGN="CENTER">
<P>28 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Corticosteroids received by more participants in INO group after day 6 (20/112 vs 6/57)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Dobyns-1999">Dobyns 1999</A>; (<A HREF="http://archie.cochrane.org/sections/documents/#REF-Dobyns-2002">Dobyns 2002</A>)</P>
</TD>
<TD ALIGN="CENTER">
<P>108 children, 7 centres, oxygenation index &gt; 15 on 2 arterial blood gases &lt; 6 hours, chest infiltrates. Mean duration of ventilation before randomization: 3.5 vs 3.7 days (INO vs control)</P>
</TD>
<TD ALIGN="CENTER">
<P>53 children, 10 ppm for 3 days, then weaned if failure criteria not met. INO for maximum of 7 days after entry</P>
</TD>
<TD ALIGN="CENTER">
<P>55 children, usual care, placebo gas (air), cross-over of participants meeting treatment failure criteria (27 participants)</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation strategy and weaning of gas standardized (peak airway pressure &lt; 35-40 cm H<SUB>2</SUB>O, tidal volume limitation, titrated PEEP, high-frequency oscillatory ventilation by clinician discretion)</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear, ventilation data reported for day 108</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Gerlach-2003">Gerlach 2003</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>40 adults with ARDS (AECC criteria), FiO<SUB>2</SUB> &#8805; 0.6, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 150 mm Hg, PEEP &#8805; 10 cm H<SUB>2</SUB>O, PAOP &#8804; 18 mm Hg, median duration of ventilation before randomization: 5.3 vs 5.9 days (INO vs control)</P>
</TD>
<TD ALIGN="CENTER">
<P>20 participants, 10 ppm with daily dose response analysis until weaning initiated</P>
</TD>
<TD ALIGN="CENTER">
<P>20 participants, usual care, no placebo, no cross-overs</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation protocols, unspecified</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear, length of stay in ICU reported for day 91</P>
</TD>
<TD ALIGN="CENTER">
<P>Standard care according to standardized protocols. Protocols for prone position (4-6 hours), extracorporeal membrane oxygenation (ECMO), permissive hypercapnia and measures to reduce pulmonary oedema</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Ibrahim-2007">Ibrahim 2007</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>32 children, single-centre, ARDS (PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 200 mm Hg, positive inspiratory pressure &#8805; 30 cm H<SUB>2</SUB>O, FiO<SUB>2</SUB> &#8805; 0.5 for &gt; 12 hours)</P>
</TD>
<TD ALIGN="CENTER">
<P>22 children, INO + supine position (11 children) and INO + prone position (11 patients). INO at 5 ppm for 18 hours, then decreased to 1 ppm for 2 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>10 participants kept in prone position for 20 hours, then back to supine position for remaining 4 hours. No placebo, usual care. No cross-over</P>
</TD>
<TD ALIGN="CENTER">
<P>Lung protective strategy (tidal volume 5-10 mL/kg), permissive hypercapnia (PaCO<SUB>2</SUB> &gt; 50 mm Hg) as long as arterial pH &gt; 7.2. Ventilation and weaning protocol</P>
</TD>
<TD ALIGN="CENTER">
<P>24 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>Prone position (11/22 in INO group and 10/10 in control group)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Lundin-1999">Lundin 1999</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>80 adults, 43 centres, INO responders with ALI (lung infiltrates, ventilated for 18-96 hours, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 165 mm Hg, PEEP &gt; 5 cm H<SUB>2</SUB>O, MAP &gt; 10 cm H<SUB>2</SUB>O, pressure- or volume-controlled ventilation, I:E ratio between 1:2 and 2:1, duration of ventilation before randomization 0.75-4 days</P>
</TD>
<TD ALIGN="CENTER">
<P>93 participants, 1-40 ppm INO at lowest effective dose for up to 30 days or until end point reached. Mean INO dose: 9 ppm (SD 8), mean number of days of INO: 9 (SD 6)</P>
</TD>
<TD ALIGN="CENTER">
<P>87 participants, no placebo gas, cross-over of treatment failures allowed (6 participants)</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation strategy and weaning test gas according to usual standards of care and at clinician discretion</P>
</TD>
<TD ALIGN="CENTER">
<P>90 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Mehta-2001">Mehta 2001</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>14 adults, single-centre, ARDS &#8804; 5 days, bilateral chest infiltrates, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 200 mm Hg, PAOP &lt; 18 cm H<SUB>2</SUB>O, PEEP &#8805; 8 cm H<SUB>2</SUB>O</P>
</TD>
<TD ALIGN="CENTER">
<P>8 participants, daily titration for 4 days (5,10, 20 ppm every 30 minutes), dose with highest PaO<SUB>2</SUB>/FiO<SUB>2</SUB> used until next day. INO until PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &gt; 200 mm Hg on FiO<SUB>2</SUB> &lt; 0.5. Mean duration of INO: 8 days (SD 9). INO 5-10 ppm used for most participants on days 2-4</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
<P>6 participants, no placebo, conventional therapy. No cross-overs</P>
</TD>
<TD ALIGN="CENTER">
<P>Clinician discretion</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear, mortality data provided at day 68</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described. Prone position protocol but not used in any participant</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Michael-1998">Michael 1998</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>40 adults and children, single-centre. ARDS, AECC criteria except PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 150 mm Hg and FiO<SUB>2</SUB> &gt; 0.8 for &#8805; 12 hours or 0.65 for &#8805; 24 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>20 participants, INO titration each 6 hours (5, 10, 15, 20 ppm) for 24 hours, then clinically adjusted, tapered if no oxygenation improvement by 72 hours. Mean INO dose: 13 ppm</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
<P>20 participants, conventional therapy. No placebo gas. Cross-over: 2 participants received INO before and 7 participants after 72 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>Mode of ventilation unchanged throughout study period with similar PEEP between groups for 72 hours. Pre-defined criteria for clinical deterioration, clinician discretion</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear, data on ARDS duration provided for day 25</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Park-2003">Park 2003</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>23 adults, single-centre, ARDS (AECC criteria)</P>
</TD>
<TD ALIGN="CENTER">
<P>6 participants received INO 5 ppm. Mean duration of INO treatment: 8.2 days</P>
</TD>
<TD ALIGN="CENTER">
<P>6 participants, conventional therapy, lung recruitment manoeuvre (LRM) twice daily, no placebo gas. No cross-overs</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation protocol (LRM + inflation pressure of 30-35 cm H<SUB>2</SUB>O for 30 seconds, volume control mode, tidal volume 6 mL/kg/ideal body weight, respiratory rate 20-25/min, plateau airway pressure &#8804; 30 cm H<SUB>2</SUB>O, PEEP to optimize PaO<SUB>2</SUB>, FiO<SUB>2</SUB> minimized), weaning protocol</P>
</TD>
<TD ALIGN="CENTER">
<P>28 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described. Prone position protocol but not used in any participant</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Payen-1999">Payen 1999</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>203 adults, 23 centres, &gt; 15 years, ARDS (AECC criteria and Murray lung injury score: 2-3 after 24-hour optimization period), mean duration of ventilation before randomization: 5.3 vs 5.9 days (INO vs control)</P>
</TD>
<TD ALIGN="CENTER">
<P>98 participants, fixed INO of 10 ppm until oxygenation and PEEP criteria met with median INO administration of 5 days. 12 participants crossed over to control group owing to treatment failure</P>
</TD>
<TD ALIGN="CENTER">
<P>105 participants, placebo gas (nitrogen), conventional therapy. 19 participants crossed over to INO group owing to treatment failure</P>
</TD>
<TD ALIGN="CENTER">
<P>Various ventilation guidelines (e.g. recruitment manoeuvres, prone position, limited tidal volume, peak and plateau inspiratory pressures) applied before randomization. No information after randomization</P>
</TD>
<TD ALIGN="CENTER">
<P>90 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Schwebel-1997">Schwebel 1997</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>19 participants, 17 centres, ARDS &#8804; 24 hours, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 200, PEEP 6-10 cm H<SUB>2</SUB>O, PAOP 10-18 cm H<SUB>2</SUB>O, chest x-ray infiltrates</P>
</TD>
<TD ALIGN="CENTER">
<P>9 participants, 10 ppm INO for 17 hours followed by clinician discretion. Mean INO treatment: 4.6 days</P>
</TD>
<TD ALIGN="CENTER">
<P>10 participants, placebo gas (nitrogen), conventional therapy. At least 5 participants crossed over to INO</P>
</TD>
<TD ALIGN="CENTER">
<P>Fixed mechanical ventilation. If PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &lt; 100 before 17 hours of treatment, cross-over, thereafter INO or other technic or change in respiratory parameters</P>
</TD>
<TD ALIGN="CENTER">
<P>Unclear</P>
</TD>
<TD ALIGN="CENTER">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Taylor-2004">Taylor 2004</A>; (<A HREF="http://archie.cochrane.org/sections/documents/#REF-Angus-2006">Angus 2006</A>)</P>
</TD>
<TD ALIGN="CENTER">
<P>385 adults, 46 centres, ALI &#8804; 3 days of duration, modified AECC criteria: PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &#8804; 250, bilateral infiltrates on x-ray, PAOP &#8804; 18 mm Hg or no signs of left atrial hypertension, FiO<SUB>2</SUB> 0.5-0.95 or PEEP &#8805; 8 cm H<SUB>2</SUB>O</P>
</TD>
<TD ALIGN="CENTER">
<P>192 participants, 5 ppm INO until oxygenation and PEEP criteria met or until end of trial (28 days)</P>
</TD>
<TD ALIGN="CENTER">
<P>193 participants, placebo (nitrogen gas), until end of trial (28 days), no cross-overs, conventional therapy</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation protocol (FiO<SUB>2 </SUB>minimized, PEEP to optimize compliance and prevent shear force injury, plateau pressure &#8804; 35 cm H<SUB>2</SUB>O). Weaning protocol</P>
</TD>
<TD ALIGN="CENTER">
<P>1 year</P>
</TD>
<TD ALIGN="CENTER">
<P>Prone position (INO 10/192 vs control 14/193)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<A HREF="http://archie.cochrane.org/sections/documents/#STD-Troncy-1998">Troncy 1998</A>
</P>
</TD>
<TD ALIGN="CENTER">
<P>30 participants, single-centre, ARDS, Murray lung injury score &#8805; 2.5</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
<P>15 participants, dose titration (2.5, 5, 10, 20, 30, 40 ppm every 10 minutes), daily re-titration. Mean duration of INO: 8 days (SD 5), mean dose: 5.3 ppm</P>
</TD>
<TD ALIGN="CENTER">
<P>15 participants, no placebo gas, conventional therapy, no cross-overs</P>
</TD>
<TD ALIGN="CENTER">
<P>Ventilation protocol (tidal volume: 10 mL/kg, PaCO<SUB>2</SUB> &#8804; 35-45 mm Hg, PEEP &#8804; 15 cm H<SUB>2</SUB>O, PaO<SUB>2</SUB> &gt; 85 mm Hg, no prone position). Weaning protocol</P>
</TD>
<TD ALIGN="CENTER">
<P>30 days</P>
</TD>
<TD ALIGN="CENTER">
<P>Protocols for sedation, curarization, intravenous perfusion, blood transfusion, parenteral or enteral feeding. Prone position protocol but not used in any participant</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>AECC: American-European Consensus Conference; ALI: acute lung injury; ARDS: acute respiratory distress syndrome; cm: centimetre; cm H<SUB>2</SUB>O: centimetre of water; CMV: continuous mandatory ventilation; ECMO: extracorporeal membrane oxygenation; FiO<SUB>2</SUB>: fraction of inspired oxygen; HFOV: high-frequency oscillatory ventilation; ICU: intensive care unit; I:E: ventilator inspiratory-to-expiratory time ratio; INO: inhaled nitric oxide; LRM: lung recruitment manoeuvre; MAP: mean arterial pressure; min: minutes; mL/kg: millilitres per kilogram; mm Hg: millimetre of mercury; OI: oxygen index; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide in arterial blood; PaO<SUB>2</SUB>: partial pressure of oxygen in arterial blood; PAOP: pulmonary artery occlusion pressure; PEEP: positive end-expiratory pressure; pH: potential hydrogen; ppm: parts per million; SaO<SUB>2</SUB>: arterial oxygen saturation; SD: standard deviation; vs: versus; x-ray: chest radiography</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-06-25 11:04:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-06-25 11:04:03 +0100" MODIFIED_BY="[Empty name]">Complications during in-patient stay: INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Hypertension</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>177</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.16 [0.01, 3.86]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Myopathy/Agitation</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>177</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.44 [0.06, 34.76]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Liver impairment</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>177</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.44 [0.06, 34.76]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Encephalopathy</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>180</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>6.55 [0.34, 125.07]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Sepsis</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>180</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.18 [0.58, 8.18]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Myocardial infarction</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>3.00 [0.13, 69.52]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Infection</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>385</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.62 [1.16, 2.26]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Pneumonia</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>385</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.80 [0.52, 1.22]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-06-25 10:56:05 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-06-25 10:56:00 +0100" MODIFIED_BY="[Empty name]">Oxygenation index: INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Oxygenation index at 72 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>134</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>-4.00 [-7.69, -0.31]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Oxygenation index change from baseline up to 24 hours</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>108</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>5.00 [-1.21, 11.21]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-06-25 10:56:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-06-25 10:56:39 +0100" MODIFIED_BY="[Empty name]">Resolution of multi-organ failure, INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>TISS score</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>385</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>4.60 [-57.24, 66.44]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>TISS score: Therapeutic Intervention Scoring System</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2016-06-25 10:56:50 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-06-25 10:56:27 +0100" MODIFIED_BY="[Empty name]">Quality of life assessment: INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>ADL score at 6 months: INO vs control</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>368</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.00 [-5.09, 3.09]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>ADL score at 12 months: INO vs control</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>368</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.00 [-5.07, 1.07]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ADL = activity of daily living</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2016-06-25 10:57:51 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-06-25 10:57:23 +0100" MODIFIED_BY="[Empty name]">Length of stay in ICU and hospital: INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of days in hospital</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>368</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.10 [-4.51, 4.71]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Mean length of stay in ICU</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>368</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.40 [-1.99, 4.79]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ICU: intensive care unit</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2016-06-25 10:58:14 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2016-06-25 10:58:06 +0100" MODIFIED_BY="[Empty name]">Cost-benefit analysis: INO versus control, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Total hospital cost in US$</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>312</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean difference (IV, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>700.00 [-9595.70, 10995.70]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2016-06-25 10:58:17 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2016-06-25 10:57:40 +0100" MODIFIED_BY="[Empty name]">Mortality: INO versus control group, single-study analyses</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Subgroup analysis</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistical method</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Effect estimate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Mortality, primary lung injury</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00 [0.58, 1.72]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Mortality, secondary lung injury</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>Risk ratio (M-H, fixed, 95% CI)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.14 [0.69, 1.90]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Mortality</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD>
<P>Relative risk (95% CI)</P>
</TD>
<TD>
<P>0.28 [0.06,1.19]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2016-06-25 10:58:37 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2009-08-13 10:34:15 +0100" MODIFIED_BY="[Empty name]">Abbreviations</TITLE>
<TABLE COLS="1" ROWS="2">
<TR>
<TD>
<P>
<B>Abbreviations</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>ADL: activity of daily living; AECC: American-European Consensus Conference; AHRF: acute hypoxaemic respiratory failure; ALI: acute lung injury; APACHE score: Acute Physiology and Chronic Health Evaluation score; APHIS: a priori heterogeneity adjusted information size; ARDS: acute respiratory distress syndrome; BMJ: British Medical Journal; CI: confidence interval; CINAHL: Cumulative Index to Nursing and Allied Health Literature; cm: centimetre; CMV: conventional mechanical ventilation; COPD: chronic obstructive pulmonary disease; ECMO: extracorporeal membrane oxygenation; FiO<SUB>2</SUB>: fraction of inspired oxygen; HFOV: high-frequency oscillatory ventilation; ICU: intensive care unit; I:E ratio: inspiratory:expiratory ratio; INO: inhaled nitric oxide; ITT: intention-to-treat analysis; LBHIS: low bias heterogeneity adjusted information size; LILACS: Latin American Caribbean Health Sciences Literature; LRM: lung recruitment manoeuvre; MAP: mean arterial pressure; min: minutes; mL/kg: millilitres per kilogram; MPAP: mean arterial pulmonary pressure; ng: nanogram; NO: nitric oxide; NO<SUB>2</SUB>: nitrogen dioxide; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide in arterial blood; PaO<SUB>2</SUB>: partial pressure of oxygen in arterial blood; PAOP: pulmonary artery occlusion pressure; PEEP: positive end-expiratory pressure; P/F ratio: PaO<SUB>2</SUB>/FiO<SUB>2</SUB>; ppm: parts per million; PVR: pulmonary vascular resistance; QWB: quality of well being scale; RCT: randomized controlled trial; RD: risk difference; RR: risk ratio; RRI: relative risk increase; RRR: relative risk reduction; SVR: systemic vascular resistance; TSA: trial sequential analysis; WMD: weighted mean difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-06-25 11:05:42 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-06-25 11:03:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Mortality: INO versus control group</NAME>
<DICH_OUTCOME CHI2="4.9246822240645844" CI_END="1.1903746724921147" CI_START="0.9000191996028166" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.035065244302898" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="221" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07568367785071739" LOG_CI_START="-0.045748225902209096" LOG_EFFECT_SIZE="0.014967725974254133" METHOD="MH" MODIFIED="2016-06-25 11:02:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9347592014155944" P_Q="1.0" P_Z="0.6289741315467303" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="654" TOTAL_2="589" WEIGHT="100.0" Z="0.4831712743249454">
<NAME>Overall mortality: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2904308807530451" CI_START="0.07071617832372805" EFFECT_SIZE="0.3020833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.11073474742195648" LOG_CI_START="-1.1504812177031811" LOG_EFFECT_SIZE="-0.5198732351406123" MODIFIED="2015-10-13 08:05:35 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.740844501034221" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="29" VAR="0.5488505747126438" WEIGHT="3.200827180377076"/>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-06-16 11:27:53 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="0.8835616695832553"/>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" MODIFIED="2009-04-24 09:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="10.183422632484977"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2009-04-16 13:22:55 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="10.406392997313898"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-05-08 22:35:54 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.7671233391665107"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" MODIFIED="2009-04-16 12:36:08 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="17.34726077948458"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-16 08:35:29 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="1.5146771478570091"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-06-16 09:45:50 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="3.9760275131246487"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2009-05-08 21:56:16 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.3061346419926383"/>
<DICH_DATA CI_END="1.3937636564951905" CI_START="0.8236397744508347" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1441891357547089" LOG_CI_START="-0.08426268899982248" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-01-18 19:30:37 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.13419373271558246" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.01800795790014119" WEIGHT="22.606991683819842"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-09 12:09:21 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4087808859773137" CI_START="0.754844306571817" EFFECT_SIZE="1.0312178387650086" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" LOG_CI_END="0.14884345058919407" LOG_CI_START="-0.12214261627748112" LOG_EFFECT_SIZE="0.013350417155856473" MODIFIED="2009-04-16 10:14:27 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.15917855708014989" STUDY_ID="STD-Taylor-2004" TOTAL_1="165" TOTAL_2="167" VAR="0.025337813034118535" WEIGHT="23.273333736462554"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2009-05-08 16:38:40 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="3.5342466783330213"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.821997967461613" CI_END="1.273376296851722" CI_START="0.9155699854323598" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.07975234084416" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="166" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.10495676146758265" LOG_CI_START="-0.03830845297298876" LOG_EFFECT_SIZE="0.03332415424729692" METHOD="MH" MODIFIED="2016-06-25 11:03:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8728156345287557" P_Q="1.0" P_Z="0.3618774689262141" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="518" WEIGHT="99.99999999999999" Z="0.9117934509783288">
<NAME>28- to 30-day mortality: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2904308807530451" CI_START="0.07071617832372805" EFFECT_SIZE="0.3020833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.11073474742195648" LOG_CI_START="-1.1504812177031811" LOG_EFFECT_SIZE="-0.5198732351406123" MODIFIED="2015-09-28 02:48:14 +0100" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.740844501034221" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="29" VAR="0.5488505747126438" WEIGHT="4.21194463216139"/>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" ORDER="178" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="13.400289949072782"/>
<DICH_DATA CI_END="1.545007009513669" CI_START="0.7772733522318684" EFFECT_SIZE="1.0958525345622119" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="35" LOG_CI_END="0.18893045410790954" LOG_CI_START="-0.10942622123962312" LOG_EFFECT_SIZE="0.039752116434143225" MODIFIED="2009-04-16 12:37:10 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.17525618798850262" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.030714731428261366" WEIGHT="21.024989242399364"/>
<DICH_DATA CI_END="5.654021140415214" CI_START="0.39794686721577543" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7523574279859218" LOG_CI_START="-0.4001749098745592" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-06-16 08:39:32 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.6770032003863301" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.45833333333333337" WEIGHT="1.3287682470509143"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-06-16 09:44:45 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="5.232024972762976"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="172" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.7187328412941176"/>
<DICH_DATA CI_END="1.5034909385726025" CI_START="0.8313663517909331" EFFECT_SIZE="1.1180124223602483" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="46" LOG_CI_END="0.17710081498407484" LOG_CI_START="-0.08020755684116218" LOG_EFFECT_SIZE="0.04844662907145632" ORDER="212" O_E="0.0" SE="0.15114421130712666" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.022844572611653353" WEIGHT="25.819341628041048"/>
<DICH_DATA CI_END="1.661602694067858" CI_START="0.7740359142596058" EFFECT_SIZE="1.1340811965811965" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.22052718767837642" LOG_CI_START="-0.11123888815055168" LOG_EFFECT_SIZE="0.05464414976391237" MODIFIED="2009-04-16 10:13:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.1948810352104739" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" VAR="0.03797861788470597" WEIGHT="22.613219622539198"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="139" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="4.650688864678201"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9246822240645844" CI_END="1.1903746724921147" CI_START="0.9000191996028166" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.035065244302898" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="221" I2="0.0" I2_Q="51.441934010867385" ID="CMP-001.03" LOG_CI_END="0.07568367785071739" LOG_CI_START="-0.045748225902209096" LOG_EFFECT_SIZE="0.014967725974254133" METHOD="MH" MODIFIED="2016-06-25 11:03:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9347592014155944" P_Q="0.15127075146177993" P_Z="0.6289741315467303" Q="2.0593900923150477" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="654" TOTAL_2="589" WEIGHT="100.0" Z="0.4831712743249454">
<NAME>Mortality: subgroup analysis, paediatric vs adult population</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5729362440572467" CI_END="1.1827657707341044" CI_START="0.5148473743304491" DF="2" EFFECT_SIZE="0.7803485448890025" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="34" I2="22.267797944102462" ID="CMP-001.03.01" LOG_CI_END="0.07289874754464386" LOG_CI_START="-0.288321497774491" LOG_EFFECT_SIZE="-0.10771137511492358" MODIFIED="2015-11-10 12:55:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2762448484973016" P_Z="0.2424545557495822" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="96" WEIGHT="14.490781847274228" Z="1.168873664675245">
<NAME>Paediatric</NAME>
<DICH_DATA CI_END="1.2904308807530451" CI_START="0.07071617832372805" EFFECT_SIZE="0.3020833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.11073474742195648" LOG_CI_START="-1.1504812177031811" LOG_EFFECT_SIZE="-0.5198732351406123" MODIFIED="2015-11-10 12:52:46 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.740844501034221" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="29" VAR="0.5488505747126438" WEIGHT="3.200827180377076"/>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-11-04 03:45:38 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="0.8835616695832553"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2015-11-10 12:55:23 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="10.406392997313898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2180122108690614" CI_END="1.2509056661153424" CI_START="0.9293917741091007" DF="8" EFFECT_SIZE="1.0782306971488358" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="187" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.0972245597091679" LOG_CI_START="-0.03180117570784531" LOG_EFFECT_SIZE="0.0327116920006613" MODIFIED="2015-11-10 12:55:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9964607732534729" P_Z="0.3203138415671596" STUDIES="10" TAU2="0.0" TOTAL_1="565" TOTAL_2="493" WEIGHT="85.50921815272578" Z="0.9938131797884585">
<NAME>Adult</NAME>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="10.183422632484977"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.7671233391665107"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="17.34726077948458"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="1.5146771478570091"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="3.9760275131246487"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.3061346419926383"/>
<DICH_DATA CI_END="1.3937636564951905" CI_START="0.8236397744508347" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1441891357547089" LOG_CI_START="-0.08426268899982248" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.13419373271558246" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.01800795790014119" WEIGHT="22.606991683819842"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4087808859773137" CI_START="0.754844306571817" EFFECT_SIZE="1.0312178387650086" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" LOG_CI_END="0.14884345058919407" LOG_CI_START="-0.12214261627748112" LOG_EFFECT_SIZE="0.013350417155856473" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.15917855708014989" STUDY_ID="STD-Taylor-2004" TOTAL_1="165" TOTAL_2="167" VAR="0.025337813034118535" WEIGHT="23.273333736462554"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-11-10 12:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="3.5342466783330213"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9736255647988326" CI_END="1.2190282733858016" CI_START="0.9205051740098236" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0593025219057548" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="213" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.08601377849208312" LOG_CI_START="-0.03597376605447976" LOG_EFFECT_SIZE="0.025020006218801703" METHOD="MH" MODIFIED="2015-10-13 08:07:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9965383225106969" P_Q="0.8424370249877143" P_Z="0.42140343831177496" Q="0.03951242535723442" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="630" TOTAL_2="560" WEIGHT="100.0" Z="0.8039888213849814">
<NAME>Mortality: subgroup analysis based on duration of drug administration</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8643503179920844" CI_END="1.2870483384821028" CI_START="0.8418417539393552" DF="3" EFFECT_SIZE="1.0409087523277467" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="88" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.10959485828108419" LOG_CI_START="-0.07476953777574114" LOG_EFFECT_SIZE="0.01741266025267153" MODIFIED="2015-10-13 08:07:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8340213295827754" P_Z="0.7112145870775584" STUDIES="5" TAU2="0.0" TOTAL_1="192" TOTAL_2="202" WEIGHT="39.12530733544049" Z="0.3702253547886678">
<NAME>Shorter than median duration of INO</NAME>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-06-16 11:29:31 +0100" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="0.91277811973631"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2009-09-14 18:35:29 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="10.750497854672096"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-06-16 09:47:13 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="4.107501538813395"/>
<DICH_DATA CI_END="1.3937636564951905" CI_START="0.8236397744508347" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1441891357547089" LOG_CI_START="-0.08426268899982248" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-01-18 19:35:38 +0000" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13419373271558246" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.01800795790014119" WEIGHT="23.354529822218687"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-29 03:32:58 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0721715212069114" CI_END="1.289937934042434" CI_START="0.8894286739551844" DF="6" EFFECT_SIZE="1.071124542786623" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="125" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.11056881452300993" LOG_CI_START="-0.050888873605573086" LOG_EFFECT_SIZE="0.029839970458718394" MODIFIED="2015-09-28 02:06:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9827278228328694" P_Z="0.4687799675294403" STUDIES="7" TAU2="0.0" TOTAL_1="438" TOTAL_2="358" WEIGHT="60.87469266455952" Z="0.7244655621756487">
<NAME>Longer than median duration of INO</NAME>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" MODIFIED="2009-09-14 18:34:47 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="10.52015460035069"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-02-02 11:26:52 +0000" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.82555623947262"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" ORDER="42" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="17.920877084156217"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" ORDER="199" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="1.5647624909765312"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2010-02-02 11:25:55 +0000" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.3493241770015016"/>
<DICH_DATA CI_END="1.4087808859773137" CI_START="0.754844306571817" EFFECT_SIZE="1.0312178387650086" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" LOG_CI_END="0.14884345058919407" LOG_CI_START="-0.12214261627748112" LOG_EFFECT_SIZE="0.013350417155856473" ORDER="27" O_E="0.0" SE="0.15917855708014989" STUDY_ID="STD-Taylor-2004" TOTAL_1="165" TOTAL_2="167" VAR="0.025337813034118535" WEIGHT="24.042905593656716"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2009-09-14 18:34:43 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="3.65111247894524"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.919509747530483" CI_END="1.206646441411445" CI_START="0.8697527352335367" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.024443284363472" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="168" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.08158003642923388" LOG_CI_START="-0.0606041967913952" LOG_EFFECT_SIZE="0.010487919818919323" METHOD="MH" MODIFIED="2016-06-25 11:03:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8964895825049602" P_Q="1.0" P_Z="0.7724702567973508" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="474" WEIGHT="99.99999999999999" Z="0.28914521184537817">
<NAME>Sensitivity analysis: excluding abstracts, INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2904308807530451" CI_START="0.07071617832372805" EFFECT_SIZE="0.3020833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.11073474742195648" LOG_CI_START="-1.1504812177031811" LOG_EFFECT_SIZE="-0.5198732351406123" MODIFIED="2015-10-13 08:20:07 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.740844501034221" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="29" VAR="0.5488505747126438" WEIGHT="4.1358092287877835"/>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-06-16 11:30:02 +0100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="1.141655672529961"/>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" ORDER="182" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="13.158065378311413"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2009-07-29 15:44:54 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="13.446166809797319"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="192" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="2.283311345059922"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" ORDER="43" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="22.414506370671564"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" ORDER="216" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="1.9571240100513614"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-06-16 09:48:25 +0100" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="5.137450526384824"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="176" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.687664907218203"/>
<DICH_DATA CI_END="1.4087808859773137" CI_START="0.754844306571817" EFFECT_SIZE="1.0312178387650086" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" LOG_CI_END="0.14884345058919407" LOG_CI_START="-0.12214261627748112" LOG_EFFECT_SIZE="0.013350417155856473" ORDER="4" O_E="0.0" SE="0.15917855708014989" STUDY_ID="STD-Taylor-2004" TOTAL_1="165" TOTAL_2="167" VAR="0.025337813034118535" WEIGHT="30.071623061067793"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="142" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="4.566622690119844"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4575961701923463" CI_END="1.257564957042951" CI_START="0.9191151829180688" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0751032720273366" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.09953042693410678" LOG_CI_START="-0.03663005970077474" LOG_EFFECT_SIZE="0.031450183616666016" METHOD="MH" MODIFIED="2016-06-25 11:03:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9933898247299645" P_Q="1.0" P_Z="0.36524283100462474" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="381" WEIGHT="100.0" Z="0.9054201952307922">
<NAME>Sensitivity analysis: excluding trials not fulfilling AECC criteria, INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" MODIFIED="2010-01-11 10:49:06 +0000" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="14.01858944276664"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2010-01-11 10:49:14 +0000" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="14.32553241422591"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-01-11 10:49:22 +0000" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="2.432637579774211"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" MODIFIED="2010-01-11 10:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="23.88039224145017"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 10:49:46 +0000" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="2.0851179255207524"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2010-01-11 10:49:52 +0000" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="5.473434554491975"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2010-01-11 10:49:58 +0000" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.7980364720070254"/>
<DICH_DATA CI_END="1.3937636564951905" CI_START="0.8236397744508347" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1441891357547089" LOG_CI_START="-0.08426268899982248" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-01-18 19:36:39 +0000" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.13419373271558246" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.01800795790014119" WEIGHT="31.120984210214903"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 10:50:11 +0000" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-01-11 10:50:18 +0000" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="4.865275159548422"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-06-25 11:03:44 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Mortality: INO versus control (bias assessment)</NAME>
<DICH_OUTCOME CHI2="4.924682224064584" CI_END="1.1903746724921147" CI_START="0.9000191996028166" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.035065244302898" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="221" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.07568367785071739" LOG_CI_START="-0.045748225902209096" LOG_EFFECT_SIZE="0.014967725974254133" METHOD="MH" MODIFIED="2016-06-25 11:03:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9347592014155944" P_Q="0.8351492722062989" P_Z="0.6289741315467303" Q="0.04330653817112341" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="654" TOTAL_2="589" WEIGHT="100.0" Z="0.4831712743249454">
<NAME>Mortality: sensitivity analysis based on overall risk of bias</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.488758163426431" CI_END="1.3380931264242255" CI_START="0.8342898924337071" DF="7" EFFECT_SIZE="1.056578236814837" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="74" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.12648633980305984" LOG_CI_START="-0.07868301793704238" LOG_EFFECT_SIZE="0.023901660933008738" MODIFIED="2015-12-21 11:32:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7220706004966797" P_Z="0.6479149206274535" STUDIES="9" TAU2="0.0" TOTAL_1="218" TOTAL_2="205" WEIGHT="33.52985894991873" Z="0.4566607325322694">
<NAME>Overall high risk of bias</NAME>
<DICH_DATA CI_END="1.2904308807530451" CI_START="0.07071617832372805" EFFECT_SIZE="0.3020833333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.11073474742195648" LOG_CI_START="-1.1504812177031811" LOG_EFFECT_SIZE="-0.5198732351406123" MODIFIED="2015-10-13 08:13:26 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.740844501034221" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="29" VAR="0.5488505747126438" WEIGHT="3.2008271803770754"/>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="0.8835616695832552"/>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="1.7671233391665104"/>
<DICH_DATA CI_END="1.6099677150694744" CI_START="0.867302748143241" EFFECT_SIZE="1.1816638370118846" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.20681716714504272" LOG_CI_START="-0.06182927749812178" LOG_EFFECT_SIZE="0.07249394482346048" MODIFIED="2015-12-21 11:32:39 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.1578042514047429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.024902181761411304" WEIGHT="17.34726077948458"/>
<DICH_DATA CI_END="2.8820490883458874" CI_START="0.34697535307212146" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.45970137363834107" LOG_CI_START="-0.459701373638341" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.5400617248673216" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.29166666666666663" WEIGHT="1.514677147857009"/>
<DICH_DATA CI_END="2.285751787512423" CI_START="0.6535386600832783" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.35902906806871127" LOG_CI_START="-0.1847287166309109" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.3194060143770026" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.102020202020202" WEIGHT="3.9760275131246483"/>
<DICH_DATA CI_END="4.872809963795854" CI_START="0.4090205855724577" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.687779474528403" LOG_CI_START="-0.38825483386173887" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.6320678792040999" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.39950980392156865" WEIGHT="1.306134641992638"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-09 12:06:54 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1088175104756295" CI_START="0.6001586167190669" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3240389990744662" LOG_CI_START="-0.2217339541797036" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2009-08-12 12:41:10 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="3.534246678333021"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2584195553356981" CI_END="1.218111556437928" CI_START="0.861179717447674" DF="3" EFFECT_SIZE="1.0242133400776232" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="147" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.08568706344206178" LOG_CI_START="-0.06490620725575388" LOG_EFFECT_SIZE="0.010390428093153943" MODIFIED="2015-10-13 08:14:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9676490287417644" P_Z="0.7868049881853295" STUDIES="4" TAU2="0.0" TOTAL_1="436" TOTAL_2="384" WEIGHT="66.47014105008127" Z="0.27046181747920983">
<NAME>Overall low risk of bias</NAME>
<DICH_DATA CI_END="1.5901362439239612" CI_START="0.6014383662349947" EFFECT_SIZE="0.9779411764705882" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="17" LOG_CI_END="0.20143433655280063" LOG_CI_START="-0.22080887135906405" LOG_EFFECT_SIZE="-0.009687267403131736" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.2480277504650178" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.061517765000737135" WEIGHT="10.183422632484975"/>
<DICH_DATA CI_END="1.4749207741058794" CI_START="0.613518729418786" EFFECT_SIZE="0.9512578616352201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.16876869265809644" LOG_CI_START="-0.21217217464998647" LOG_EFFECT_SIZE="-0.021701740995945008" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.22376655114447302" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.050071469411092064" WEIGHT="10.406392997313896"/>
<DICH_DATA CI_END="1.3937636564951905" CI_START="0.8236397744508347" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1441891357547089" LOG_CI_START="-0.08426268899982248" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-01-20 19:34:43 +0000" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.13419373271558246" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.01800795790014119" WEIGHT="22.60699168381984"/>
<DICH_DATA CI_END="1.4087808859773137" CI_START="0.754844306571817" EFFECT_SIZE="1.0312178387650086" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="53" LOG_CI_END="0.14884345058919407" LOG_CI_START="-0.12214261627748112" LOG_EFFECT_SIZE="0.013350417155856473" MODIFIED="2009-08-06 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.15917855708014989" STUDY_ID="STD-Taylor-2004" TOTAL_1="165" TOTAL_2="167" VAR="0.025337813034118535" WEIGHT="23.27333373646255"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-06-25 11:04:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Bleeding events: INO versus control</NAME>
<DICH_OUTCOME CHI2="1.9314420998455042" CI_END="1.7886475997026794" CI_START="0.42874728943811896" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875715598886146" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2525247840664728" LOG_CI_START="-0.3677986125720043" LOG_EFFECT_SIZE="-0.05763691425276579" METHOD="MH" MODIFIED="2016-06-25 11:04:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5867576253713754" P_Q="1.0" P_Z="0.7156957024755879" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="339" TOTAL_2="275" WEIGHT="99.99999999999999" Z="0.36421736380606246">
<NAME>Bleeding events: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.76215689670289" CI_START="0.05948685933407728" EFFECT_SIZE="1.43801652892562" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.541106715396732" LOG_CI_START="-1.2255789594644324" LOG_EFFECT_SIZE="0.15776387796614966" MODIFIED="2009-04-24 09:54:53 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.6251648607284137" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="2.641160824546404" WEIGHT="4.436786850892856"/>
<DICH_DATA CI_END="2.1621806537805663" CI_START="0.3098822759546942" EFFECT_SIZE="0.8185483870967742" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.33489197715768926" LOG_CI_START="-0.5088032629836959" LOG_EFFECT_SIZE="-0.08695564291300333" MODIFIED="2009-04-16 13:03:20 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.4955907604178438" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.24561020181153664" WEIGHT="54.25835864596025"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="209" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-05-08 15:04:57 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="3.2817555632637245"/>
<DICH_DATA CI_END="2.0836755183323143" CI_START="0.13773247964638077" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3188300891142148" LOG_CI_START="-0.8609636336872907" LOG_EFFECT_SIZE="-0.27106677228653797" MODIFIED="2009-06-16 09:28:07 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.6930166728467198" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.4802721088435374" WEIGHT="38.023098939883155"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-06-25 11:05:00 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Complications during the in-patient stay: INO versus control</NAME>
<DICH_OUTCOME CHI2="1.6946179557609993" CI_END="2.1610807908576204" CI_START="1.16635370663874" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5876349047443385" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="51" I2="0.0" I2_Q="32.642867039635895" ID="CMP-004.01" LOG_CI_END="0.3346710030552866" LOG_CI_START="0.06683027387656724" LOG_EFFECT_SIZE="0.2007506384659269" METHOD="MH" MODIFIED="2016-06-25 11:04:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.638131094739065" P_Q="0.22305283466033055" P_Z="0.0033028936762605227" Q="1.4846237600232242" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="503" TOTAL_2="442" WEIGHT="100.00000000000001" Z="2.9380447288440235">
<NAME>Renal impairment: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.016481634696399" CI_START="1.1862613841142224" DF="0" EFFECT_SIZE="2.182795698924731" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.6038457854987892" LOG_CI_START="0.07418039321976631" LOG_EFFECT_SIZE="0.33901308935927776" MODIFIED="2016-06-25 11:04:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.012108874306954382" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="87" WEIGHT="23.4053283127281" Z="2.508955484415774">
<NAME>Trials with overall high risk of bias</NAME>
<DICH_DATA CI_END="4.016481634696399" CI_START="1.1862613841142224" EFFECT_SIZE="2.182795698924731" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" LOG_CI_END="0.6038457854987892" LOG_CI_START="0.07418039321976631" LOG_EFFECT_SIZE="0.33901308935927776" MODIFIED="2009-09-15 19:40:36 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.3111280733106751" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.09680067800201281" WEIGHT="23.4053283127281"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.149968917714291" CI_END="2.0136230682938656" CI_START="0.9814088086811703" DF="2" EFFECT_SIZE="1.405769332638611" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="39" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.30397817789556375" LOG_CI_START="-0.008150048306950878" LOG_EFFECT_SIZE="0.14791406479430644" MODIFIED="2010-03-16 12:07:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9277579231939451" P_Z="0.06322443320217115" STUDIES="3" TAU2="0.0" TOTAL_1="410" TOTAL_2="355" WEIGHT="76.59467168727191" Z="1.8576098889285844">
<NAME>Trials with overall low risk of bias</NAME>
<DICH_DATA CI_END="3.02310746731254" CI_START="0.6092528150615897" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.48045358602374516" LOG_CI_START="-0.2152024554745632" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2010-03-16 12:07:12 +0000" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.40863180232904867" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="0.1669799498746867" WEIGHT="17.91550554282085"/>
<DICH_DATA CI_END="2.09891965610352" CI_START="0.8810728441173485" EFFECT_SIZE="1.35989010989011" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.3219958146763905" LOG_CI_START="-0.05498818410736498" LOG_EFFECT_SIZE="0.13350381528451274" MODIFIED="2010-03-16 12:07:20 +0000" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.22144226698646802" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.049036677608106184" WEIGHT="47.383423280495144"/>
<DICH_DATA CI_END="4.51872028335901" CI_START="0.6211467271705692" EFFECT_SIZE="1.6753472222222223" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6550154585798201" LOG_CI_START="-0.20680579873865906" LOG_EFFECT_SIZE="0.22410482992058053" MODIFIED="2010-03-16 12:07:22 +0000" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.5062380726329009" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" VAR="0.25627698618307426" WEIGHT="11.295742863955914"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0582556258509447E-4" CI_END="1.2560816860634065" CI_START="0.5253321382589129" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.812317719840919" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="39" I2="0.0" I2_Q="100.0" ID="CMP-004.02" LOG_CI_END="0.09901788355167225" LOG_CI_START="-0.2795660295384926" LOG_EFFECT_SIZE="-0.09027407299341018" METHOD="MH" MODIFIED="2016-06-25 11:04:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9860474105809265" P_Q="0.0" P_Z="0.34993547621291976" Q="1.5577614827300336E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="280" WEIGHT="99.99999999999999" Z="0.93471447511128">
<NAME>Pneumothorax: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1621806537805663" CI_START="0.3098822759546942" EFFECT_SIZE="0.8185483870967742" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.33489197715768926" LOG_CI_START="-0.5088032629836959" LOG_EFFECT_SIZE="-0.08695564291300333" MODIFIED="2009-04-16 12:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.4955907604178438" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.24561020181153664" WEIGHT="21.095890410958905"/>
<DICH_DATA CI_END="1.31994788828352" CI_START="0.49786546815226956" EFFECT_SIZE="0.8106518817204301" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" LOG_CI_END="0.12055678554095767" LOG_CI_START="-0.30288799525697946" LOG_EFFECT_SIZE="-0.09116560485801091" MODIFIED="2009-04-16 10:51:17 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.24873356032617844" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" VAR="0.061868384032536645" WEIGHT="78.90410958904108"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9354368025259622" CI_START="0.046199058853228045" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2078853046594982" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.028985547812663028" LOG_CI_START="-1.3353668716086575" LOG_EFFECT_SIZE="-0.6821762097106603" METHOD="MH" MODIFIED="2016-06-25 11:04:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.04066417017288439" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="87" WEIGHT="100.0" Z="2.0469380230541794">
<NAME>Severe respiratory failure: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9354368025259622" CI_START="0.046199058853228045" EFFECT_SIZE="0.2078853046594982" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.028985547812663028" LOG_CI_START="-1.3353668716086575" LOG_EFFECT_SIZE="-0.6821762097106603" MODIFIED="2009-04-16 12:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.7673748562896134" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.588864170065505" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8277276928838064" CI_END="2.4690528976072983" CI_START="0.8962501324630623" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4875782287123083" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.392530394465291" LOG_CI_START="-0.047570767136726165" LOG_EFFECT_SIZE="0.1724798136642824" METHOD="MH" MODIFIED="2016-06-25 11:05:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3629304805318042" P_Q="1.0" P_Z="0.12447538595574315" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="142" WEIGHT="100.0" Z="1.5362568988076197">
<NAME>Circulatory failure and shock: INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.554004227605568" CI_START="0.048473841947429507" EFFECT_SIZE="0.5188679245283019" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7446062059913132" LOG_CI_START="-1.3144925575323658" LOG_EFFECT_SIZE="-0.2849431757705264" MODIFIED="2009-04-16 13:37:52 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.2095248063970743" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="1.46295025728988" WEIGHT="10.051204248056136"/>
<DICH_DATA CI_END="2.6908521011570246" CI_START="0.9464135142132404" EFFECT_SIZE="1.5958254269449716" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.42988982804374254" LOG_CI_START="-0.023919066873011277" LOG_EFFECT_SIZE="0.2029853805853656" MODIFIED="2009-04-16 12:59:06 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.2665695912643603" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.07105934698684813" WEIGHT="89.94879575194386"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-06-25 11:05:10 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> (mm Hg): INO versus control</NAME>
<CONT_OUTCOME CHI2="13.337095203088989" CI_END="23.561066694451767" CI_START="8.254386158058562" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="15.907726426255165" ESTIMABLE="YES" I2="25.021154548826257" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2016-06-23 04:00:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2054304712228633" P_Q="0.9752421529740223" P_Z="4.624199544978333E-5" Q="9.631304189158979E-4" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="36.892853619231126" TOTALS="YES" TOTAL_1="348" TOTAL_2="266" UNITS="" WEIGHT="100.0" Z="4.073851387601111">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 24 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.471013040032341" CI_END="20.304749469313116" CI_START="8.229698182821036" DF="8" EFFECT_SIZE="14.267223826067076" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" MODIFIED="2009-09-14 12:11:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9014276875585576" P_Z="3.6289680718554213E-6" STUDIES="9" TAU2="0.0" TOTAL_1="179" TOTAL_2="159" WEIGHT="76.7031818260587" Z="4.631573679483197">
<NAME>High risk of bias trials</NAME>
<CONT_DATA CI_END="27.58117844677882" CI_START="-35.38117844677883" EFFECT_SIZE="-3.9000000000000057" ESTIMABLE="YES" MEAN_1="77.3" MEAN_2="81.2" MODIFIED="2009-09-01 19:43:04 +0100" MODIFIED_BY="[Empty name]" ORDER="320" SD_1="35.7" SD_2="37.7" SE="16.062120883392932" STUDY_ID="STD-Day-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="5.170753070690747"/>
<CONT_DATA CI_END="40.59654346476403" CI_START="-14.596543464764032" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="129.0" MODIFIED="2009-05-08 22:47:01 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="46.0" SD_2="43.0" SE="14.080127840328723" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.484463927683425"/>
<CONT_DATA CI_END="22.698828708684495" CI_START="7.301171291315503" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="170.0" MEAN_2="155.0" MODIFIED="2009-04-16 11:52:41 +0100" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="9.5" SD_2="8.5" SE="3.9280460097286864" STUDY_ID="STD-Ibrahim-2007" TOTAL_1="11" TOTAL_2="10" WEIGHT="29.14192351915012"/>
<CONT_DATA CI_END="23.64228347289699" CI_START="-9.642283472896992" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="138.0" MEAN_2="131.0" MODIFIED="2009-09-01 19:44:08 +0100" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="48.0" SD_2="53.0" SE="8.491116981826808" STUDY_ID="STD-Lundin-1999" TOTAL_1="78" TOTAL_2="66" WEIGHT="13.989801584399014"/>
<CONT_DATA CI_END="59.693764520577254" CI_START="-21.693764520577254" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="96.0" MODIFIED="2009-09-01 19:44:42 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="48.0" SD_2="29.3" SE="20.762506271321552" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" WEIGHT="3.2582443830807777"/>
<CONT_DATA CI_END="39.4520871332197" CI_START="0.547912866780301" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="92.0" MEAN_2="72.0" MODIFIED="2009-09-01 19:45:03 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="30.0" SD_2="26.0" SE="9.924716620639604" STUDY_ID="STD-Michael-1998" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.261859923822966"/>
<CONT_DATA CI_END="102.68107829245581" CI_START="-89.88107829245585" EFFECT_SIZE="6.399999999999977" ESTIMABLE="YES" MEAN_1="254.2" MEAN_2="247.8" MODIFIED="2009-05-08 22:09:30 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="109.5" SD_2="89.1" SE="49.12390179202714" STUDY_ID="STD-Park-2003" TOTAL_1="11" TOTAL_2="6" WEIGHT="0.6223444381263927"/>
<CONT_DATA CI_END="86.3057422698614" CI_START="-14.305742269861398" EFFECT_SIZE="36.0" ESTIMABLE="YES" MEAN_1="213.0" MEAN_2="177.0" MODIFIED="2009-09-01 19:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="67.0" SD_2="40.0" SE="25.666666666666668" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" WEIGHT="2.1918064143148817"/>
<CONT_DATA CI_END="57.2138493905652" CI_START="-10.213849390565201" EFFECT_SIZE="23.5" ESTIMABLE="YES" MEAN_1="189.8" MEAN_2="166.3" MODIFIED="2009-09-01 19:45:37 +0100" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="40.1" SD_2="53.2" SE="17.201259643797407" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.58198456479038"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.791843974852124" CI_END="56.98442404079214" CI_START="-27.104837532994416" DF="1" EFFECT_SIZE="14.939793253898863" ESTIMABLE="YES" I2="87.16606745171667" ID="CMP-005.01.02" MODIFIED="2009-09-14 12:11:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005248275661387525" P_Z="0.4861549027349491" STUDIES="2" TAU2="805.8502935911205" TOTAL_1="169" TOTAL_2="107" WEIGHT="23.296818173941297" Z="0.6964374800323909">
<NAME>Low risk of bias trials</NAME>
<CONT_DATA CI_END="49.76343394895079" CI_START="20.236566051049206" EFFECT_SIZE="35.0" ESTIMABLE="YES" MEAN_1="166.0" MEAN_2="131.0" MODIFIED="2009-09-14 12:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="54.0" SD_2="43.0" SE="7.5325026711729794" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" WEIGHT="16.28486315599764"/>
<CONT_DATA CI_END="18.33660837217433" CI_START="-34.336608372174325" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="127.0" MEAN_2="135.0" MODIFIED="2009-09-14 12:11:42 +0100" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="59.0" SD_2="74.0" SE="13.437292001237847" STUDY_ID="STD-Dobyns-1999" TOTAL_1="49" TOTAL_2="50" WEIGHT="7.011955017943658"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.321239492045221" CI_END="20.10871964184216" CI_START="-2.8012073652251104" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="8.653756138308525" ESTIMABLE="YES" I2="36.72127112042372" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2016-06-25 11:05:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17640826019871625" P_Q="1.0" P_Z="0.1386938442072918" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="61.28482372573149" TOTALS="YES" TOTAL_1="249" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="1.4806725797812426">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 48 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INO</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.567400709642875" CI_START="-21.567400709642875" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="157.0" MODIFIED="2009-04-24 09:41:17 +0100" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="46.0" SD_2="69.0" SE="10.49376461602147" STUDY_ID="STD-Dellinger-1998" TOTAL_1="114" TOTAL_2="52" WEIGHT="19.92831084525562"/>
<CONT_DATA CI_END="39.43637415349838" CI_START="8.563625846501623" EFFECT_SIZE="24.0" ESTIMABLE="YES" MEAN_1="255.0" MEAN_2="231.0" MODIFIED="2009-09-01 19:47:10 +0100" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="23.0" SD_2="26.0" SE="7.875845819238785" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="19" WEIGHT="27.699992940156182"/>
<CONT_DATA CI_END="24.845083053383544" CI_START="-8.845083053383544" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="153.0" MEAN_2="145.0" MODIFIED="2009-09-01 19:47:56 +0100" MODIFIED_BY="[Empty name]" ORDER="324" SD_1="56.0" SD_2="54.0" SE="8.594588056849721" STUDY_ID="STD-Lundin-1999" TOTAL_1="91" TOTAL_2="74" WEIGHT="25.27373966004409"/>
<CONT_DATA CI_END="20.64874337997334" CI_START="-54.64874337997334" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="100.0" MEAN_2="117.0" MODIFIED="2009-09-01 19:48:16 +0100" MODIFIED_BY="[Empty name]" ORDER="325" SD_1="34.0" SD_2="36.7" SE="19.208895508765377" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" WEIGHT="7.938779024173828"/>
<CONT_DATA CI_END="29.200251932965628" CI_START="-13.200251932965628" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="86.0" MODIFIED="2009-09-01 19:47:25 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="24.0" SD_2="36.0" SE="10.816653826391969" STUDY_ID="STD-Michael-1998" TOTAL_1="16" TOTAL_2="16" WEIGHT="19.15917753037028"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4512536900775306" CI_END="17.67697583174433" CI_START="-3.908575576585763" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="6.884200127579284" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2016-06-23 04:01:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4853292299370435" P_Q="1.0" P_Z="0.21123815734480744" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="262" TOTAL_2="188" UNITS="" WEIGHT="100.00000000000001" Z="1.2501681386016792">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 72 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INO</GRAPH_LABEL_2>
<CONT_DATA CI_END="29.268403051388255" CI_START="-5.268403051388255" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="155.0" MEAN_2="143.0" MODIFIED="2009-04-24 09:43:15 +0100" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="53.0" SD_2="48.0" SE="8.810571616417043" STUDY_ID="STD-Dellinger-1998" TOTAL_1="102" TOTAL_2="46" WEIGHT="39.0626722587893"/>
<CONT_DATA CI_END="40.1667269054431" CI_START="-54.1667269054431" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="168.0" MEAN_2="175.0" MODIFIED="2009-09-01 19:49:02 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="111.0" SD_2="128.0" SE="24.065098786247205" STUDY_ID="STD-Dobyns-1999" TOTAL_1="49" TOTAL_2="50" WEIGHT="5.235941958565249"/>
<CONT_DATA CI_END="30.132140712801217" CI_START="-6.132140712801217" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="167.0" MEAN_2="155.0" MODIFIED="2009-09-01 19:50:18 +0100" MODIFIED_BY="[Empty name]" ORDER="326" SD_1="64.0" SD_2="53.0" SE="9.251262194522567" STUDY_ID="STD-Lundin-1999" TOTAL_1="89" TOTAL_2="71" WEIGHT="35.42975440462356"/>
<CONT_DATA CI_END="16.530645585053044" CI_START="-66.53064558505304" EFFECT_SIZE="-25.0" ESTIMABLE="YES" MEAN_1="108.0" MEAN_2="133.0" MODIFIED="2009-09-01 19:50:43 +0100" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="34.0" SD_2="35.8" SE="21.189494252262527" STUDY_ID="STD-Mehta-2001" TOTAL_1="6" TOTAL_2="5" WEIGHT="6.753500539722763"/>
<CONT_DATA CI_END="29.35450956355686" CI_START="-29.35450956355686" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="101.0" MODIFIED="2009-09-01 19:49:57 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="50.0" SD_2="33.0" SE="14.97706580075016" STUDY_ID="STD-Michael-1998" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.518130838299138"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5940976732262936" CI_END="25.37929934965532" CI_START="3.6418470757520023" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="14.510573212703662" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2016-06-23 04:01:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.897782243159281" P_Q="1.0" P_Z="0.008878421005113305" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="2.616700479298988">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> up to 96 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.68536866797333" CI_START="-9.685368667973329" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="155.0" MEAN_2="143.0" MODIFIED="2009-09-01 19:53:00 +0100" MODIFIED_BY="[Empty name]" ORDER="328" SD_1="50.0" SD_2="62.0" SE="11.064166912772249" STUDY_ID="STD-Dellinger-1998" TOTAL_1="95" TOTAL_2="40" WEIGHT="25.1202334937336"/>
<CONT_DATA CI_END="31.036343928950235" CI_START="-1.0363439289502345" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="281.0" MEAN_2="266.0" MODIFIED="2009-09-01 19:53:22 +0100" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="23.0" SD_2="26.0" SE="8.181958472422385" STUDY_ID="STD-Gerlach-2003" TOTAL_1="18" TOTAL_2="18" WEIGHT="45.935301135416005"/>
<CONT_DATA CI_END="40.873829868455985" CI_START="-2.873829868455985" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="181.0" MEAN_2="162.0" MODIFIED="2009-09-01 19:53:48 +0100" MODIFIED_BY="[Empty name]" ORDER="330" SD_1="74.0" SD_2="64.0" SE="11.160322353366675" STUDY_ID="STD-Lundin-1999" TOTAL_1="84" TOTAL_2="69" WEIGHT="24.689234907429704"/>
<CONT_DATA CI_END="50.68865381738547" CI_START="-54.68865381738547" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="128.0" MODIFIED="2009-09-01 19:54:08 +0100" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="44.0" SD_2="40.0" SE="26.882460204874604" STUDY_ID="STD-Mehta-2001" TOTAL_1="6" TOTAL_2="4" WEIGHT="4.255230463420686"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.73059717918731" CI_END="65.2332036676246" CI_START="20.571870898918668" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="42.902537283271634" ESTIMABLE="YES" I2="57.72203964439879" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2016-06-23 04:01:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.09392147123912442" P_Q="1.0" P_Z="1.6617728857149105E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="213.81567055955233" TOTALS="YES" TOTAL_1="79" TOTAL_2="76" UNITS="" WEIGHT="100.0" Z="3.7655583793737173">
<NAME>PaO<SUB>2</SUB>/FiO<SUB>2</SUB> difference from baseline up to 24 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INO</GRAPH_LABEL_2>
<CONT_DATA CI_END="52.98140731762875" CI_START="5.018592682371249" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="18.0" MODIFIED="2009-06-16 12:56:41 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="73.0" SD_2="52.0" SE="12.235636729445556" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" WEIGHT="35.70846135999426"/>
<CONT_DATA CI_END="84.1344192659387" CI_START="-32.13441926593871" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="78.0" MEAN_2="52.0" MODIFIED="2009-06-16 11:47:29 +0100" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="83.0" SD_2="39.0" SE="29.66096301998179" STUDY_ID="STD-Park-2003" TOTAL_1="11" TOTAL_2="6" WEIGHT="11.870070287450083"/>
<CONT_DATA CI_END="67.59670323702265" CI_START="44.80329676297735" EFFECT_SIZE="56.2" ESTIMABLE="YES" MEAN_1="70.4" MEAN_2="14.2" MODIFIED="2009-05-08 22:18:52 +0100" MODIFIED_BY="[Empty name]" ORDER="186" SD_1="13.4" SD_2="18.1" SE="5.814751356105722" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="52.42146835255566"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-06-25 11:05:22 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Ventilator-free days up to day 30: INO versus control</NAME>
<CONT_OUTCOME CHI2="2.3977354572358074" CI_END="0.6852611655563431" CI_START="-1.8212231877434935" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5679810110935751" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2016-06-25 11:05:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6630366067233857" P_Q="1.0" P_Z="0.37439344107163997" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="428" TOTAL_2="376" UNITS="" WEIGHT="100.0" Z="0.8882739077788162">
<NAME>Ventilator-free days (28-30 days), INO vs control</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7713419563224733" CI_START="-3.9713419563224743" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="7.2" MODIFIED="2009-09-02 16:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="7.7" SD_2="9.6" SE="1.464997305548088" STUDY_ID="STD-Dellinger-1998" TOTAL_1="112" TOTAL_2="57" WEIGHT="19.050227679722937"/>
<CONT_DATA CI_END="12.46871016764937" CI_START="-6.068710167649371" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="5.9" MODIFIED="2009-09-02 16:05:33 +0100" MODIFIED_BY="[Empty name]" ORDER="297" SD_1="10.8" SD_2="8.4" SE="4.729020655869074" STUDY_ID="STD-Park-2003" TOTAL_1="11" TOTAL_2="6" WEIGHT="1.8282323965819895"/>
<CONT_DATA CI_END="0.6347105948787299" CI_START="-3.63471059487873" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="13.5" MODIFIED="2009-09-02 16:06:07 +0100" MODIFIED_BY="[Empty name]" ORDER="298" SD_1="8.9" SD_2="6.3" SE="1.089158072146761" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" WEIGHT="34.46608806171956"/>
<CONT_DATA CI_END="2.0478420110161" CI_START="-1.847842011016101" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="10.6" MODIFIED="2009-04-16 11:07:27 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="9.7" SD_2="9.8" SE="0.9938152059835944" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" WEIGHT="41.39639740570659"/>
<CONT_DATA CI_END="8.74207327762257" CI_START="-5.14207327762257" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="5.9" MODIFIED="2009-09-02 16:06:44 +0100" MODIFIED_BY="[Empty name]" ORDER="299" SD_1="9.7" SD_2="9.7" SE="3.541939205200074" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.2590544562689217"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2015-11-06 03:18:26 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Duration of mechanical ventilation: INO versus control</NAME>
<CONT_OUTCOME CHI2="21.113697498548955" CI_END="4.118118402424175" CI_START="-2.0827283884815952" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="1.01769500697129" ESTIMABLE="YES" I2="76.31869074403653" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2015-11-06 03:18:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.709556162330822E-4" P_Q="1.0" P_Z="0.5199994986255487" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="7.473760275015408" TOTALS="YES" TOTAL_1="200" TOTAL_2="190" UNITS="" WEIGHT="99.99999999999999" Z="0.6433461842132068">
<NAME>Duration of mechanical ventilation</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0927275278398962" CI_START="-0.09272752783989602" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="2.8" MODIFIED="2009-05-08 21:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="170" SD_1="1.8" SD_2="0.7" SE="0.5575242894559244" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" WEIGHT="32.14473748448998"/>
<CONT_DATA CI_END="5.668628646226233" CI_START="-24.268628646226233" EFFECT_SIZE="-9.3" ESTIMABLE="YES" MEAN_1="19.9" MEAN_2="29.2" MODIFIED="2009-08-17 09:16:38 +0100" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="17.0" SD_2="51.2" SE="7.637195767012489" STUDY_ID="STD-Dobyns-1999" TOTAL_1="49" TOTAL_2="50" WEIGHT="3.802914019864411"/>
<CONT_DATA CI_END="9.370252956064526" CI_START="-5.370252956064526" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="32.0" MODIFIED="2009-09-02 16:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="300" SD_1="12.5" SD_2="11.25" SE="3.760402239122831" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.577184119738078"/>
<CONT_DATA CI_END="13.9572398126794" CI_START="4.0427601873205985" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="15.0" MODIFIED="2009-09-02 16:09:13 +0100" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="21.0" SD_2="12.0" SE="2.529250461631681" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" WEIGHT="18.040234745845073"/>
<CONT_DATA CI_END="7.836119523958821" CI_START="-20.036119523958817" EFFECT_SIZE="-6.099999999999998" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="23.7" MODIFIED="2009-09-02 16:09:47 +0100" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="14.9" SD_2="13.5" SE="7.110395718434191" STUDY_ID="STD-Park-2003" TOTAL_1="11" TOTAL_2="6" WEIGHT="4.312033493160775"/>
<CONT_DATA CI_END="-0.010805856282843251" CI_START="-3.589194143717158" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="24.1" MODIFIED="2009-05-08 16:57:18 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="2.5" SD_2="2.5" SE="0.9128709291752769" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.122896136901673"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2016-01-21 09:36:48 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Oxygenation index: INO versus control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.220396539853852" CI_START="-19.37960346014615" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2016-01-21 09:36:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.002278597005100894" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="3.051290893933744">
<NAME>Oxygenation index at 4 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.220396539853851" CI_START="-19.37960346014615" EFFECT_SIZE="-11.8" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="26.1" MODIFIED="2015-10-14 10:30:59 +0100" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="5.5" SD_2="19.5" SE="3.867215683519235" STUDY_ID="STD-Bronicki-2015" TOTAL_1="22" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.009526653107688" CI_START="-18.590473346892313" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2016-01-21 09:36:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0288849867198351" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="2.185052646258576">
<NAME>Oxygenation index at 12 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iNO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.009526653107688" CI_START="-18.590473346892313" EFFECT_SIZE="-9.8" ESTIMABLE="YES" MEAN_1="14.7" MEAN_2="24.5" MODIFIED="2015-10-14 10:31:17 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="6.0" SD_2="22.0" SE="4.485017794321959" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8707176954279254" CI_END="-1.8910867930845097" CI_START="-2.7310662321058015" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3110765125951556" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2015-10-14 10:57:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9287237582669648" P_Q="1.0" P_Z="4.048488795701497E-27" Q="0.0" RANDOM="NO" SCALE="22.52072159793104" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="215" TOTAL_2="153" UNITS="" WEIGHT="100.00000000000001" Z="10.785089538574091">
<NAME>Oxygenation index at 24 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.358895298540605" CI_START="-8.758895298540605" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="17.3" MODIFIED="2015-10-14 10:32:00 +0100" MODIFIED_BY="[Empty name]" ORDER="268" SD_1="10.3" SD_2="16.8" SE="3.8566501007999157" STUDY_ID="STD-Bronicki-2015" TOTAL_1="24" TOTAL_2="27" WEIGHT="0.3087170817009111"/>
<CONT_DATA CI_END="16.662188440433802" CI_START="-17.662188440433802" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="33.2" MEAN_2="33.7" MODIFIED="2009-09-01 19:55:24 +0100" MODIFIED_BY="[Empty name]" ORDER="274" SD_1="23.4" SD_2="16.4" SE="8.756379492586065" STUDY_ID="STD-Day-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.05988692132167068"/>
<CONT_DATA CI_END="-0.6457110843335103" CI_START="-5.35428891566649" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="17.0" MODIFIED="2009-04-24 09:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="6.0" SD_2="8.0" SE="1.2011898862615946" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="56" WEIGHT="3.1824222631329198"/>
<CONT_DATA CI_END="9.068803273786072" CI_START="-8.068803273786072" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="24.8" MEAN_2="24.3" MODIFIED="2009-08-17 09:12:00 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="21.5" SD_2="22.0" SE="4.371918740025683" STUDY_ID="STD-Dobyns-1999" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.24023538443842682"/>
<CONT_DATA CI_END="-1.871815048365948" CI_START="-2.7281849516340535" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.9" MODIFIED="2015-10-14 10:56:21 +0100" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="0.5" SD_2="0.5" SE="0.21846572437632575" STUDY_ID="STD-Ibrahim-2007" TOTAL_1="11" TOTAL_2="10" WEIGHT="96.20873834940609"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.851468383022879" CI_END="14.377811282194985" CI_START="-10.402475252616375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.987668014789305" ESTIMABLE="YES" I2="74.03587669554915" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2015-11-10 12:58:17 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.049702509973464926" P_Q="1.0" P_Z="0.7531990728343675" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="62.560315807738974" TOTALS="YES" TOTAL_1="123" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="0.3144239447543517">
<NAME>Oxygenation index at 48 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.641387856595323" CI_START="-2.6413878565953226" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="28.0" MEAN_2="18.0" MODIFIED="2009-08-11 14:26:42 +0100" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="16.0" SD_2="12.0" SE="6.44980619863884" STUDY_ID="STD-Day-1997" TOTAL_1="10" TOTAL_2="9" WEIGHT="38.366677036840805"/>
<CONT_DATA CI_END="-0.04092923600445708" CI_START="-5.959070763995543" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="16.0" MODIFIED="2009-04-24 09:50:02 +0100" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="6.0" SD_2="10.0" SE="1.5097577237828426" STUDY_ID="STD-Dellinger-1998" TOTAL_1="113" TOTAL_2="51" WEIGHT="61.6333229631592"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9225873909098864" CI_END="-0.1522709574964587" CI_START="-6.801898011443819" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4770844844701387" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2015-11-10 12:58:17 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3367966671175092" P_Q="1.0" P_Z="0.040391069766657" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="95" UNITS="" WEIGHT="100.00000000000001" Z="2.049727091602525">
<NAME>Oxygenation index at 72 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5081618047493173" CI_START="-7.491838195250683" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="18.0" MODIFIED="2009-04-24 09:50:30 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="7.0" SD_2="11.0" SE="1.7815828366203954" STUDY_ID="STD-Dellinger-1998" TOTAL_1="101" TOTAL_2="45" WEIGHT="90.66222293696677"/>
<CONT_DATA CI_END="12.480417048615724" CI_START="-9.280417048615728" EFFECT_SIZE="1.5999999999999979" ESTIMABLE="YES" MEAN_1="19.7" MEAN_2="18.1" MODIFIED="2009-08-17 09:14:12 +0100" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="31.2" SD_2="23.4" SE="5.551335195156169" STUDY_ID="STD-Dobyns-1999" TOTAL_1="49" TOTAL_2="50" WEIGHT="9.33777706303324"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-05-29 16:17:29 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Mean pulmonary arterial pressure (mm Hg): INO versus control</NAME>
<CONT_OUTCOME CHI2="4.059899812973242" CI_END="-0.11670035375491494" CI_START="-3.405710838842681" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.761205596298798" ESTIMABLE="YES" I2="1.4754012594555863" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2009-09-01 20:09:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39796022945623866" P_Q="1.0" P_Z="0.03581245001381124" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="81" UNITS="" WEIGHT="100.00000000000001" Z="2.099050491791863">
<NAME>MPAP up to 24 hours</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.25396574015752" CI_START="-2.2539657401575166" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="33.5" MODIFIED="2009-09-01 19:57:56 +0100" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="7.14" SD_2="6.36" SE="5.741924764397388" STUDY_ID="STD-Day-1997" TOTAL_1="4" TOTAL_2="2" WEIGHT="2.135302198404792"/>
<CONT_DATA CI_END="-0.20229113026428225" CI_START="-4.39770886973572" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="29.8" MEAN_2="32.1" MODIFIED="2009-04-24 09:45:15 +0100" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="5.9" SD_2="5.8" SE="1.0702792940493695" STUDY_ID="STD-Dellinger-1998" TOTAL_1="81" TOTAL_2="47" WEIGHT="61.45823667424273"/>
<CONT_DATA CI_END="3.040569265332552" CI_START="-5.040569265332552" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="26.0" MODIFIED="2009-06-16 11:58:52 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="6.0" SD_2="7.0" SE="2.0615528128088303" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.564770091940346"/>
<CONT_DATA CI_END="4.769977739357617" CI_START="-6.769977739357617" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="32.0" MODIFIED="2009-09-01 19:58:25 +0100" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="6.0" SD_2="5.0" SE="2.9439202887759492" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" WEIGHT="8.123108410470746"/>
<CONT_DATA CI_END="2.303941598825655" CI_START="-7.303941598825655" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="29.5" MODIFIED="2009-09-01 19:59:01 +0100" MODIFIED_BY="[Empty name]" ORDER="335" SD_1="4.5" SD_2="5.0" SE="2.4510356500009864" STUDY_ID="STD-Park-2003" TOTAL_1="11" TOTAL_2="6" WEIGHT="11.718582624941407"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7803923695899038" CI_END="0.6510926527653007" CI_START="-3.4276894735267067" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.388298410380703" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2009-09-01 20:09:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6769242536566362" P_Q="1.0" P_Z="0.18212878836672614" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="67" UNITS="" WEIGHT="100.00000000000001" Z="1.334229090885049">
<NAME>MPAP up to 48 hours</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0498804883731014" CI_START="-4.249880488373105" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="31.5" MEAN_2="33.1" MODIFIED="2009-05-08 15:55:15 +0100" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="6.9" SD_2="7.0" SE="1.3520046844100309" STUDY_ID="STD-Dellinger-1998" TOTAL_1="72" TOTAL_2="42" WEIGHT="59.230915991254584"/>
<CONT_DATA CI_END="1.8351979925936832" CI_START="-5.835197992593683" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="26.0" MODIFIED="2009-09-01 19:59:45 +0100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="5.0" SD_2="7.0" SE="1.9567696257917162" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="19" WEIGHT="28.276486486936104"/>
<CONT_DATA CI_END="6.769977739357617" CI_START="-4.769977739357617" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="31.0" MODIFIED="2009-09-01 20:00:07 +0100" MODIFIED_BY="[Empty name]" ORDER="336" SD_1="6.0" SD_2="5.0" SE="2.9439202887759492" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" WEIGHT="12.492597521809317"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00107116565432095" CI_END="0.5219464832168048" CI_START="-4.36412807681352" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9210907967983577" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2009-09-01 20:09:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9738909650382093" P_Q="1.0" P_Z="0.12326217035786123" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="42" UNITS="" WEIGHT="100.00000000000001" Z="1.5412244436698763">
<NAME>MPAP up to 72 hours</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8502125858169616" CI_START="-4.650212585816959" EFFECT_SIZE="-1.8999999999999986" ESTIMABLE="YES" MEAN_1="31.6" MEAN_2="33.5" MODIFIED="2009-04-24 09:46:27 +0100" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="6.9" SD_2="6.7" SE="1.4031954706873626" STUDY_ID="STD-Dellinger-1998" TOTAL_1="63" TOTAL_2="37" WEIGHT="78.90920320164109"/>
<CONT_DATA CI_END="3.3196566285597857" CI_START="-7.319656628559786" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="32.0" MODIFIED="2009-09-01 20:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="337" SD_1="5.0" SD_2="4.0" SE="2.714160398109638" STUDY_ID="STD-Mehta-2001" TOTAL_1="6" TOTAL_2="5" WEIGHT="21.090796798358927"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6562117453223824" CI_END="0.3021521370514677" CI_START="-3.77369021272607" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.735769037837301" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2009-09-01 20:10:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7202868179846164" P_Q="1.0" P_Z="0.0950440434124262" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="1.6693701609074938">
<NAME>MPAP up to 96 hours</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3977123587966154" CI_START="-5.7977123587966215" EFFECT_SIZE="-2.700000000000003" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="33.7" MODIFIED="2009-09-01 20:02:14 +0100" MODIFIED_BY="[Empty name]" ORDER="338" SD_1="5.8" SD_2="7.5" SE="1.5804945311398464" STUDY_ID="STD-Dellinger-1998" TOTAL_1="54" TOTAL_2="30" WEIGHT="43.28053163748824"/>
<CONT_DATA CI_END="2.5182430242654052" CI_START="-4.518243024265406" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="23.0" MODIFIED="2009-09-01 20:02:35 +0100" MODIFIED_BY="[Empty name]" ORDER="339" SD_1="3.0" SD_2="7.0" SE="1.7950549357115013" STUDY_ID="STD-Gerlach-2003" TOTAL_1="18" TOTAL_2="18" WEIGHT="33.55236156655626"/>
<CONT_DATA CI_END="3.2340061206741213" CI_START="-5.234006120674121" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="31.0" MODIFIED="2009-09-01 20:02:59 +0100" MODIFIED_BY="[Empty name]" ORDER="340" SD_1="2.0" SD_2="4.0" SE="2.160246899469287" STUDY_ID="STD-Mehta-2001" TOTAL_1="6" TOTAL_2="4" WEIGHT="23.167106795955508"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2016-06-25 11:05:33 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Reversal of ALI: INO versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.460143111554143" CI_START="0.8815179897183112" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1345229924502402" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.16439542394355555" LOG_CI_START="-0.05476882034064084" LOG_EFFECT_SIZE="0.054813301801457354" METHOD="MH" MODIFIED="2016-06-25 11:05:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3268986968852875" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="87" WEIGHT="100.0" Z="0.9803797855390197">
<NAME>Reversal of ALI</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.460143111554143" CI_START="0.8815179897183112" EFFECT_SIZE="1.1345229924502402" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="47" LOG_CI_END="0.16439542394355555" LOG_CI_START="-0.05476882034064084" LOG_EFFECT_SIZE="0.054813301801457354" MODIFIED="2009-04-16 13:01:04 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.1287381619730429" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="0.01657351434819743" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2016-06-25 11:05:42 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Methaemoglobin concentration &gt; 5%: INO versus control</NAME>
<DICH_OUTCOME CHI2="0.5310503705582014" CI_END="3.7917119315799312" CI_START="0.2019736694961773" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8751148338896084" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.5788353351856762" LOG_CI_START="-0.6947052441071575" LOG_EFFECT_SIZE="-0.0579349544607407" METHOD="MH" MODIFIED="2016-06-25 11:05:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7668031451334472" P_Q="1.0" P_Z="0.8584697660979141" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="679" TOTAL_2="596" WEIGHT="100.0" Z="0.17832242809580792">
<NAME>Methaemoglobin &gt; 5%</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-09 12:03:41 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.0" STUDY_ID="STD-Day-1997" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.400258271190655" CI_START="0.15153625839926244" EFFECT_SIZE="1.425" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.127113168862719" LOG_CI_START="-0.8194834401736607" LOG_EFFECT_SIZE="0.153814864344529" MODIFIED="2009-05-08 16:10:59 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="1.1434404839565884" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="1.307456140350877" WEIGHT="34.89823040271611"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:01:02 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.0" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:05:38 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.0" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-26 22:38:37 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.0" STUDY_ID="STD-Ibrahim-2007" TOTAL_1="22" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.72662534979024" CI_START="0.0594250245425885" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1681032383651009" LOG_CI_START="-1.226030630235734" LOG_EFFECT_SIZE="-0.028963695935316617" MODIFIED="2009-05-08 23:02:22 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.406326085569913" STUDY_ID="STD-Lundin-1999" TOTAL_1="93" TOTAL_2="87" VAR="1.9777530589543937" WEIGHT="26.595359752736574"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-16 08:46:13 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:00:06 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Michael-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:06:28 +0100" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.0" STUDY_ID="STD-Park-2003" TOTAL_1="17" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-16 09:31:57 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.0" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-09 12:05:05 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.0" STUDY_ID="STD-Schwebel-1997" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.173969664323877" CI_START="0.01373451445601025" EFFECT_SIZE="0.33506044905008636" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9124330216015115" LOG_CI_START="-1.8621866891959318" LOG_EFFECT_SIZE="-0.47487683379721013" MODIFIED="2009-05-08 23:06:54 +0100" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.6298253527114952" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" VAR="2.6563306803411497" WEIGHT="38.50640984454732"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:00:31 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.0" STUDY_ID="STD-Troncy-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2016-06-23 04:03:25 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>NO<SUB>2</SUB> concentration &gt; 3 ppm: INO versus control</NAME>
<DICH_OUTCOME CHI2="2.181383169152037E-32" CI_END="63.890484437385474" CI_START="0.17621592154132676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3553719008264467" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="1.805436181099517" LOG_CI_START="-0.753954854578029" LOG_EFFECT_SIZE="0.5257406632607441" METHOD="MH" MODIFIED="2016-06-23 04:03:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.42069439451472734" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="513" TOTAL_2="446" WEIGHT="100.0" Z="0.8052171401987215">
<NAME>NO<SUB>2</SUB> concentration &gt; 3 ppm</NAME>
<GROUP_LABEL_1>INO</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="63.890484437385474" CI_START="0.1762159215413267" EFFECT_SIZE="3.355371900826446" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.805436181099517" LOG_CI_START="-0.7539548545780291" LOG_EFFECT_SIZE="0.525740663260744" MODIFIED="2009-05-08 16:13:18 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.5033989635469434" STUDY_ID="STD-Dellinger-1998" TOTAL_1="120" TOTAL_2="57" VAR="2.2602084435940233" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:01:42 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Dobyns-1999" TOTAL_1="53" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:05:53 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.0" STUDY_ID="STD-Gerlach-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-26 22:39:08 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.0" STUDY_ID="STD-Ibrahim-2007" TOTAL_1="22" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="208" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehta-2001" TOTAL_1="8" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-16 09:32:09 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.0" STUDY_ID="STD-Payen-1999" TOTAL_1="98" TOTAL_2="105" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-08 23:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.0" STUDY_ID="STD-Taylor-2004" TOTAL_1="192" TOTAL_2="193" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-06-25 11:06:00 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Figure5.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-06-25 11:05:46 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>INO search result.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAPACAMAAAArKL6BAAADAFBMVEUAAAAQEBAJEBcFCAwCBAYH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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-06-25 10:39:59 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-06-25 10:39:59 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASIAAAK+CAIAAACJkIREAAAj/klEQVR42u2dsW4USduFR0JCBA4c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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-06-25 11:05:48 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Mortality, outcome: 1.1 Longest follow-up, mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-06-25 11:05:49 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Mortality, outcome: 1.2 28- to 30-day mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="INO overall mortality all trials included longest follow-up.TSA.PNG" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-06-25 11:05:55 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>TSA of all trials of the effect of INO on mortality (longest follow-up).</B> The TSA-adjusted confidence interval for the meta-analysis of the primary outcome with continuity correction for zero events trials (0.001 event in each arm) in a fixed-effect model results in an RR of 1.04 (95% CI 0.90 to 1.19; I² statistic = 0%, diversity D² = 0%). With an accrued information size of 1243 participants and no boundaries crossed so far, only 41.92% of the required information size is actually available at this stage for rejection or acceptance of a 4% RRI for overall mortality. However, solid evidence may be obtained with fewer participants if eventually the cumulative meta-analysis z-curve crosses the trial sequential monitoring boundary constructed for a required information size of 3015 randomized participants. However, regarding the TSA analysis for this outcome, it is important to bear in mind that only 4 out of the 14 included studies are classified as low risk of bias trials. Therefore, TSA is not able to directly adjust for the impact of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABekAAAPXCAIAAAAwmle2AAB9s0lEQVR42uzdf2jVd74n/jASoqvF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</FILE>
</FIGURE>
<FIGURE FILENAME="PF ratio TSA.PNG" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-06-25 11:06:00 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>TSA of all trials of the effect of INO on PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio at 24 hours.</B> Application of TSA to analysis of the PaO<SUB>2</SUB>/FiO<SUB>2</SUB> ratio at 24 hours indicates statistical significance in favour of improved oxygenation, even with adjustment for repetitive testing on accumulating data in the cumulative meta-analysis, because the z-curve crossed the trial sequential monitoring boundary. The a priori information size (335 participants) is determined by a TSA-adjusted mean difference (MD) of 15.91. The cumulative z-curve (blue line with filled squares) at the current accrued information size of 614 participants crosses the boundary (red lines with open diamonds) (with 80% power and alpha 0.05, assuming a double-sided type 1 risk of 5% and type 2 risk of 20%). However, it is important to note that only two trials had low risk of bias and the TSA-adjusted confidence interval for the meta-analysis in a random-effects model results in an MD of 15.91 with substantial heterogeneity and diversity (95% CI 8.25 to 23.56; I² statistic = 25%, diversity D² = 49%).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABekAAAPaCAIAAACMBERoAACAAElEQVR42uzdD2idZ34veN1mhG3i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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-06-25 11:06:33 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-06-25 11:06:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-13 10:28:44 +0100" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-25 11:06:02 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="7">
<TR>
<TD>
<P>
<B>Database</B>
</P>
</TD>
<TD>
<P>
<B>Search strategy</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1 MeSH descriptor Anoxia explode all trees<BR/>#2 MeSH descriptor Respiratory Paralysis explode all trees<BR/>#3 MeSH descriptor Respiratory Insufficiency explode all trees<BR/>#4 MeSH descriptor Respiratory Distress Syndrome, Adult explode all trees<BR/>#5 MeSH descriptor Respiratory Distress Syndrome, Newborn explode all trees<BR/>#6 (Acute near (hypox* or respiratory)):ti,ab<BR/>#7 (respirat* near (distress or failure)):ti,ab<BR/>#8 lung injury<BR/>#9 (hypoxia or hypoxemia):ti<BR/>#10 AHRF or ARDS or ALI<BR/>#11 (#1 OR #2 OR #3 OR # OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 MeSH descriptor Nitric Oxide explode all trees<BR/>#13 MeSH descriptor Endothelium-Dependent Relaxing Factors explode all trees<BR/>#14 Nitric near oxide<BR/>#15 (#12 OR #13 OR #14)<BR/>#16 (#11 AND #15)</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (Ovid SP)</P>
</TD>
<TD>
<P>1. exp respiratory-distress/<BR/>2. exp acute-respiratory-tract-disease/<BR/>3. exp acute-respiratory-failure/<BR/>4. exp adult-respiratory-distress-syndrome/<BR/>5. exp neonatal-respiratory-distress-syndrome/<BR/>6. exp acute-lung-injury/<BR/>7. exp idiopathic-respiratory-distress-syndrome/<BR/>8. exp transfusion-related-acute-lung-injury/<BR/>9. exp hypoxemia/ or hypoxia/<BR/>10. (Acute adj3 (hypox* or respirator*)).mp.<BR/>11. (respirat* adj3 (distress or failure)).mp.<BR/>12. lung injury.mp.<BR/>13. (hypoxia or hypoxemia).ti.<BR/>14. (AHRF or ARDS or AL).mp.<BR/>15. or/1-14<BR/>16. nitric-oxide/<BR/>17. endothelial?derived relax*.mp.<BR/>18. Endothelium?Dependent Relax*.mp.<BR/>19. Nitric oxide.ti,ab.<BR/>20. or/16-19<BR/>21. 20 and 15<BR/>22. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) and human*.ec,hw,fs.<BR/>23. 22 and 21</P>
</TD>
</TR>
<TR>
<TD>
<P>ISI Web of Science and</P>
<P>BIOSIS Previews</P>
<P/>
</TD>
<TD>
<P>#1TS=(Respirat* SAME Insufficiency) or TS=(Respirat* SAME Paralysis) or TS=(Respirat* SAME Distress*) or TS=(Respirat* SAME failure) or TS=(Anoxemia or Anoxia) or TS=(Acute SAME hypox*) or TS=(Acute SAME respiratory) or TS=(lung injur*) OR TS=(AHRF or ARDS or ALI)<BR/>#2 TS=(nitric oxide) or TS=(Endothel* SAME Depend* SAME Relaxi*)<BR/>#3#2 AND #1<BR/>#4 TS=random* or TS=placebo or TS=(controlled trial*)<BR/>#5 #4 AND #3</P>
</TD>
</TR>
<TR>
<TD>
<P>LILACS (via BIREME)</P>
</TD>
<TD>
<P>("RESPIRATORY DISTRESS" or "RESPIRATORY INSUFFIENCY" or ((lesion$ or ferimento) and pulm$) or ((insuficiência or escasez) and respirat$) or (síndrome de distress respiratorio agudo) or (distress and sindrome) or (SDRA or VAFO or ARDS) or (alta frecuencia oscilatoria) or (lung and injury) or (Anox$) or (Acute and (hypox$ or respirator$))) and (nitric$ and oxid$)</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD>
<P>1. Anoxia/ or Anoxemia/ or exp Respiratory-Paralysis/ or exp Respiratory-Insufficiency/ or exp Respiratory-Distress-Syndrome-Newborn/ or exp Respiratory-Distress-Syndrome-Adult/ or (Acute adj3 (hypox* or respiratory)).mp. or (respirat* adj3 (distress or failure)).mp. or lung injury.mp. or (hypoxia or hypoxemia).ti,ab. or (AHRF or ARDS or ALI).mp.<BR/>2. exp nitric-oxide/ or exp Endothelium-Dependent-Relaxing-Factors/ or (Nitric adj3 oxide).mp.<BR/>3. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) and humans.sh.<BR/>4. 1 and 2 and 3</P>
</TD>
</TR>
<TR>
<TD>
<P>CINAHL (EBSCO host)</P>
</TD>
<TD>
<P>S1 MW Anoxia<BR/>S2 MW Anoxemia<BR/>S3 (MH "Respiratory Failure+")<BR/>S4 (MH "Respiratory Distress Syndrome+") or (MM "Respiratory Distress Syndrome, Acute")<BR/>S5 Acute and (hypox* or respiratory)<BR/>S6 respirat* and (distress or failure)<BR/>S7 TX lung injury<BR/>S8 TI hypoxia or hypoxemia<BR/>S9 TX AHRF or ARDS or ALI<BR/>S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9<BR/>S11 (MM "Nitric Oxide")<BR/>S12 TX Nitric oxide<BR/>S13 S11 or S12<BR/>S14 S10 and S13<BR/>S15 ("random") or (MH "Random Assignment") or (MM "Random Sample+") or (MM "Clinical Trials+")<BR/>S16 (MM "Double-Blind Studies") or (MM "Single-Blind Studies") or (MM "Triple-Blind Studies") or (MM "Concurrent Prospective Studies")<BR/>S17 (MM "Placebos")<BR/>S18 TX placebo* or random*<BR/>S19 TI trail*<BR/>S20 S15 or S16 or S17 or S18 or S19<BR/>S21 S14 and S20</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-06-25 11:06:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-02-23 08:20:02 +0000" MODIFIED_BY="[Empty name]">Assessment of risk of bias in included studies</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-25 11:06:05 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Random sequence generation</HEADING>
<P>Assessment of randomization: sufficiency of the method in producing two comparable groups before intervention.</P>
<P>Grade: &#8217;low risk&#8217;: a truly random process (e.g. random computer number generator, coin tossing, throwing dice); &#8217;high risk&#8217;: any non-random process (e.g. date of birth, date of admission by hospital or clinic record number or by availability of the intervention); or &#8217;unclear risk&#8217;: insufficient information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Allocation concealment</HEADING>
<P>Allocation method prevented investigators or participants from foreseeing assignment.</P>
<P>Grade: &#8217;low risk&#8217;: central allocation or sealed opaque envelopes; &#8217;high risk&#8217;: use of open allocation schedule or other unconcealed procedure; or &#8217;unclear risk&#8217;: insufficient information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Blinding</HEADING>
<P>Assessment of appropriate blinding of the team of investigators and participants: person responsible for participant care, participants and outcome assessors.</P>
<P>Grade: &#8217;low risk&#8217;: blinding considered adequate if participants and personnel were kept unaware of intervention allocations after inclusion of participants into the study, and if the method of blinding involved a placebo indistinguishable from the intervention, as mortality is an objective outcome; &#8217;high risk&#8217;: not double-blinded, categorized as an open-label study, or without use of a placebo indistinguishable from the intervention; &#8217;unclear risk&#8217;: blinding not described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Incomplete outcome data</HEADING>
<P>Completeness of outcome data, including attrition and exclusions.</P>
<P>Grade: &#8217;low risk&#8217;: numbers and reasons for dropouts and withdrawals in the intervention groups described, or no dropouts or withdrawals specified; &#8217;high risk&#8217;: no description of dropouts and withdrawals provided; &#8217;unclear risk&#8217;: report gave the impression of no dropouts or withdrawals, but this was not specifically stated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Selective reporting</HEADING>
<P>The possibility of selective outcome reporting.</P>
<P>Grade: &#8217;low risk&#8217;: reported outcomes are pre-specified in an available study protocol, or, if this is not available, published report includes all expected outcomes; &#8217;high risk&#8217;: not all pre-specified outcomes reported, reported using non-pre-specified subscales, reported incompletely or report fails to include a key outcome that would have been expected for such a study; &#8217;unclear risk&#8217;: insufficient information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Funding bias</HEADING>
<P>Assessment of any possible funding bias:</P>
<P>Grade: &#8217;low risk&#8217;: reported no funding, funding from universities or public institutions; &#8217;high risk&#8217;: funding from private investors,</P>
<P>pharmaceutical companies or trial investigator employed by the pharmaceutical company; &#8217;unclear risk&#8217;: insufficient information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Other bias</HEADING>
<P>Assessment of any possible sources of bias not addressed in domains 1 to 6.</P>
<P>Grade: &#8217;low risk&#8217;: report appears to be free of such biases; &#8217;high risk&#8217;: at least one important bias is present that is related to study design, early stopping because of some data-dependent process, extreme baseline imbalance, academic bias, claimed fraudulence or other problems; or &#8217;unclear risk&#8217;: insufficient information, or evidence that an identified problem will introduce bias.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-06-25 11:06:06 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-01-04 21:19:42 +0000" MODIFIED_BY="[Empty name]">Bias assessment of mortality: INO versus control (sensitivity analysis)</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-25 11:06:06 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="16">
<TR>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>Studies</B>
</P>
</TD>
<TD>
<P>
<B>Participants</B>
</P>
</TD>
<TD>
<P>
<B>Statistical Method</B>
</P>
</TD>
<TD>
<P>
<B>Effect Estimate</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sensitivity analysis based on random sequence generation</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
<TD ALIGN="RIGHT">
<P>1243</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.90, 1.19]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Adequate</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD ALIGN="RIGHT">
<P>1014</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.06 [0.91, 1.23]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Inadequate or unclear</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
<TD ALIGN="RIGHT">
<P>229</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>0.91 [0.62, 1.35]</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sensitivity analysis based on allocation concealment</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>12</P>
</TD>
<TD ALIGN="RIGHT">
<P>911</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.89, 1.21]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Adequate</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD ALIGN="RIGHT">
<P>727</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.06 [0.89, 1.25]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Inadequate or unclear</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD ALIGN="RIGHT">
<P>184</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>0.94 [0.65, 1.38]</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sensitivity analysis based on blinding</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
<TD ALIGN="RIGHT">
<P>1243</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.90, 1.19]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Adequate</P>
</TD>
<TD ALIGN="RIGHT">
<P>6</P>
</TD>
<TD ALIGN="RIGHT">
<P>892</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>0.99 [0.83, 1.18]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Inadequate or unclear</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
<TD ALIGN="RIGHT">
<P>351</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.14 [0.89, 1.44]</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sensitivity analysis based on degree of follow-up</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
<TD ALIGN="RIGHT">
<P>1243</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.90, 1.19]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Adequate</P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
<TD ALIGN="RIGHT">
<P>1116</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.90, 1.21]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Inadequate or unclear</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
<TD ALIGN="RIGHT">
<P>127</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>0.95 [0.61, 1.47]</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sensitivity analysis based on sample size calculation and early stopping</B>
</P>
</TD>
<TD ALIGN="RIGHT">
<P>13</P>
</TD>
<TD ALIGN="RIGHT">
<P>1243</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.04 [0.90, 1.19]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Adequate</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
<TD ALIGN="RIGHT">
<P>766</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.05 [0.88, 1.25]</P>
</TD>
</TR>
<TR>
<TD>
<P>- Inadequate or unclear</P>
</TD>
<TD ALIGN="RIGHT">
<P>8</P>
</TD>
<TD ALIGN="RIGHT">
<P>477</P>
</TD>
<TD>
<P>Risk Ratio (M-H, Fixed, 95% CI)</P>
</TD>
<TD>
<P>1.01 [0.81, 1.27]</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-06-25 11:06:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-06-25 11:06:15 +0100" MODIFIED_BY="[Empty name]">Definition of variables and outcome measures and abbreviations in included studies</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-25 11:06:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="10">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Outcome measure/ variable/ abbreviation</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Definition</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Studies</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Oxygenation index</P>
</TD>
<TD ALIGN="CENTER">
<P>100 × mean airway pressure/(PaO<SUB>2</SUB>/FiO<SUB>2</SUB>)</P>
<P>or</P>
<P>(mean airway pressure × FiO<SUB>2</SUB> × 100)/systemic arterial oxygen tension</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Bronicki-2015" TYPE="STUDY">Bronicki 2015</LINK>; <LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PaO<SUB>2</SUB>/FiO<SUB>2</SUB>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Partial pressure of arterial oxygen/fraction of inspired oxygen</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Day-1997" TYPE="STUDY">Day 1997</LINK>; <LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Reversal of ALI</P>
</TD>
<TD ALIGN="CENTER">
<P>Ability to maintain PaO<SUB>2</SUB> &#8805;11 kPa if &lt; 60 years and PaO<SUB>2 </SUB>&#8805; 10 kPa if &gt; 60 with FiO<SUB>2 </SUB>&#8804; 0.35 and PEEP &#8804; 5 cm H<SUB>2</SUB>O;</P>
<P>On ventilator/mask CPAP system, PEEP &#8804; 5 cm H<SUB>2</SUB>O, PaO<SUB>2</SUB>/FiO<SUB>2</SUB> &gt; 31 kPa if &lt; 60 years and PaO<SUB>2</SUB>/FiO<SUB>2 </SUB>&gt; 29 kPa if &gt; 60 years</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Severe respiratory failure</P>
</TD>
<TD ALIGN="CENTER">
<P>Defined as FiO<SUB>2</SUB> 1.0 with PaO<SUB>2</SUB> &lt; 8 kPa for at least 8 hours, pressure-controlled ventilation (rate 5 to 30 beats/min), peak airway pressure &#8805; 20 cm H<SUB>2</SUB>O, mean airway pressure &gt;10 cm H<SUB>2</SUB>O; or as FiO<SUB>2 </SUB>&gt; 0.9 with PaO<SUB>2</SUB> &lt; 8 kPa in 3 blood gas analyses (4 hours apart), pressure-controlled/limited ventilation (rate 5-30), PEEP &#8805; 10 cm H<SUB>2</SUB>O, mean airway pressure &#8805; 20 cm H<SUB>2</SUB>O; or 2 arterial blood gases 2 hours apart at FiO<SUB>2</SUB> &#8805; 1.00, resulting in PaO<SUB>2 </SUB>&lt; 6 kPa</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Renal dysfunction</P>
</TD>
<TD ALIGN="CENTER">
<P>New renal replacement therapy ± new raised creatinine concentration (&gt; 300 µmol/L) or creatinine concentration &gt; 177 µmol/L or &#8807; 265 µmol/L</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Liver impairment</P>
</TD>
<TD ALIGN="CENTER">
<P>Bilirubin &#8807; 0.4 mg/dL, platelets &#8804; 50 × 10<SUP>3</SUP>/mm<SUP>3</SUP> and prothrombin time &#8807; 1.5 times normal</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>ADL score</P>
</TD>
<TD ALIGN="CENTER">
<P>Activity of daily living scale</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK> (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>TISS score</P>
</TD>
<TD ALIGN="CENTER">
<P>Therapeutic Intervention Scoring System</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Angus-2006" TYPE="REFERENCE">Angus 2006</LINK> (<LINK REF="STD-Taylor-2004" TYPE="STUDY">Taylor 2004</LINK>)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>AECC criteria</P>
</TD>
<TD ALIGN="CENTER">
<P>American-European Consensus Conference criteria for ALI and ARDS</P>
<P>ARDS: acute non-cardiogenic pulmonary oedema, acute severe hypoxaemia (PaO<SUB>2 </SUB>to FiO<SUB>2 </SUB>ratio (P/F ratio) &lt; 200, bilateral infiltrates on chest radiography, pulmonary artery occlusion pressure (PAOP) &#8804; 18. ALI = hypoxia score 200-300 mm Hg + ARDS criteria</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dellinger-1998" TYPE="STUDY">Dellinger 1998</LINK>; <LINK REF="STD-Dobyns-1999" TYPE="STUDY">Dobyns 1999</LINK>; <LINK REF="STD-Gerlach-2003" TYPE="STUDY">Gerlach 2003</LINK>; <LINK REF="STD-Ibrahim-2007" TYPE="STUDY">Ibrahim 2007</LINK>; <LINK REF="STD-Lundin-1999" TYPE="STUDY">Lundin 1999</LINK>; <LINK REF="STD-Mehta-2001" TYPE="STUDY">Mehta 2001</LINK>; <LINK REF="STD-Michael-1998" TYPE="STUDY">Michael 1998</LINK>; <LINK REF="STD-Park-2003" TYPE="STUDY">Park 2003</LINK>; <LINK REF="STD-Payen-1999" TYPE="STUDY">Payen 1999</LINK>; <LINK REF="STD-Schwebel-1997" TYPE="STUDY">Schwebel 1997</LINK>; <LINK REF="STD-Troncy-1998" TYPE="STUDY">Troncy 1998</LINK>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-09-12 08:43:40 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>